4-chromanone compounds that degrade WDR5 and uses thereof

A 4-chromanone derivative compound targets WDR5 for degradation, addressing the challenges of specificity and drug resistance in cancer treatments by inhibiting H3K4 methyltransferase activity, providing an effective anticancer therapy for various cancers, including triple-negative breast cancer.

WO2024232597A1PCT designated stage expired Publication Date: 2024-11-14ELGEN THERAPEUTICS INC

Patent Information

Application Number
PCT/KR2024/005950
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-04-30
Filing Date
2024-05-02
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current cancer treatments, particularly for triple-negative breast cancer, face challenges with specificity and drug resistance, and existing therapies are ineffective in inhibiting WDR5-driven carcinogenesis and metastasis in various cancers.

Method used

A novel 4-chromanone derivative compound is developed as an anticancer pharmaceutical composition that decomposes WDR5 using the Ubiquitin Proteasome system, inhibiting H3K4 methyltransferase activity and targeting WDR5 for degradation, thereby regulating cancer-related transcription factors.

Benefits of technology

The compound effectively inhibits WDR5 expression in solid and blood cancers, offering a potential solution to overcome issues of specificity and drug resistance in existing cancer therapies, with the ability to target undruggable proteins and function at lower concentrations, minimizing side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTKR2024005950-APPB-IMG-000001
    Figure PCTKR2024005950-APPB-IMG-000001
  • Figure PCTKR2024005950-APPB-IMG-000002
    Figure PCTKR2024005950-APPB-IMG-000002
  • Figure PCTKR2024005950-APPB-IMG-000003
    Figure PCTKR2024005950-APPB-IMG-000003
Patent Text Reader

Abstract

The present invention relates to an anticancer pharmaceutical composition containing a 4-chromanone derivative compound having a novel structure as an active ingredient, and a method for preparing same, wherein the composition containing a 4-chromanone derivative compound as an active ingredient suppresses the activity of MLL1 and degrades WDR5, and thus can be useful as a composition for preventing or treating cancer.
Need to check novelty before this filing date? Find Prior Art

Description

4-chromanone compound that decomposes WDR5 and its use

[0001] The present invention relates to an anticancer pharmaceutical composition containing a 4-chromanone derivative compound of a novel structure as an active ingredient and a method for producing the same.

[0002] Histone methyltransferases (HMTs), which are among the epigenetic regulators, are enzymes that control selective methylation at specific amino acid sites of histones. They control changes in the chromatin structure of eukaryotic DNA, resulting in heritable changes in gene expression. This, in turn, contributes to disease development and progression, as well as the expression of oncogenes and tumor suppressor genes, leading to cancer. MLL1 is a histone methyltransferase that regulates H3K4 methylation, and MLL abnormalities account for a high proportion of acute myeloid leukemia and acute lymphoblastic leukemia (G. Senisterra et al., 2013).

[0003] WD repeat-containing protein 5 (WDR5), a member of the WD40-repeat protein family, serves as a core scaffolding component of many multiprotein complexes that carry out various important chromatin-centric processes in the nucleus (A. Patel et al., 2008; X. Chen et al., 2021; BP Jain et al., 2018). WDR5 interacts with MLL / SET (MLL1-4, SETd1A, and SETd1B), members of the histone methyltransferase (HMT) complex, to promote histone H3 lysine 4 (H3K4) di- or trimethylation (Z. Odho et al., 2010; M. Wu et al., 2011). WDR5 interacts with MLL1 at the WIN site and functions by forming a core multiprotein complex with four components: MLL, WDR5, RbBP5, and ASH2L, which are required for maximal enzymatic activity of H3K4 methylation (Y. Dou et al., 2006). WDR5 interacts with c-Myc at the WBM site and is known to be a key cooperator of Myc-induced carcinogenesis. Various proteins that interact with WDR5 play diverse biological roles, such as reproduction, development, immunity, neuronal and humoral regulation (ER Aho et al., 2019).

[0004] WDR5 overexpression is observed in various cancers, including leukemia, breast cancer, liver cancer, bladder cancer, colorectal cancer, gastric cancer, pancreatic cancer, prostate cancer, neuroblastoma, and head and neck squamous cell carcinoma, and is associated with poor prognosis (X. Dai et al., 2015; A. Carugo et al., 2016). Therefore, targeting WDR5 and modulating its associated gene activity is an attractive therapeutic target for hematological and solid tumors.

[0005] A Proteolysis Targeting Chimara (PROTAC) is a heterobifunctional molecule consisting of a targeting protein ligand and an E3 ligase ligand linked by a linker. It utilizes the body's ubiquitine proteasome system (UPS) to degrade disease-causing target proteins. One PROTAC ligand binds to the cellular target protein, and the other ligand binds to the E3 ligase, forming a ternary complex that brings the target protein into close proximity to the E3 ligase, allowing the E3 ligase to recognize the target protein as a substrate and trigger polyubiquitination and subsequent proteasomal degradation. PROTACs have the advantage of being able to bind close to the target protein's degradative site, regardless of the binding site, and can inhibit its function by degrading the target protein. In addition, because they are event-driven drugs based on irreversible degradation, they can function at much lower concentrations, minimizing side effects. Furthermore, since inhibition of a specific active site is not essential, it is possible to target 'undruggable' proteins through degradation (M. Pettersson et al., 2019; X. Sun et al., 2019). In this respect, Protac has high potential as a disease therapeutic.

[0006] Since Avinas' estrogen receptor inhibitor ARV-471 entered clinical trials in 2019, several companies' degraders are undergoing clinical trials. Furthermore, protacs targeting various target proteins, including BRD9, IRAK4, and BTK, are undergoing clinical trials, and numerous protacs targeting even more proteins are undergoing preclinical research (M. Bekes et al., 2022).

[0007] Breast cancer can be divided into hormone-positive breast cancer, HER2-positive breast cancer, and triple-negative breast cancer that lacks both hormones and HER2, depending on the expression levels of estrogen receptors (ER), HER2, and Ki-67 (an intracellular protein). Triple-negative breast cancer accounts for approximately 10-20% of breast cancer patients, but its prevalence is relatively high in young people under 35 years of age and premenopausal women, and it is difficult to expect the effect of hormone therapy or HER2-targeted therapy, and the possibility of metastasis and recurrence is high with existing standard chemotherapy, and there is still no clear treatment (E. Nolan et al., 2023; H. Qin et al., 2022).

[0008] The WDR5 decomposition agent proposed in this patent is effective in inhibiting carcinogenesis and metastasis by decomposing WDR5, the expression of which is increased in solid cancers including breast cancer and blood cancers, thereby inhibiting H3K4 methyltransferase activity and regulating transcription factors related to cancer. In addition, it can be developed as a therapeutic agent that can overcome problems such as specificity and drug resistance of existing inhibitors.

[0009] The purpose of the present invention is to provide an anticancer pharmaceutical composition containing a novel 4-chromanone derivative compound as an active ingredient and a method for producing the same.

[0010] The present invention relates to a compound represented by the following chemical formula 1, a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof.

[0011] [Chemical Formula 1]

[0012]

[0013] In the above formula,

[0014] R1 is hydrogen, NH, N(t-butoxycarbonyl) or C1-C5 alkyl;

[0015] R2 is hydrogen or C1-C5 alkyl;

[0016] R3 is or And,

[0017] The above R3' is hydrogen, C1-C5 alkyl or halo C1-C5 alkyl,

[0018] The above R3” is independently hydrogen, halogen or C1-C5 alkyl;

[0019] R4 is hydrogen or halogen;

[0020] R5 is hydrogen or C1-C5 alkyl;

[0021] is a single bond or a double bond, and there are only two Not all bonds are double bonds;

[0022] r is independently 0 or 1, provided that r is not simultaneously 0 and 1;

[0023] X is CH or N;

[0024] W is , , , , , , , , , , , , , , or And,

[0025] The above A, B, C, D, E, F, and G are substituted by the chemical formulas 2 to 8 below,

[0026] [Chemical Formula 2] Structure A

[0027]

[0028] [Chemical Formula 3] B Structure

[0029]

[0030] [Chemical Formula 4] C Structure

[0031]

[0032] [Chemical Formula 5] D Structure

[0033]

[0034] [Chemical Formula 6] E Structure

[0035]

[0036] [Chemical Formula 7] F Structure

[0037]

[0038] [Chemical Formula 8] G Structure

[0039]

[0040] wherein R6 is hydrogen or methyl;

[0041] m is an integer from 0 to 5;

[0042] n is an integer from 1 to 3;

[0043] p is an integer from 0 to 2;

[0044] q is 0 or 1;

[0045] The present invention relates to a compound in which W in the above chemical formula 1 is substituted with the following chemical formula 2, a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof.

[0046] W is , , , , or And,

[0047] The above A is substituted with the chemical formula 2 below.

[0048] [Chemical Formula 2]

[0049]

[0050] The present invention relates to a compound in which W in the above chemical formula 1 is substituted with the following chemical formula 3, a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof.

[0051] W is or And,

[0052] The above B is substituted with the chemical formula 3 below.

[0053] [Chemical Formula 3]

[0054]

[0055] The present invention relates to a compound in which W in the above chemical formula 1 is substituted with the following chemical formula 4, a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof.

[0056] W is or And,

[0057] The above C is substituted with the chemical formula 4 below.

[0058] [Chemical Formula 4]

[0059]

[0060] The present invention relates to a compound in which W in the above chemical formula 1 is substituted with the following chemical formula 5, a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof.

[0061] W is And,

[0062] The above D is substituted with the chemical formula 5 below.

[0063] [Chemical Formula 5]

[0064]

[0065] The present invention relates to a compound in which W in the above chemical formula 1 is substituted with the following chemical formula 6, a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof.

[0066] W is or And,

[0067] The above E is substituted with the chemical formula 6 below.

[0068] [Chemical Formula 6]

[0069]

[0070] The present invention relates to a compound in which W in the above chemical formula 1 is substituted with the following chemical formula 8, a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof.

[0071] W is And,

[0072] The above G is substituted with the chemical formula 8 below.

[0073] [Chemical Formula 8]

[0074]

[0075] In addition, the compound represented by the chemical formula 1 in the present invention relates to a compound, a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, characterized in that the compound is selected from the following compound group.

[0076] tert-Butyl (1-((3-(4-chloro-3-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)benzyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate (Compound 1);

[0077] (2S,4R)-1-((2S)-2-(2-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (Compound 2);

[0078] 2-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)-N-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)acetamide hydrochloride (Compound 3);

[0079] (2S,4R)-N-(2-(3-(2-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)acetamido)propoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide hydrochloride (Compound 4);

[0080] (2S,4R)-1-((2S)-2-(5-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)pentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (Compound 5);

[0081] (2S,4R)-1-((2S)-2-(5-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)pentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (Compound 6);

[0082] 5-(2-chloro-5-((8-(6-fluoro-2-methylpyridin-3-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)-N-(2,6-dioxopiperidin-4-yl)pentanamide hydrochloride (Compound 7);

[0083] (2S,4R)-1-((2S)-2-(5-(2-chloro-5-((8-(6-fluoro-2-methylpyridin-3-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)pentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (Compound 8);

[0084] (2S,4R)-1-((2S)-2-(tert-butyl)-14-(5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)-4-oxo-6,9,12-trioxa-3-azatetradecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (Compound 9);

[0085] N-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)-2-(2-(2-(5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)ethoxy)ethoxy)ethoxy)acetamide hydrochloride (Compound 10);

[0086] (2S,4R)-1-((S)-2-(2-(2-fluoro-5-(((S)-8-(4-fluoro-2-methylphenyl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (Compound 11);

[0087] (2S,4R)-1-((S)-2-(2-(5-(((S)-8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (Compound 12);

[0088] (2S,4R)-N-(2-(3-(2-(2-fluoro-5-(((S)-8-(4-fluoro-2-methylphenyl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)acetamido)propoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide hydrochloride (Compound 13);

[0089] (2S,4R)-1-((S)-2-(2-fluoro-5-(((S)-8-(4-fluoro-2-methylphenyl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)benzamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (Compound 14);

[0090] (2S,4R)-1-((S)-2-(3-(2-fluoro-5-(((S)-8-(4-fluoro-2-methylphenyl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)benzamido)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (Compound 15);

[0091] (2S,4R)-N-(2-((2-(1-(6-(((R)-8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-4-oxo-8,11-dioxa-2,5-diazatridecan-13-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide (Compound 16);

[0092] (2S,4R)-1-((S)-2-(2-((1-(6-(((R)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)amino)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 17);

[0093] N-1-((R)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N4-methyl-N4-(1-(4-methyl-6-(((R)-6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)pyridin-2-yl)azetidin-3-yl)succinimide (Compound 18);

[0094] 2-(4-(2,6-dioxopiperidin-3-yl)phenoxy)-N-methyl-N-(1-(4-methyl-6-(((R)-6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)pyridin-2-yl)azetidin-3-yl)acetamide (Compound 19);

[0095] (2S,4R)-1-((S)-2-(2-(5-(((S)-8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 20);

[0096] 5-((8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenyl 2-(3-(2,6-dioxopiperidin-3-yl)phenoxy)acetate (Compound 21);

[0097] N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethyl)-2-(5-(((S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamide (Compound 22);

[0098] N1-(1-(6-(((R)-8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-3-fluoropyridin-2-yl)azetidin-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)succinamide (Compound 23);

[0099] N1-(1-(6-(((S)-8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-3-fluoropyridin-2-yl)azetidin-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)succinamide (Compound 24);

[0100] (2S,4R)-1-((2S)-2-(3-(3,4-dichlorophenyl)-3-(6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 25);

[0101] (2S,4R)-1-((S)-2-(2-((1-(6-(((S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)amino)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 26);

[0102] N-1-(1-(6-(((S)-8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylsuccinamide (Compound 27);

[0103] N1-(1-(6-(((R)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylsuccinamide (Compound 28);

[0104] N1-(1-(6-(((S)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylsuccinamide (Compound 29);

[0105] (2S,4R)-1-((S)-2-(2-(5-(((S)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 30);

[0106] (2S,4R)-1-((S)-2-(2-(5-(((S)-6-((1H-imidazol-1-yl)methyl)-8-(4-fluoro-2-methylphenyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 31);

[0107] 2-(5-(((S)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)-N-(1-(6-(((R)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N-methylacetamide (Compound 32); and

[0108] (S,E)-N-(2-(2-(2,6-dimethoxy-4-(3-oxo-3-(6-oxo-3,6-dihydropyridin-1(2H)-yl)prop-1-phen-1-yl)phenoxy)ethoxy)ethyl)-2-(5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamide (Compound 33);

[0109] Additionally, the following terms in the present invention have the following meanings unless otherwise specified. Any undefined term has the meaning understood in the art.

[0110] The term “alkyl” above means a straight or branched chain hydrocarbon group having 1 to 20 carbon atoms and preferably 1 to 6 carbon atoms, and includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, 1-methylpropyl, pentyl and hexyl.

[0111] The above term “alkoxy” means an oxygen group bonded to a straight or branched chain saturated hydrocarbon having 1 to 20 carbon atoms, and preferably 1 to 6 carbon atoms, and includes methoxy, ethoxy, propoxy, n-butoxy, tert-butoxy, 1-methylpropoxy, etc.

[0112] The above term “Boc” means tert-butoxycarbonyl.

[0113] The terms “halo” and “halogen” are used in their usual sense to refer to fluoro, chloro, bromo or iodo substituents.

[0114] The term "haloalkyl" above refers to an alkyl group in which one or more hydrogen atoms of the alkyl group are replaced by a halo group, wherein the alkyl and halo groups are as disclosed above.

[0115] The term "haloalkoxy" above refers to an alkoxy group in which one or more hydrogen atoms of the alkoxy group are replaced by a halo group, wherein halo and alkoxy are as disclosed above.

[0116] The compound of chemical formula 1 of the present invention may include not only pharmaceutically acceptable salts, but also all salts, solvates thereof, stereoisomers thereof, and prodrugs thereof that can be prepared by conventional methods.

[0117] “Pharmaceutically acceptable” means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients comprising the formulation and / or the mammal being treated therewith.

[0118] “Hydrate” means a solvate in which the solvent molecule(s) is water.

[0119] "Prodrug" means a compound that can be converted in vivo to the parent compound by metabolic means (e.g., hydrolysis), typically such prodrugs have a metabolically cleavable group and are rapidly converted in vivo, e.g., by hydrolysis in the blood, to yield the parent compound, typically including ester and amide analogs of the parent compound. Prodrugs are formulated for improved chemical stability, improved patient acceptability and compliance, improved bioavailability, prolonged duration of action, improved organ selectivity, improved formulation (e.g., increased aqueous solubility), and / or reduced side effects (e.g., toxicity). Typically, the prodrug itself has little or no biological activity and is stable under ordinary conditions.

[0120] "Solvate" refers to a complex of various stoichiometries formed by a solute (e.g., a compound of Formula I' or Formula I) and a solvent (e.g., water, ethanol, or acetic acid). This physical association may involve varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain cases, for example, when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid, the solvate becomes isolable. Generally, such solvents selected for the purposes of the present disclosure do not interfere with the biological activity of the solute. Solvates include both solution-phase and isolable solvates. Representative solvates include hydrates, ethanolates, methanolates, and the like.

[0121] “Stereoisomers” are mixtures of enantiomers, diastereomers, and cis / trans isomers produced from the procedure described above, which can be separated into their single components by chromatography using chiral salt techniques, normal, reversed phase, or chiral columns, depending on the nature of the separation.

[0122] Any resulting racemates of the compounds or intermediates of the present disclosure can be resolved into their optical enantiomers by known methods, for example, by separation of their diastereomeric salts obtained using optically active acids or bases, and by liberating optically active acid or base compounds. Thus, in particular, a basic moiety can be utilized to resolve the compounds of the present disclosure into their optical enantiomers, for example, by fractional crystallization of salts formed with optically active acids such as tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O'-p-toluoyl tartaric acid, mandelic acid, malic acid, or camphor-10-sulfonic acid. Furthermore, racemic compounds or racemic intermediates of the present disclosure can be resolved by chiral chromatography, for example, high pressure liquid chromatography (HPLC) using a chiral adsorbent. Any resulting mixture of stereoisomers can be separated into pure or substantially pure geometric or optical isomers, diastereomers, racemates, based on physicochemical differences of the constituents, for example, by chromatography and / or fractional crystallization, and all such compounds and stereoisomers are included within the scope of the present invention.

[0123] In the present invention, the pharmaceutically acceptable salt refers to a salt or complex of chemical formula 1 having desirable biological activity. Examples of such salts include, but are not limited to, acid addition salts formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, etc.), and acid salts formed with acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, fumaric acid, maleic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalene sulfonic acid, naphthalene disulfonic acid, and poly-galacturonic acid. and salts formed with organic acids such as . The compounds may also be administered as pharmaceutically acceptable quaternary salts known to those skilled in the art, particularly chlorides, bromides, iodides, -O-alkyls, toluenesulfonates, methylsulfonates, sulfonates, phosphates, or carboxylates (e.g., benzoates, succinates, acetates, glycolates, maleates, malates, fumarates, citrates, tartrates, ascorbates, cinnamoates, mandeloates, and diphenylacetates).

[0124] The acid addition salt according to the present invention can be prepared by a conventional method, for example, by dissolving the derivative of chemical formula 1 in an organic solvent such as methanol, ethanol, acetone, dichloromethane, acetonitrile, etc., adding an organic acid or inorganic acid, filtering and drying the resulting precipitate, or by distilling the solvent and an excess acid under reduced pressure, drying, and crystallizing in the presence of an organic solvent.

[0125] Additionally, pharmaceutically acceptable metal salts can be prepared using bases. Alkali metal or alkaline earth metal salts can be obtained, for example, by dissolving a compound in an excess alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering out the undissolved compound salt, and evaporating and drying the filtrate. Among the metal salts, sodium, potassium, or calcium salts are pharmaceutically suitable. Furthermore, the corresponding salts can be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (e.g., silver nitrate).

[0126] The present invention relates to a pharmaceutical composition characterized in that it prevents or treats cancer using a 4-chromanone derivative compound.

[0127] The above solid cancers include brain cancer, brain tumor, benign astrocytoma, malignant astrocytoma, pituitary adenoma, meningioma, brain lymphoma, oligodendroglioma, intracranial tumor, ependymoma, brainstem tumor, head and neck tumor, glioma, glioblastoma, laryngeal cancer, oropharyngeal cancer, nasal cancer, nasopharyngeal cancer, salivary gland cancer, hypopharyngeal cancer, tonsil cancer, thyroid cancer, oral cancer, esophageal cancer, eye cancer, thoracic tumor, small cell lung cancer, non-small cell lung cancer, thymic cancer, lung adenocarcinoma, lung cancer, lung squamous cell carcinoma, pleural cancer, mediastinal tumor, breast cancer, male breast cancer, abdominal tumor, stomach cancer, gastric mastoid tumor, liver cancer, hepatoblastoma, gallbladder cancer, biliary tract cancer, pancreatic cancer, small intestine cancer, colon cancer, colon cancer, rectal cancer, duodenal cancer, anal cancer, bladder cancer, kidney cancer, renal pelvis cancer, heart cancer, peritoneal cancer. It may be selected from the group consisting of adrenal cancer, spinal cord cancer, bone cancer, genital tumor, penile cancer, prostate cancer, female genital tumor, cervical cancer, endometrial cancer, ovarian cancer, uterine sarcoma, vaginal cancer, female external genital cancer, female urethral cancer, or skin cancer, but is not particularly limited thereto.

[0128] In addition, the blood cancer may be selected from the group consisting of acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, childhood lymphoma, malignant lymphoma, multiple myeloma, or aplastic anemia, but is not particularly limited thereto.

[0129] The pharmaceutical composition according to the present invention can be formulated into a suitable form together with a pharmaceutically acceptable carrier commonly used. "Pharmaceutically acceptable" refers to a composition that is physiologically tolerable and does not typically cause allergic reactions or similar reactions such as gastrointestinal disorders or dizziness when administered to humans. In addition, the composition can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injectable solutions, each according to a conventional method.

[0130] Carriers, excipients and diluents that may be included in the above composition include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl parahydroxybenzoate, propyl parahydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, the composition is prepared using diluents or excipients such as commonly used fillers, stabilizers, binders, disintegrants and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations are prepared by mixing the compound of the present invention with at least one excipient, such as starch, microcrystalline cellulose, sucrose or lactose, low-substituted hydroxypropyl cellulose, hypromellose, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, oral solutions, emulsions, syrups, etc., and in addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, flavoring agents, preservatives, etc. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases include witepsol, macrogol, Tween 61, cocoa butter, laurin, glycerol, and gelatin.In order to formulate a formulation for parenteral administration, the compound of the above chemical formula 1 or a pharmaceutically acceptable salt thereof is mixed in water together with sterilized or preservatives, stabilizers, wetting agents or emulsifying promoters, salts or buffers for osmotic pressure control, and other therapeutically useful substances to prepare a solution or suspension, which can be prepared in an ampoule or vial unit dosage form.

[0131] The pharmaceutical composition comprising the compound of chemical formula 1 disclosed in the present invention as an active ingredient can be administered to mammals such as mice, livestock, and humans by various routes. All modes of administration are conceivable, and for example, it can be administered orally, rectally, or by intravenous, intramuscular, subcutaneous, intrauterine, or intracerebrovascular injection. The dosage will vary depending on the age, sex, and body weight of the subject to be treated, the specific disease or pathological condition to be treated, the severity of the disease or pathological condition, the time of administration, the route of administration, the absorption, distribution, and excretion rates of the drug, the types of other drugs used, and the judgment of the prescriber. Determination of the dosage based on these factors is within the level of those skilled in the art, and the dosage generally ranges from 0.01 mg / kg / day to approximately 2000 mg / kg / day. A more preferred dosage is 1 mg / kg / day to 500 mg / kg / day. The dosage can be administered once a day or divided into several doses. The above dosage does not limit the scope of the present invention in any way.

[0132] In addition, the pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, hormone therapy, chemotherapy, and biological response modifiers for the prevention or treatment of cancer.

[0133] The present invention relates to an anticancer pharmaceutical composition containing a novel 4-chromanone derivative compound as an active ingredient and a method for producing the same. The composition containing the 4-chromanone derivative compound as an active ingredient can be usefully used as a composition for preventing or treating cancer through excellent MLL1 HMT inhibitory activity and WDR5 decomposition activity.

[0134] Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. Rather, the content presented herein is intended to be thorough and complete, and to fully convey the spirit of the present invention to those skilled in the art.

[0135] <Example 1. Synthesis of compound and confirmation of physicochemical properties>

[0136] The synthesis process of compounds 1 to 33 of the present invention is as follows.

[0137] Compound 1. tert-Butyl (1-((3-(4-chloro-3-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)benzyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate

[0138]

[0139] Step 1) Preparation of Methyl 2-(2-chloro-5-formylphenoxy)acetate (Compound 1-1)

[0140] To a solution of 4-chloro-3-hydroxybenzaldehyde (CAS NO. 56962-12-0) (3.0 g, 19.160 mmol) in DMF (25 mL) at 0°C were added K2CO3 (5.296 g, 38.320 mmol) and methyl bromoacetate (CAS NO. 96-32-2) (1.8 mL, 19.160 mmol). The resulting mixture was stirred at 60°C for 2 h. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate, and the organic phase was washed with water, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by MPLC (ethyl acetate:n-heptane = 1:5 to 1:2) to obtain compound 1-1 (4.166 g, 95%).

[0141] 1 H NMR (400 MHz, CDCl3) δ 9.93 (d,J= 0.8 Hz, 1H), 7.59 (d,J= 8.0 Hz, 1H), 7.46 (ddd,J= 8.0, 1.7, 0.8 Hz, 1H), 7.33 (d,J= 1.7 Hz, 1H), 4.81 (s, 2H), 3.83 (d,J= 0.8 Hz, 2H), 1.57 (d,J= 0.8 Hz, 3H). ESI-MS m / z 229.1 (M+H) +

[0142] Step 2) Preparation of Methyl (E)-2-(5-((8-bromo-6-(bromomethyl)-4-oxochroman-3-ylidene)methyl)-2-chlorophenoxy) acetate (Compound 1-2)

[0143] To a solution of 8-bromo-6-(bromomethyl)chroman-4-one (2.799 g, 8.747 mmol) in toluene (25 mL) were added compound 1-1 (3.0 g, 13.12 mmol) and p-toluene sulfonic acid (151 mg, 0.875 mmol). The reaction mixture was refluxed for 24 h. After cooling to ambient temperature, the resulting residue was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate:n-heptane=1:5) to give compound 1-2 (2.5 g, 54%).

[0144] 1 H NMR (400 MHz, CDCl3) δ 7.99 (d,J= 2.3 Hz, 1H), 7.84 - 7.77 (m, 2H), 7.48 (d,J= 8.2 Hz, 1H), 6.89 (d,J= 8.7 Hz, 1H), 6.78 (d,J= 1.9 Hz, 1H), 5.41 (d,J= 2.0 Hz, 2H), 4.76 (s, 2H), 4.46 (s, 2H), 3.85 (s, 3H).

[0145] Step 3) Preparation of Methyl 2-(5-((8-bromo-6-(bromomethyl)-4-oxochroman-3-yl)methyl)-2-chlorophenoxy)acetate (Compound 1-3)

[0146] To a mixture of compounds 1-2 (1.957 g, 3.688 mmol) in EtOAc (50 mL) was added PtO2 (84 mg, 0.369 mmol) at room temperature. The reaction mixture was stirred at room temperature for 15 h under a H2 atmosphere (balloon pressure). The catalyst was removed by filtration through a pad of Celite and washed with EtOAc. The filtrate was concentrated and purified by MPLC (CH2Cl2:n-heptane = 3:1 to 10:1) to give compound 1-3 (1.316 g, 68%).

[0147] 1 H NMR (400 MHz, CDCl3) δ 7.88 (d,J= 2.3 Hz, 1H), 7.80 (d,J= 2.3 Hz, 1H), 7.33 (d,J= 8.1 Hz, 1H), 6.82 (dd,J= 8.1, 1.9 Hz, 1H), 6.72 (d,J= 1.9 Hz, 1H), 4.73 (s, 2H), 4.51 (dd,J= 11.6, 4.4 Hz, 1H), 4.43 (s, 2H), 4.26 (dd,J= 11.6, 8.9 Hz, 1H), 3.83 (s, 3H), 3.20 (dd,J= 14.1, 4.8 Hz, 1H), 2.94 (tt,J= 9.1, 4.6 Hz, 1H), 2.72 (dd,J= 14.1, 9.7 Hz, 1H).

[0148] Step 4) Preparation of Methyl 2-(5-((8-bromo-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-chlorophenoxy)acetate (Compound 1-4)

[0149] Compound 1-3 (1316 mg, 2.473 mmol), 1-methyl-1,3-dihydro-2H-imidazol-2-imine (360 mg, 3.710 mmol), DIEA (1.29 mL, 7.241 mmol), KI (410 mg, 2.473 mmol), and MeCN (20 mL) were heated at 60°C for 2 h. After cooling to ambient temperature, the reaction mixture was diluted with ethyl acetate, and the organic phase was washed with water, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, 2% to 10%) to give compound 1-4 (860 mg, 63%).

[0150] 1H NMR (400 MHz, CDCl3) δ 7.92 (d,J= 2.3 Hz, 1H), 7.81 (d,J= 2.2 Hz, 1H), 7.62 (s, 1H), 7.31 (d,J= 8.1 Hz, 1H), 6.81 (dd,J= 8.2, 1.8 Hz, 1H), 6.73 (d,J= 1.9 Hz, 1H), 6.63 (dd,J= 15.8, 2.5 Hz, 2H), 5.46 (s, 2H), 4.74 (s, 2H), 4.50 (dd,J= 11.7, 4.5 Hz, 1H), 4.26 (dd,J= 11.8, 9.0 Hz, 1H), 3.82 (d,J= 6.4 Hz, 6H), 3.16 (dd,J= 14.1, 5.1 Hz, 1H), 2.96 (tt,J= 9.4, 4.8 Hz, 1H), 2.69 (dd,J= 14.1, 9.4 Hz, 1H). ESI-MS m / z 550.1 (M+H) +

[0151] Step 5) Preparation of Methyl 2-(5-((8-bromo-6-((2-((tert-butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-chlorophenoxy)acetate (Compound 1-5)

[0152] A solution of compound 1-4 (860 mg, 1.568 mmol), (Boc)2O (2.4 mL, 3.136 mmol), and THF (20 mL) was stirred at room temperature. After 10 min, DMAP (96 mg, 0.784 mmol) was added and stirred for 15 h. The reaction mixture was diluted with CH2Cl2, and the organic phase was washed with water, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2 = 1:50 to 1:10) to give protected compound 1-5 (448 mg, 44%).

[0153] 1H NMR (400 MHz, CDCl3) δ 7.78 - 7.70 (m, 2H), 7.34 (d,J= 8.1 Hz, 1H), 6.84 (dd,J= 8.1, 1.9 Hz, 1H), 6.73 (d,J= 1.9 Hz, 1H), 6.58 (d,J= 2.5 Hz, 1H), 6.48 (d,J= 2.5 Hz, 1H), 5.04 (s, 2H), 4.74 (s, 2H), 4.51 (dd,J= 11.7, 4.4 Hz, 1H), 4.26 (dd,J= 11.7, 8.7 Hz, 1H), 3.85 (s, 3H), 3.51 (s, 3H), 3.20 (dd,J= 14.1, 4.8 Hz, 1H), 2.93 (dt,J= 9.1, 4.6 Hz, 1H), 2.72 (dd,J= 14.1, 9.6 Hz, 1H), 1.54 (s, 9H). ESI-MS m / z 650.1 (M+H) +

[0154] 단계 6)Methyl 2-(5-((6-((2-((tert-butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-chlorophenoxy)acetate (화합물 1-6)의 제조

[0155] To a solution of compound 1-5 (269 mg, 0.414 mmol) in 1,4-dioxane / H2O (10:1, 5.5 mL) at room temperature were added Cs2CO3 (270 mg, 0.828 mmol) and Pd(amphos)Cl2 (30 mg, 0.042 mmol). After 10 min, (1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)boronic acid (129 mg, 0.621 mmol) was added and heated at 100 °C for 2 h. After cooling to room temperature, 1,4-dioxane was removed under reduced pressure, and the resulting residue was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, 2% to 10%) to give compound 1-6 (237 mg, 78%).

[0156] 1 H NMR (400 MHz, CDCl3) δ 7.84 (d,J= 2.3 Hz, 1H), 7.59 (s, 1H), 7.46 (s, 1H), 7.33 (d,J= 8.0 Hz, 1H), 6.83 (dd,J= 8.1, 1.9 Hz, 1H), 6.73 (d,J= 1.9 Hz, 1H), 6.58 (d,J= 29.7 Hz, 2H), 5.09 (s, 2H), 4.72 (s, 2H), 4.37 (dd,J= 11.7, 4.1 Hz, 1H), 4.26 (q,J= 7.4 Hz, 2H), 4.17 (dd,J= 11.5, 7.8 Hz, 1H), 3.81 (s, 3H), 3.54 (s, 3H), 3.19 (dd,J= 13.9, 4.4 Hz, 1H), 2.87 (d,J= 9.4 Hz, 1H), 2.73 (dd,J= 13.9, 10.0 Hz, 1H), 1.59 (d,J= 7.2 Hz, 3H), 1.51 (s, 9H). ESI-MS m / z 732.2 (M+H) +

[0157] Step 7) 2-(5-((6-((2-((tert-Butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-chlorophenoxy)acetic acid (compound 1-7) Preparation

[0158] To a solution of compound 1-6 (122 mg, 0.166 mmol) was added LiOH (6 mg, 0.249 mmol) in MeOH / H2O (2 / 0.2 mL) at 0°C. The reaction mixture was stirred at room temperature for 2 h and evaporated. The reaction mixture was cooled to 0°C and the pH was adjusted to 3–4 by adding 1 N HCl solution. The reaction mixture was diluted with ethyl acetate and water, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was used in the next step without further purification (97 mg, 81%).

[0159] 1 H NMR (400 MHz, MeOD) δ 7.91 - 7.83 (m, 2H), 7.57 (dd,J= 17.0, 2.4 Hz, 2H), 7.47 (d,J= 2.5 Hz, 1H), 7.27 (d,J= 8.1 Hz, 1H), 6.81 (dd,J= 8.1, 1.9 Hz, 1H), 6.76 (d,J= 2.0 Hz, 1H), 5.32 (s, 2H), 4.54 (s, 2H), 4.46 (dd,J= 11.7, 4.2 Hz, 1H), 4.28 (h,J= 8.2, 7.8 Hz, 3H), 3.74 (s, 3H), 3.12 (dd,J= 13.7, 5.7 Hz, 1H), 3.01 (q,J= 7.0, 5.3 Hz, 1H), 2.83 (dd,J= 13.7, 8.4 Hz, 1H), 1.53 (t,J= 7.4 Hz, 3H), 1.45 (s, 9H). ESI-MS m / z 718.3 (M+H)+

[0160] Step 8)tert-butyl (1-((3-(4-chloro-3-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino) -2-oxoethoxy)benzyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate Preparation of (Compound 1)

[0161] To a solution of compounds 1-7 (39.5 mg, 0.055 mmol) in DMF (1 mL) were added HATU (42 mg, 0.11 mmol) and DIEA (48 μL, 0.275 mmol) at room temperature. After stirring for 30 min, the reaction mixture was added (S,R,S)-AHPC (26 mg, 0.060 mmol) in DMF (0.5 mL), and the mixture was stirred at room temperature for 15 h. The reaction mixture was quenched with H2O, brine, and ethyl acetate at 0 °C, extracted with ethyl acetate (x3), washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2: = 1:50 to 1:10) to give compound 1 (22 mg, 36%).

[0162] 1H NMR (400 MHz, CDCl3) δ 8.68 (s, 1H), 8.05 (s, 1H), 7.59 (d,J= 1.1 Hz, 1H), 7.42 (s, 1H), 7.38 - 7.30 (m, 5H), 7.21 (d,J= 8.0 Hz, 1H), 6.80 (d,J= 2.5 Hz, 1H), 6.71 (dd,J= 8.0, 2.0 Hz, 1H), 6.60 (d,J= 2.5 Hz, 1H), 6.09 (d,J= 2.0 Hz, 1H), 5.22 - 5.11 (m, 2H), 4.98 (d,J=16.9 Hz, 1H), 4.78 (t,J= 7.9 Hz, 1H), 4.69 (d,J= 14.4 Hz, 1H), 4.65 - 4.47 (m, 5H), 4.39 - 4.24 (m, 3H), 4.21 - 4.02 (m, 4H), 3.59 - 3.53 (m, 1H), 3.49 (s, 3H), 3.05 (t,J= 13.0 Hz, 1H), 2.95 (s, 1H), 2.84 (dd,J= 13.5, 4.9 Hz, 1H), 2.71 - 2.63 (m, 1H), 2.63 - 2.57 (m, 1H), 2.52 (s, 3H), 2.17 - 2.08 (m, 1H), 1.59 (t,J= 7.3 Hz, 3H), 1.41 (s, 9H), 0.91 (s, 9H). ESI-MS m / z 1152 (M+Na) +

[0163] Compound 2. (2S,4R)-1-((2S)-2-(2-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride

[0164]

[0165] To a solution of compound 1 (5 mg, 0.004 mmol) in anhydrous CH2Cl2 (2 mL) was added dropwise 4N-HCl in dioxane (0.5 mL) at 0°C. The resulting mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure. The resulting solid was filtered, rinsed with diethyl ether (2 mL x 8), and concentrated in vacuo to obtain compound 2 as an HCl salt (3.0 mg, 64%).

[0166] 1 H NMR (400 MHz, MeOD) δ 9.49 (s, 1H), 7.83 (s, 1H), 7.71 (s, 1H), 7.65 (s, 1H), 7.58 (s, 1H), 7.48 - 7.45 (m, 4H), 7.39 (s, 1H), 7.22 (d,J= 8.1 Hz, 1H), 6.95 (d,J= 8.0 Hz, 1H), 6.07 (d,J= 1.9 Hz, 1H), 4.66 (d,J= 8.8 Hz, 2H), 4.51 (s, 3H), 4.39 (s, 1H), 4.25 (d,J= 7.3 Hz, 1H), 4.04 (s, 2H), 3.81 (d,J= 11.4 Hz, 2H), 3.74 (s, 3H), 3.70 (d,J= 3.4 Hz, 2H), 3.67 (d,J= 3.4 Hz, 1H), 3.64 (d,J= 5.3 Hz, 2H), 3.05 (dd,J= 13.5, 5.4 Hz, 1H), 2.99 - 2.90 (m, 1H), 2.75 (s, 1H), 2.52 (s, 3H), 2.28 (d,J= 5.5 Hz, 1H), 2.07 (d,J= 3.8 Hz, 1H), 1.51 (t,J= 7.3 Hz, 3H), 1.11 (s, 9H). ESI-MS m / z 1052 (M+Na) +

[0167] Compound 3. 2-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)-N-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)acetamide hydrochloride

[0168]

[0169] Step 1) tert-butyl (1-((3-(4-chloro-3-(2-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)amino)-2-oxoethoxy)benzyl)-8- (1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate Preparation of (Compound 3-1)

[0170] To a solution of compounds 1-7 (20 mg, 0.0278 mmol) in DMF (1 mL) were added HATU (16 mg, 0.0417 mmol) and DIEA (50 μL, 0.278 mmol) at room temperature. After stirring for 30 min, 5-(4-aminopiperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (CRBN ligand) (12 mg, 0.0334 mmol) in DMF (1 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 15 h. The reaction mixture was quenched with H2O, brine, and ethyl acetate at 0 °C, extracted with ethyl acetate (x3), washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2: = 1:50 to 1:10) to obtain compound 3-1 (4.4 mg, 15%).

[0171] 1 H NMR (400 MHz, CDCl3) δ 8.07 - 7.97 (m, 1H), 7.87 (s, 1H), 7.72 (d,J= 8.5 Hz, 1H), 7.64 (s, 1H), 7.48 (s, 1H), 7.36 - 7.31 (m, 2H), 7.10 (dd,J= 9.0, 2.3 Hz, 1H), 6.86 (d,J= 9.4 Hz, 2H), 6.78 (s, 2H), 5.13 (s, 2H), 4.97 (dd,J= 9.5, 5.2 Hz, 1H), 4.53 (s, 2H), 4.44 - 4.38 (m, 1H), 4.24 (dd,J= 14.6, 8.2 Hz, 5H), 3.91 (d,J= 13.4 Hz, 2H), 3.65 (s, 3H), 3.19 (d,J= 11.6 Hz, 3H), 2.85 (dt,J= 32.4, 10.3 Hz, 6H), 2.14 (d,J= 10.3 Hz, 2H), 1.66 (s, 2H), 1.57 (d,J= 7.3 Hz, 3H), 1.53 (s, 9H). ESI-MS m / z 1056(M+H) +

[0172] 단계 2) 2-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)-N-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)acetamidehydrochloride (화합물 3)의 제조

[0173] To a solution of compound 3-1 (4.4 mg, 0.004 mmol) in anhydrous CH2Cl2 (1 mL) at 0°C was added dropwise 4 N-HCl dissolved in 1,4-dioxane (0.5 mL). The resulting mixture was stirred at room temperature for 2 h and concentrated under reduced pressure. The resulting solid was filtered, rinsed with diethyl ether (2 mL x 8), and concentrated in vacuo to obtain compound 3 as an HCl salt (2.5 mg, 61%).

[0174] 1 H NMR (400 MHz, MeOD) δ 7.95 - 7.83 (m, 2H), 7.68 (d,J= 8.6 Hz, 1H), 7.48 - 7.40 (m, 1H), 7.33 (d,J= 7.9 Hz, 2H), 7.23 (d,J= 8.8 Hz, 1H), 7.02 - 6.83 (m, 4H), 5.13 (s, 2H), 5.11 - 5.03 (m, 1H), 4.60 (d,J= 5.0 Hz, 2H), 4.52 - 4.40 (m, 1H), 4.27 (q,J= 7.6 Hz, 3H), 4.07 (s, 1H), 3.94 (d,J= 13.6 Hz, 2H), 3.60 (t,J= 4.8 Hz, 1H), 3.56 (d,J= 3.6 Hz, 3H), 3.27 - 2.98 (m, 4H), 2.90 - 2.72 (m, 3H), 2.13 (s, 1H), 2.03 (t,J= 10.2 Hz, 2H), 1.64 (t,J= 11.6 Hz, 2H), 1.51 (t,J= 7.4 Hz, 3H). ESI-MS m / z 956.4 (M+H) +

[0175] Compound 4. (2S,4R)-N-(2-(3-(2-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)acetamido)propoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide hydrochloride

[0176]

[0177] Step 1) Preparation of tert-butyl (3-(2-(((2S,4R)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)propyl)carbamate (Compound 4-1)

[0178] To a mixture of (2S,4R)-4-hydroxy-N-[[2-hydroxy-4-(4-methylthiazol-5-yl)phenyl]methyl]-1-[(2S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl]pyrrolidine-2-carboxamide (CAS NO. 1448188-69-9) (30 mg, 0.055 mmol) and tert-butyl (3-iodopropyl)carbamate (CAS NO. 167479-01-8) (47 mg, 0.164 mmol) in N,N-dimethylformamide (2 mL) was added Cs2CO3 (54 mg, 0.164 mmol). After stirring at room temperature for 2 h, the reaction mixture was diluted with EtOAc (10 mL), washed with water (5 x 10 mL), and the organic phase was dried (Na2SO4) and evaporated under vacuum. The crude product was purified by flash column chromatography. Silica gel (CH2Cl2:MeOH / 1% to 5%) gave 38 mg of the product (quantitative).

[0179] 1H NMR (400 MHz, CDCl3) δ 8.72 (s, 1H), 7.80 - 7.67 (m, 1H), 7.49 (d,J= 8.1 Hz, 2H), 7.40 (d,J= 7.3 Hz, 2H), 7.34 (d,J= 7.6 Hz, 1H), 6.97 (d,J= 7.6 Hz, 1H), 6.89 (s, 1H), 5.46 (s, 1H), 4.76 (d,J= 10.9 Hz, 1H), 4.72 - 4.62 (m, 2H), 4.57 - 4.39 (m, 4H), 4.38 - 4.28 (m, 1H), 4.11 (d,J= 3.0 Hz, 2H), 3.75 - 3.62 (m, 1H), 3.42 (t,J= 7.1 Hz, 2H), 2.54 (s, 4H), 2.40 (d,J= 14.9 Hz, 1H), 2.09 (d,J= 10.0 Hz, 3H), 1.40 (s, 9H), 0.84 (d,J= 6.0 Hz, 6H). ESI-MS m / z 706.4 (M+H) +

[0180] Step 2) Preparation of (2S,4R)-N-(2-(3-aminopropoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide (compound 4-2)

[0181] Compound 4-1 (38 mg, 0.0538 mmol) was suspended in CH2Cl2 (1 mL) under a nitrogen atmosphere. TFA (0.5 mL) was added at 0°C, and the reaction mixture was stirred at room temperature for 1 h and concentrated under reduced pressure. The residue was used in the next step without further purification (38 mg, quant.).

[0182] 1H NMR (400 MHz, MeOD) δ 9.02 (d,J= 30.7 Hz, 1H), 7.81 (dt,J= 7.7, 1.0 Hz, 1H), 7.69 - 7.57 (m, 2H), 7.53 (t,J= 7.3 Hz, 1H), 7.47 (d,J= 7.7 Hz, 1H), 7.14 - 7.05 (m, 2H), 4.86 (d,J= 10.6 Hz, 1H), 4.63 (d,J= 17.9 Hz, 1H), 4.58 - 4.47 (m, 4H), 4.42 (d,J= 15.4 Hz, 1H), 4.25 (t,J= 5.6 Hz, 2H), 4.01 (d,J= 11.1 Hz, 1H), 3.91 (dd,J= 11.1, 3.9 Hz, 1H), 3.27 (d,J= 7.3 Hz, 2H), 2.53 (q,J= 1.2 Hz, 3H), 2.45 (dt,J= 10.9, 6.6 Hz, 1H), 2.30 - 2.20 (m, 3H), 2.09 (ddd,J= 13.3, 9.1, 4.4 Hz, 1H), 1.02 (d,J= 6.5 Hz, 3H), 0.85 (d,J= 6.7 Hz, 3H). ESI-MS m / z 606.2(M+H) +

[0183] 단계 3) tert-Butyl (1-((3-(4-chloro-3-(2-((3-(2-(((2S,4R)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)propyl)amino)-2-oxoethoxy)benzyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate (화합물 4-3)의 제조

[0184] To a solution of compound 1-7 (13 mg, 0.018 mmol) in DMF (1 mL) were added EDCI (6 mg, 0.036 mmol), HOBt (6 mg, 0.036 mmol), compound 4-2 (VHL-3C-NH2, 14 mg, 0.0198 mmol), and DIEA (32 uL, 0.18 mmol) at 0 °C. The mixture was stirred at room temperature for 20 h. The reaction mixture was quenched with H2O, brine, and ethyl acetate at 0 °C, extracted with ethyl acetate (x3), washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2:=1:20) to give compound 4-3 (14.3 mg, 61%).

[0185] 1H NMR (400 MHz, MeOD) δ 9.41 (s, 1H), 7.85 (s, 2H), 7.78 (d,J= 7.6 Hz, 1H), 7.68 - 7.55 (m, 4H), 7.48 (d,J= 6.7 Hz, 3H), 7.27 (d,J= 7.2 Hz, 1H), 7.09 (d,J= 7.1 Hz, 1H), 7.04 (s, 1H), 6.95 - 6.90 (m, 1H), 6.86 - 6.79 (m, 1H), 5.34 (s, 2H), 4.65 - 4.55 (m, 3H), 4.52 (dd,J= 15.1, 8.3 Hz, 2H), 4.44 (d,J= 15.7 Hz, 4H), 4.27 (s, 2H), 4.20 (s, 1H), 4.13 (d,J= 5.8 Hz, 2H), 3.96 (d,J= 10.8 Hz, 1H), 3.88 (d,J= 11.1 Hz, 1H), 3.76 (s, 3H), 3.11 (d,J= 13.4 Hz, 1H), 3.01 (s, 1H), 2.92 (d,J= 9.9 Hz, 2H), 2.76 (s, 1H), 2.56 (s, 3H), 2.43 (s, 1H), 2.20 (s, 3H), 2.10 (s, 1H), 1.51 (s, 3H), 1.43 (s, 9H), 1.02 (d,J= 6.3 Hz, 3H), 0.82 (d,J= 6.1 Hz, 3H). ESI-MS m / z 1305.4(M+H) +

[0186] Step 4) (2S,4R)-N-(2-(3-(2-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3 -yl)methyl)phenoxy)acetamido)propoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide Preparation of hydrochloride (compound 4)

[0187] To a solution of compound 4-3 (14.3 mg, 11 μmol) in anhydrous CH2Cl2 (1 mL) was added dropwise 4 N-HCl in dioxane (0.5 mL) at 0°C. The resulting mixture was stirred at room temperature for 15 h. The reaction mixture was concentrated under reduced pressure. The resulting solid was filtered, rinsed with diethyl ether (2 mL x 8), and concentrated in vacuo to give compound 4 as an HCl salt (7.1 mg, 52%).

[0188] 1H NMR (400 MHz, MeOD) δ 9.64 (s, 1H), 7.91 (s, 1H), 7.83 - 7.75 (m, 2H), 7.59 (dt,J= 16.0, 7.3 Hz, 2H), 7.50 (d,J= 6.8 Hz, 2H), 7.43 (s, 1H), 7.27 (d,J= 6.9 Hz, 1H), 7.08 (d,J= 20.2 Hz, 2H), 6.90 (d,J= 40.2 Hz, 4H), 5.13 (s, 2H), 4.83 (s, 1H), 4.64 - 4.40 (m, 9H), 4.27 (s, 3H), 4.18 - 4.09 (m, 2H), 3.96 (d,J= 10.6 Hz, 1H), 3.88 (t,J= 6.1 Hz, 1H), 3.55 (s, 3H), 3.15 (s, 1H), 3.02 (s, 1H), 2.92 (d,J= 16.3 Hz, 2H), 2.73 (d,J= 14.0 Hz, 1H), 2.59 (s, 3H), 2.43 (s, 1H), 2.09 (d,J= 26.1 Hz, 4H), 1.51 (s, 3H), 1.02 (d,J= 5.9 Hz, 3H), 0.82 (d,J= 5.8 Hz, 3H). ESI-MS m / z 1206.3 (M+H) +

[0189] Compound 5. (2S,4R)-1-((2S)-2-(5-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)pentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride

[0190]

[0191]

[0192] Step 1) Preparation of Ethyl 5-(2-chloro-5-formylphenoxy)pentanoate (Compound 5-1)

[0193] A solution of 4-chloro-3-hydroxybenzaldehyde (CAS NO. 56962-12-0) (500 mg, 3.193 mmol), ethyl 5-bromovalerate (CAS NO. 14660-52-7) (0.6 mL, 3.832 mmol), K2CO3 (662 mg, 4.789 mmol), and DMF (5 mL) was stirred at 50°C for 15 h. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate, and the organic phase was washed with water, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by MPLC (ethyl acetate:n-heptane = 1:5 to 1:2) to obtain compound 5-1 (920 mg, quantitative).

[0194] 1 H NMR (400 MHz, CDCl3) δ 9.93 (d,J= 0.6 Hz, 1H), 7.54 (d,J= 7.9 Hz, 1H), 7.45 - 7.35 (m, 2H), 4.18 - 4.08 (m, 4H), 2.42 (t,J= 7.1 Hz, 2H), 1.98 - 1.82 (m, 4H), 1.26 (t,J= 7.1 Hz, 3H). ESI-MS m / z 285.1 (M+H) +

[0195] Step 2) Preparation of Ethyl (E)-5-(5-((8-bromo-6-(bromomethyl)-4-oxochroman-3-ylidene)methyl)-2-Chlorophenoxy)pentanoate (Compound 5-2)

[0196] To a solution of compound 5-1 (1072 mg, 3.35 mmol) in toluene (20 mL) were added benzaldehyde (893 mg, 3.13 mmol) and p-toluene sulfonic acid (123 mg, 0.714 mmol). The reaction mixture was refluxed for 17 h. After cooling to ambient temperature, the resulting residue was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by MPLC (ethyl acetate:n-heptane = 1:5 to 1:2) to obtain compound 5-2 (958 mg, 52%).

[0197] 1 H NMR (400 MHz, CDCl3) δ 7.98 (d,J= 2.3 Hz, 1H), 7.81 (t,J= 1.8 Hz, 2H), 7.43 (d,J= 8.1 Hz, 1H), 6.87 - 6.77 (m, 2H), 5.45 (d,J= 1.9 Hz, 2H), 4.46 (s, 2H), 4.14 (q,J= 7.1 Hz, 2H), 4.07 (t,J= 5.7 Hz, 2H), 2.43 (t,J= 7.0 Hz, 2H), 1.97 - 1.83 (m, 4H), 1.26 (t,J= 7.1 Hz, 3H). ESI-MS m / z 586.9 (M+H) +

[0198] Step 3) Preparation of Ethyl 5-(5-((8-bromo-6-(bromomethyl)-4-oxochroman-3-yl)methyl)-2-chlorophenoxy)pentanoate (Compound 5-3)

[0199] To a mixture of compound 5-2 (912 mg, 1.554 mmol) in EtOAc (17 mL) was added PtO2 (35.5 mg, 0.155 mmol) at room temperature. The reaction mixture was stirred at room temperature for 17 h under a H2 atmosphere (balloon pressure). The catalyst was removed by filtration through a pad of Celite and washed with EtOAc. The filtrate was concentrated and purified by MPLC (ethyl acetate:n-heptane = 1:10 to 1:2) to obtain compound 5-3 (711 mg, 78%).

[0200] 1 H NMR (400 MHz, CDCl3) δ 7.89 (d,J= 2.3 Hz, 1H), 7.80 (d,J= 2.3 Hz, 1H), 7.29 (d,J= 7.9 Hz, 1H), 6.80 - 6.71 (m, 2H), 4.52 (dd,J= 11.6, 4.5 Hz, 1H), 4.43 (s, 2H), 4.27 (dd,J= 11.6, 9.1 Hz, 1H), 4.13 (q,J= 7.1 Hz, 2H), 4.04 (t,J= 5.8 Hz, 2H), 3.23 (dd,J= 14.1, 4.8 Hz, 1H), 2.97 (dt,J= 9.4, 4.7 Hz, 1H), 2.70 (dd,J= 14.1, 9.7 Hz, 1H), 2.42 (td,J= 7.0, 1.6 Hz, 2H), 1.91 - 1.86 (m, 4H), 1.26 (s, 3H). ESI-MS m / z 588.9 (M+H) +

[0201] Step 4) Preparation of Ethyl 5-(5-((8-bromo-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-chlorophenoxy)pentanoate (Compound 5-4)

[0202] A solution of compound 5-3 (691 mg, 1.173 mmol), 1-methyl-1,3-dihydro-2H-imidazol-2-imine (342 mg, 3.52 mmol), DIEA (610 uL, 3.52 mmol), KI (114 mg, 1.173 mmol), and ACN (13 mL) was heated at 60°C for 2 h. After cooling to ambient temperature, the reaction mixture was diluted with ethyl acetate, and the organic phase was washed with water, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, 2% to 10%) to give compound 5-4 (217 mg, 45%).

[0203] 1 H NMR (400 MHz, CDCl3) δ 7.93 (d,J= 2.3 Hz, 1H), 7.80 (d,J= 2.2 Hz, 1H), 7.29 (s, 1H), 6.78 (d,J= 1.9 Hz, 1H), 6.72 (dd,J= 7.9, 1.9 Hz, 1H), 6.62 (d,J= 2.5 Hz, 1H), 6.56 (d,J= 2.5 Hz, 1H), 5.46 (s, 2H), 4.52 (dd,J= 11.7, 4.5 Hz, 1H), 4.27 (dd,J= 11.7, 9.1 Hz, 1H), 4.13 (dd,J=7.1, 3.0 Hz, 2H), 4.03 (t,J= 5.7 Hz, 2H), 3.82 (s, 3H), 3.20 (dd,J= 14.1, 4.9 Hz, 1H), 2.98 (dt,J= 9.4, 4.6 Hz, 1H), 2.67 (dd,J= 14.1, 9.6 Hz, 1H), 2.42 (t,J= 6.8 Hz, 2H), 1.87 (d,J= 4.7 Hz, 4H), 1.27 (d,J= 2.9 Hz, 3H). ESI-MS m / z 605.9 (M+H) +

[0204] Step 5) Preparation of Ethyl 5-(5-((8-bromo-6-((2-((tert-butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-chlorophenoxy)pentanoate (Compound 5-5)

[0205] A solution of compound 5-4 (690 mg, 1.15 mmol, 1.0 equiv), (Boc)2O (1.05 mL, 1.37 mmol, 1.2 equiv), and THF (10 mL) was stirred at room temperature. After 10 min, DMAP (70 mg, 0.57 mmol, 0.5 equiv) was added and stirred for 15 h. The reaction mixture was diluted with CH2Cl2, and the organic phase was washed with water, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, 2% to 10%) to give protected compound 5-5 (523 mg, 65%).

[0206] 1H NMR (400 MHz, CDCl3) δ 7.74 (d,J= 2.2 Hz, 1H), 7.70 (d,J= 2.3 Hz, 1H), 7.29 (d,J= 8.1 Hz, 1H), 6.77 (d,J= 2.0 Hz, 1H), 6.74 (d,J= 8.0 Hz, 1H), 6.52 (d,J= 2.6 Hz, 1H), 6.41 (d,J= 2.5 Hz, 1H), 4.99 (s, 2H), 4.50 (dd,J= 11.6, 4.3 Hz, 1H), 4.25 (dd,J= 11.7, 9.0 Hz, 1H), 4.13 (q,J= 7.2 Hz, 2H), 4.03 (d,J= 5.9 Hz, 2H), 3.46 (s, 3H), 3.21 (dd,J= 14.1, 4.6 Hz, 1H), 2.94 (dq,J= 9.4, 4.8 Hz, 1H), 2.68 (dd,J= 14.1, 9.9 Hz, 1H), 2.42 (t,J= 6.8 Hz, 2H), 1.85 (s, 4H), 1.58 (s, 3H), 1.53 (s, 9H), 1.26 (d,J= 2.8 Hz, 3H).

[0207] 단계 6) Ethyl 5-(5-((6-((2-((tert-butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-chlorophenoxy)pentanoate (화합물 5-6)의 제조

[0208] Compound 5-5 (520 mg, 0.74 mmol, 1.0 equiv), (1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)boronic acid (229 mg, 1.1 mmol, 1.5 eq), Pd(Amphos)Cl2 (26 mg, 0.037 mmol, 0.05 equiv), and NaOAc (121 mg, 1.5 mmol, 2.0 equiv) were dissolved in H2O:1,4-dioxane (1:10). The reaction mixture was stirred at 90°C for 1 h. The reaction was cooled to room temperature, and the solvent was removed under reduced pressure. The crude product was purified by MPLC to give compound 5-6 (170 mg, 20% yield).

[0209] 1 H NMR (400 MHz, CDCl3) δ 7.84 (d,J= 2.3 Hz, 1H), 7.60 (s, 1H), 7.44 (d,J= 2.4 Hz, 1H), 7.27 (d,J= 8.0 Hz, 1H), 6.80 (d,J= 1.9 Hz, 1H), 6.74 (dd,J= 8.0, 1.9 Hz, 1H), 6.66 (d,J= 2.6 Hz, 1H), 6.58 (d,J= 2.5 Hz, 1H), 5.06 (s, 2H), 4.37 (dd,J= 11.7, 4.3 Hz, 1H), 4.24 (q,J= 7.3 Hz, 2H), 4.22 - 4.17 (m, 1H), 4.13 (q,J= 7.1 Hz, 2H), 4.05 - 4.00 (m, 2H), 3.51 (s, 3H), 3.19 (dd,J= 13.9, 4.6 Hz, 1H), 2.91 (dp,J= 12.8, 4.4 Hz, 1H), 2.70 (dd,J= 14.0, 10.0 Hz, 1H), 2.44 - 2.38 (m, 2H), 1.93 - 1.81 (m, 4H), 1.55 (t,J= 7.3 Hz, 3H), 1.48 (s, 9H), 1.25 (t,J= 7.1 Hz, 3H).

[0210] Step 7) 5-(5-((6-((2-((tert-Butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-chlorophenoxy)pentanoicacid Preparation of (Compound 5-7)

[0211] Compounds 5-6 (130 mg, 0.16 mmol) and NaHCO3 (42 mg, 0.5 mmol, 5.0 equiv) were dissolved in H2O:MeOH = 1:3, and the reaction mixture was heated to 110°C in a microwave for 3 h. After cooling to room temperature, the solvent was removed under reduced pressure. The crude product was diluted with H2O, acidified to pH = 4-5 with 1 N HCl in H2O at 0°C, and extracted with DCM. The combined organic layers were dried over Na2SO4 and concentrated. The crude product was purified by MPLC to obtain compounds 5-7 (57 mg, 44% yield).

[0212] ESI-MS m / z 760.8 (M+H) +

[0213] Step 8) tert-Butyl (1-((3-(4-chloro-3-((5-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5 -oxopentyl)oxy)benzyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate Preparation of (Compound 5-8)

[0214] To a DMF solution of compound 5-7 (40 mg, 0.052 mmol, 1 equiv) were added DIEA (28 μL, 0.156 mmol, 3 equiv) and HATU (40 mg, 0.1 mmol, 2 equiv) and stirred at room temperature. After 1 h, VHL (25 mg, 0.057 mmol, 1 equiv) was added. The reaction mixture was stirred at room temperature overnight. Upon completion of the reaction, the solvent was removed, and the residue was partitioned between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. Compound 5-8 was purified by MPLC (45 mg, 74%).

[0215] ESI-MS m / z 1172.5 (M+H) +

[0216] Step 9) (2S,4R)-1-((2S)-2-(5-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl )-4-oxochroman-3-yl)methyl)phenoxy)pentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide Preparation of hydrochloride (compound 5)

[0217] A solution of compounds 5-8 (20 mg, 0.017 mmol, 1 equiv) dissolved in CH2Cl2 (1.5 mL) was treated with 4 N-HCl in 1,4-dioxane (1 mL) at 0°C. The reaction was stirred at room temperature, and upon completion of the reaction, the solvent was removed to obtain compound 5 (17 mg, 90%).

[0218] ESI-MS m / z 1072.4 (M+H) +

[0219] Compound 6. (2S,4R)-1-((2S)-2-(5-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)pentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride

[0220]

[0221] Step 1) (2S,4R)-1-((2S)-2-(5-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-ox ochroman-3-yl)methyl)phenoxy)pentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide Preparation of (Compound 6-1)

[0222] To a solution of compounds 5-7 (71 mg, 0.093 mmol, 1.0 equiv) in DMF (1 mL) were added HATU (71 mg, 0.187 mmol, 2 equiv) and DIEA (50 μL, 0.280 mmol, 3 equiv) at room temperature. After stirring for 30 min, the reaction mixture was added to (S,R,S)-AHPC-Me·HCl (CAS NO. 1948273-03-7) (50 mg, 0.103 mmol, 1.1 equiv.) in DMF (0.5 mL), and the mixture was stirred at room temperature for 15 h. The reaction mixture was quenched with H2O, brine, and ethyl acetate at 0 °C, extracted with ethyl acetate (x3), washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2= 1:50 to 1:10) to obtain compound 6-1 (99 mg, 90%).

[0223] ESI-MS m / z 1186 (M+H)+

[0224] Step 2) (2S,4R)-1-((2S)-2-(5-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-ox ochroman-3-yl)methyl)phenoxy)pentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide Preparation of hydrochloride (compound 6)

[0225] Compound 6-1 (93 mg, 0.085 mmol) was dissolved in CH2Cl2 (3 mL) and treated with 4 N-HCl in dioxane (1 mL) at 0°C. The reaction was stirred at room temperature. Upon completion of the reaction, the solvent was removed to obtain compound 6 as an HCl salt (20 mg, 24%).

[0226] 1 H NMR (400 MHz, DMSO) δ 8.99 (s, 1H), 8.38 (d,J= 7.9 Hz, 1H), 8.10 (s, 1H), 7.99 (s, 2H), 7.90 - 7.80 (m, 2H), 7.52 (d,J= 2.4 Hz, 1H), 7.44 (d,J= 8.1 Hz, 2H), 7.38 (d,J= 8.1 Hz, 2H), 7.32 (d,J= 8.0 Hz, 1H), 7.15 (d,J= 2.5 Hz, 1H), 7.07 (d,J= 2.5 Hz, 1H), 7.04 (s, 1H), 6.82 - 6.76 (m, 1H), 5.17 - 5.08 (m, 3H), 4.93 (d,J= 7.2 Hz, 1H), 4.53 (d,J= 9.3 Hz, 1H), 4.47 - 4.33 (m, 2H), 4.25 (dt,J= 12.0, 5.8 Hz, 4H), 4.02 (d,J= 6.8 Hz, 2H), 3.60 (s, 2H), 3.46 (s, 3H), 3.24 - 3.09 (m, 3H), 2.67 (t,J= 11.2 Hz, 1H), 2.46 (s, 4H), 2.40 - 2.27 (m, 2H), 2.26 - 2.16 (m, 1H), 2.00 (d,J= 7.9 Hz, 2H), 1.84 - 1.61 (m, 6H), 1.43 (t,J= 7.3 Hz, 3H), 1.38 (d,J= 7.1 Hz, 3H), 1.32 (s, 1H), 0.86 (t,J= 6.7 Hz, 2H).

[0227] Compound 7. 5-(2-chloro-5-((8-(6-fluoro-2-methylpyridin-3-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)-N-(2,6-dioxopiperidin-4-yl)pentanamide hydrochloride

[0228]

[0229] Step 1) Ethyl 5-(5-((6-((2-((tert-butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-8-(6-fluoro-2-methylpyridin-3-yl)-4-oxochroman-3-yl)methyl)-2-chlorophenoxy)pentanoate (Compound 7-1) manufacturing

[0230] To compound 5-5 (600 mg, 0.85 mmol, 1.0 equiv) in 1,4-dioxane / H2O (10:1, 5 mL) at room temperature were added Cs2CO3 (553.8 mg, 1.7 mmol, 2.0 equiv) and Pd(amphos)Cl2 (60 mg, 0.085 mmol, 0.1 equiv). After 10 min, (6-fluoro-2-methylpyridin-3-yl)boronic acid (CAS NO. 904326-91-6) (197 mg, 1.27 mmol, 1.5 equiv) was added and heated for 2 h. After cooling to room temperature, 1,4-dioxane was removed under reduced pressure, and the resulting residue was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, from 2% to 10%) to give compound 7-1 (557 mg, 89%).

[0231] 1H NMR (400 MHz, CDCl3) δ 7.87 (d,J= 2.4 Hz, 1H), 7.54 (t,J= 8.1 Hz, 1H), 7.35 (d,J= 2.4 Hz, 1H), 7.26 (s, 1H), 6.79 (dd,J= 8.3, 3.1 Hz, 1H), 6.75 (d,J= 2.0 Hz, 1H), 6.69 (dd,J= 8.1, 1.9 Hz, 1H), 6.53 (d,J= 2.5 Hz, 1H), 6.49 (d,J= 2.6 Hz, 1H), 5.04 (s, 2H), 4.36 (dd,J= 11.7, 4.3 Hz, 1H), 4.18 - 4.08 (m, 3H), 3.99 (d,J= 5.7 Hz, 2H), 3.45 (s, 3H), 3.22 (dd,J= 14.1, 4.5 Hz, 1H), 2.93 (tt,J= 9.3, 4.6 Hz, 1H), 2.69 (dd,J= 14.0, 9.7 Hz, 1H), 2.45 - 2.36 (m, 2H), 2.30 (s, 3H), 1.87 (qd,J= 7.2, 4.5, 3.9 Hz, 4H), 1.46 (s, 9H), 1.25 (t,J= 7.2 Hz, 3H).

[0232] 단계 2) 5-(5-((6-((2-((tert-Butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-8-(6-fluoro-2-methylpyridin-3-yl)-4-oxochroman-3-yl)methyl)-2-chlorophenoxy)pentanoic acid (화합물 7-2)의 제조

[0233] Compound 7-1 (80 mg, 0.1 mmol, 1.0 equiv) and NaHCO3 (45 mg, 0.54 mmol, 5.0 equiv) were dissolved in H2O (0.5 mL) / MeOH (1.5 mL), and the reaction mixture was stirred in a microwave at 110°C for 3 h. After cooling to room temperature, the solvent was removed under reduced pressure. The crude product was diluted with H2O, acidified to pH=4–5 with 1 N HCl in H2O at 0°C, and extracted with CH2Cl2. The combined organic layers were dried over Na2SO4 and concentrated. The crude product (63 mg, 89%) was used in the next step.

[0234] ESI-MS m / z 707.8 (M+H)+

[0235] Step 3) tert-butyl (1-((3-(4-chloro-3-((5-((2,6-dioxopiperidin-4-yl)amino)-5-oxopentyl)oxy)benzyl)-8-(6-fluoro-2-methylpyridin-3-yl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate Preparation of (Compound 7-3)

[0236] To a solution of compound 7-2 (10 mg, 0.0132 mmol) in DMF (0.5 mL) were added HATU (7.5 mg, 0.0198 mmol) and DIEA (23 μL, 0.132 mmol) at room temperature. After stirring for 30 min, 4-aminopiperidine-2,6-dione·HCl (2.6 mg, 0.0159 mmol) in DMF (0.5 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 15 h. The reaction mixture was quenched with H2O, brine, and ethyl acetate at 0 °C, extracted with ethyl acetate (x3), washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2: = 1:50 to 1:10) to obtain compound 7-3 (5.3 mg, 46%).

[0237] 1 H NMR (400 MHz, CDCl3) δ 7.90 (s, 1H), 7.62 - 7.52 (m, 1H), 7.34 (s, 1H), 7.25 (d,J= 8.0 Hz, 1H), 6.85 - 6.65 (m, 5H), 5.07 (s, 2H), 4.59 (d,J= 12.2 Hz, 1H), 4.38 (d,J= 11.6 Hz, 1H), 4.14 (q,J= 8.8, 7.2 Hz, 1H), 4.02 (s, 2H), 3.53 (s, 3H), 3.45 (d,J= 2.3 Hz, 1H), 3.19 (d,J= 13.4 Hz, 1H), 2.95 (d,J= 10.3 Hz, 2H), 2.78 - 2.70 (m, 2H), 2.42 (d,J= 7.3 Hz, 2H), 2.30 (s, 3H), 1.88 (s, 4H), 1.46 (s, 9H), 1.26 (s, 3H). ESI-MS m / z 817.3 (M+H) +

[0238] Step 4) 5-(2-chloro-5-((8-(6-fluoro-2-methylpyridin-3-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)-N-(2,6-dioxopiperidin-4-yl)pentanamide hydrochloride Preparation of (Compound 7)

[0239] To a solution of compound 7-3 (5.3 mg, 0.006 mmol) in anhydrous CH2Cl2 (1 mL) was added dropwise 4 N-HCl in 1,4-dioxane (0.5 mL) at 0°C. The resulting mixture was stirred at room temperature for 17 h. The reaction mixture was concentrated under reduced pressure. The resulting solid was filtered, rinsed with diethyl ether (2 mL x 8), and concentrated in vacuo to give compound 7 HCl salt product (3.1 mg, 69%).

[0240] 1 H NMR (400 MHz, MeOD) δ 7.89 (d,J= 2.5 Hz, 1H), 7.73 (t,J= 8.1 Hz, 1H), 7.45 (d,J= 2.4 Hz, 1H), 7.24 (d,J= 8.0 Hz, 1H), 7.04 - 6.92 (m, 4H), 6.77 (d,J= 8.1 Hz, 1H), 5.14 (s, 2H), 4.65 (dd,J= 12.6, 5.4 Hz, 1H), 4.47 (dd,J= 11.6, 4.4 Hz, 1H), 4.34 - 4.23 (m, 1H), 4.04 (s, 2H), 3.56 (s, 3H), 3.51 (d,J= 7.0 Hz, 1H), 3.19 (dd,J= 14.0, 5.5 Hz, 1H), 3.09 (d,J= 8.0 Hz, 1H), 2.87 - 2.63 (m, 3H), 2.39 (s, 2H), 2.30 (s, 3H), 1.93 - 1.81 (m, 4H), 1.20 (t,J= 7.0 Hz, 3H). ESI-MS m / z 718.3 (M+H) +

[0241] Compound 8. (2S,4R)-1-((2S)-2-(5-(2-chloro-5-((8-(6-fluoro-2-methylpyridin-3-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)pentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride

[0242]

[0243] Step 1) tert-butyl (1-((3-(4-chloro-3-((5-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)a mino)-5-oxopentyl)oxy)benzyl)-8-(6-fluoro-2-methylpyridin-3-yl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate Preparation of (Compound 8-1)

[0244] To a solution of compound 7-2 (40 mg, 0.056 mmol, 1 equiv) in DMF (2 mL) were added DIEA (30 μL, 0.168 mmol, 3 equiv) and HATU (43 mg, 0.11 mmol, 2 equiv). After stirring at room temperature for 1 h, (S,R,S)-AHPC (CAS NO. 1448297-52-6) (27 mg, 0.062 mmol, 1 equiv) was added to the mixture. The reaction mixture was stirred at room temperature overnight. Upon completion of the reaction, the solvent was removed, and the residue was partitioned between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. Compound 8-1 (45 mg, 72%) was purified by MPLC.

[0245] ESI-MS m / z 1119.5 (M+H) +

[0246] Step 2) (2S,4R)-1-((2S)-2-(5-(2-chloro-5-((8-(6-fluoro-2-methylpyridin-3-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxo chroman-3-yl)methyl)phenoxy)pentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide Preparation of hydrochloride (compound 8)

[0247] To a solution of compound 8-1 (20 mg, 0.018 mmol, 1 equiv) in CH2Cl2 (1.5 mL) at 0°C was added 4 N-HCl in 1,4-dioxane (0.5 mL). The reaction was stirred at room temperature for 4 h. Upon completion of the reaction, the solvent was removed, the solid was collected, and washed with Et2O to give pure compound 8 as an HCl salt (17 mg, 93%).

[0248] ESI-MS m / z 1019.3 (M+H) +

[0249] Compound 9. (2S,4R)-1-((2S)-2-(tert-butyl)-14-(5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)-4-oxo-6,9,12-trioxa-3-azatetradecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride

[0250]

[0251]

[0252] Step 1) Preparation of 4-(2-(Benzyloxy)ethoxy)-1-(l1-oxidaneyl)butan-2-ol (Compound 9-1)

[0253] To a solution of 4-(2-hydroxyethoxy)-1-(11-oxydanyl)butan-2-ol (triethylene glycol; CAS NO. 112-27-6) (2 g, 13.32 mmol), silver oxide (2.51 g, 14.65 mmol), and potassium iodide (442 mg, 2.66 mmol) in CH2Cl2 (50 mL) at 0°C was added benzyl bromide (2.51 g, 14.65 mmol). After stirring at room temperature for 3 h, the reaction mixture was filtered through a pad of Celite. The mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (EtOAc:Hep = 1:1) to give compound 9-1 (2.18 g, 68%).

[0254] 1 H NMR (400 MHz, CDCl3) δ2.74 (br. s, 1H), 3.60-3.70 (m, 12H), 4.57 (s, 2H), 7.25-7.35 (m, 5H)

[0255] Step 2) Preparation of Methyl 1-phenyl-2,5,8,11-tetraoxatridecan-13-oate (Compound 9-2)

[0256] To a solution of compound 9-1 (2.2 g, 9.15 mmol) in THF (50 mL) was added a 60% dispersion of sodium hydride-mineral oil (550 mg, 13.72 mmol) at 0°C. After stirring at room temperature for 45 min, methyl bromoacetate (1.89 g, 12.36 mmol) was added dropwise to the stirred reaction mixture. The reaction mixture was stirred at 80°C overnight. The reaction mixture was quenched with H2O at 0°C, extracted with ethyl acetate, washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (EtOAc:Hep=1:1) to give compound 9-2 (1.5 g, 50%).

[0257] 1 H NMR (400 MHz, CDCl3) δ 3.55-3.84 (m, 15H), 4.17 (s, 2H), 4.57 (s, 2H), 7.27-7.40 (m, 5H)

[0258] Step 3) Preparation of Methyl 2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)acetate (Compound 9-3)

[0259] To a solution of compound 9-2 (1.37 g, 4.20 mmol) in EtOH (30 mL) at room temperature was added 10% palladium on carbon (45 mg, catalytic amount). After evacuating the reaction flask, a hydrogen balloon was attached to the reaction flask. After stirring at room temperature for 2 h, the reaction mixture was filtered through a pad of Celite. The mixture was concentrated under reduced pressure. The residue was used directly in the next step (950 mg, 96%).

[0260] 1 H NMR (400 MHz, CDCl3) δ 4.17 (d, J= 1.6 Hz, 2H), 3.77 - 3.66 (m, 13H), 3.62 - 3.59 (m, 2H), 2.64 (s, 1H).

[0261] Step 4) Preparation of Methyl 2-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)acetate (Compound 9-4)

[0262] To a solution of compound 9-3 (50 mg, 0.212 mmol), 4-(dimethylamino)pyridine (2.6 mg, 0.021 mmol), and triethylamine (23 mg, 0.222 mmol) in CH2Cl2 (2 mL) at 0°C was added tosyl chloride (42 mg, 0.216 mmol), and the mixture was stirred overnight. The reaction mixture was quenched with H2O, methylene chloride was extracted, washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (EtOAc:Hep= 1:1) to give compound 9-4 (28 mg, 32%).

[0263] 1 H NMR (400 MHz, CDCl3) δ 7.79 (d,J= 8.3 Hz, 2H), 7.37 - 7.31 (m, 2H), 4.18 - 4.14 (m, 4H), 3.74 (s, 3H), 3.72 - 3.64 (m, 6H), 3.58 (s, 4H), 2.44 (s, 3H).

[0264] Step 5) Preparation of Methyl 2-(2-(2-(2-(2-fluoro-5-formylphenoxy)ethoxy)ethoxy)ethoxy)acetate (Compound 9-5)

[0265] To a solution of 4-chloro-3-hydroxybenzaldehyde (2.678 g, 19.118 mmol) in DMF (30 mL) at 0°C were added K2CO3 (4.403 g, 31.862 mmol) and compound 9-4 (5.997 g, 15.931 mmol). The resulting mixture was stirred at 50°C for 17 h. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate, and the organic phase was washed with water, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by MPLC (ethyl acetate:n-heptane = 1:5 to 1:1) to obtain compound 9-5 (4.368 g, 80%).

[0266] 1 H NMR (500 MHz, CDCl3) δ 9.91 (s, 1H), 7.54 (dd,J= 8.2, 2.0 Hz, 1H), 7.46 (ddd,J= 8.2, 4.4, 1.9 Hz, 1H), 7.23 (dd,J= 10.5, 8.2 Hz, 1H), 4.31 - 4.24 (m, 2H), 4.17 (s, 2H), 3.94 - 3.89 (m, 2H), 3.77 - 3.68 (m, 11H). ESI-MS m / z 345.1 (M+H) +

[0267] Step 6) Preparation of Methyl (E)-2-(2-(2-(2-(5-((8-bromo-6-(bromomethyl)-4-oxochroman-3-ylidene)methyl)-2-fluorophenoxy)ethoxy)ethoxy)ethoxy)acetate (Compound 9-6)

[0268] To a solution of 8-bromo-6-(bromomethyl)chroman-4-one (4.815 g, 15.048 mmol) in toluene (35 mL) were added compound 9-5 (4.318 g, 12.539 mmol) and p-toluene sulfonic acid (431 mg, 2.508 mmol). The reaction mixture was refluxed for 17 h. After cooling to ambient temperature, the resulting residue was diluted with CH2Cl2, brine, and H2O, extracted with CH2Cl2 (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate:CH2Cl2 = 1:10) to give compound 9-6 (3.475 g, 43%).

[0269] 1 H NMR (400 MHz, CDCl3) δ 7.98 (d,J= 2.3 Hz, 1H), 7.81 (d,J= 2.2 Hz, 2H), 7.15 (dd,J= 10.8, 8.3 Hz, 1H), 6.99 (dd,J= 8.0, 2.1 Hz, 1H), 6.86 (ddd,J= 8.3, 4.2, 2.1 Hz, 1H), 5.46 (d,J= 1.9 Hz, 2H), 4.46 (s, 2H), 4.24 (dd,J= 5.6, 3.9 Hz, 2H), 4.16 (s, 2H), 3.93 - 3.87 (m, 2H), 3.75 - 3.69 (m, 11H). ESI-MS m / z 646.9 (M+H) +

[0270] Step 7) Preparation of Methyl 2-(2-(2-(2-(5-((8-bromo-6-(bromomethyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)ethoxy)ethoxy)ethoxy)acetate (Compound 9-7)

[0271] To a mixture of compound 9-6 (3.317 g, 5.132 mmol) in EtOAc (20 mL) was added PtO2 (116 mg, 0.513 mmol) at room temperature. The reaction mixture was stirred at room temperature for 17 h under a H2 atmosphere (balloon pressure). The catalyst was removed by filtration through a pad of Celite and washed with EtOAc. The filtrate was concentrated and purified by MPLC (ethyl acetate:n-heptane = 1:5 to 1:2) to obtain compound 9-7 (1.303 g, 39%).

[0272] 1 H NMR (400 MHz, CDCl3) δ 7.89 (d,J= 2.3 Hz, 1H), 7.80 (d,J= 2.3 Hz, 1H), 7.01 (dd,J= 11.1, 8.2 Hz, 1H), 6.86 (dd,J= 8.0, 2.1 Hz, 1H), 6.74 (ddd,J= 8.2, 4.1, 2.1 Hz, 1H), 4.52 (dd,J= 11.6, 4.5 Hz, 1H), 4.43 (s, 2H), 4.27 (dd,J= 11.6, 9.1 Hz, 1H), 4.19 (dd,J= 5.7, 4.0 Hz, 2H), 4.17 (s, 2H), 3.90 - 3.87 (m, 2H), 3.76 - 3.70 (m, 11H), 3.21 (dd,J= 14.1, 4.8 Hz, 1H), 2.95 (dq,J= 9.4, 4.7 Hz, 1H), 2.69 (dd,J= 14.1, 9.8 Hz, 1H). ESI-MS m / z 647.0 (M+H) +

[0273] Step 8) Preparation of Methyl 2-(2-(2-(2-(5-((8-bromo-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)ethoxy)ethoxy)ethoxy)acetate (Compound 9-8)

[0274] A solution of compound 9-7 (1.291 g, 1.991 mmol), 1-methyl-1,3-dihydro-2H-imidazol-2-imine (387 mg, 3.982 mmol), DIEA (695 uL, 3.982 mmol), KI (330 mg, 1.991 mmol), and MeCN (20 mL) was heated at 60°C for 3 h. After cooling to ambient temperature, the reaction mixture was diluted with ethyl acetate, and the organic phase was washed with water, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, 2% to 10%) to give compound 9-8 (453 mg, 34%).

[0275] 1 H NMR (400 MHz, CDCl3) δ 7.93 (d,J= 2.2 Hz, 1H), 7.79 (d,J= 2.2 Hz, 1H), 7.63 (s, 1H), 6.99 (dd,J= 11.1, 8.2 Hz, 1H), 6.85 (dd,J= 8.0, 2.1 Hz, 1H), 6.73 (ddd,J= 8.2, 4.1, 2.0 Hz, 1H), 6.63 (d,J= 2.5 Hz, 1H), 6.58 (d,J= 2.5 Hz, 1H), 5.47 (d,J= 2.6 Hz, 2H), 4.52 (dd,J=11.7, 4.5 Hz, 1H), 4.29 (dd,J= 11.7, 8.9 Hz, 1H), 4.17 (d,J= 10.1 Hz, 4H), 3.88 (dd,J= 5.6, 3.9 Hz, 2H), 3.82 (s, 3H), 3.77 - 3.67 (m, 11H), 3.17 (dd,J= 14.1, 5.1 Hz, 1H), 2.97 (dt,J= 9.0, 4.5 Hz, 1H), 2.70 (dd,J= 14.2, 9.3 Hz, 1H). ESI-MS m / z 664.1 (M+H) +

[0276] Step 9) Methyl 2-(2-(2-(2-(5-((8-bromo-6-((2-((tert-butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)ethoxy)ethoxy)ethoxy)acetate (compound 9-9) Preparation of

[0277] A solution of compound 9-8 (445 mg, 0.669 mmol), (Boc)2O (0.61 mL, 0.803 mmol), and THF (10 mL) was stirred at room temperature. After 10 min, DMAP (41 mg, 0.335 mmol) was added and stirred for 15 h. The reaction mixture was diluted with CH2Cl2, and the organic phase was washed with water, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, 2% to 10%) to give protected compound 9-9 (310 mg, 61%).

[0278] 1H NMR (400 MHz, CDCl3) δ 7.72 (dd,J= 12.3, 2.1 Hz, 2H), 7.00 (dd,J= 11.1, 8.3 Hz, 1H), 6.86 (dd,J= 7.9, 2.0 Hz, 1H), 6.74 (ddd,J= 8.2, 4.0, 2.0 Hz, 1H), 6.55 (d,J= 2.4 Hz, 1H), 6.44 (d,J= 2.5 Hz, 1H), 5.00 (s, 2H), 4.50 (dd,J= 11.7, 4.5 Hz, 1H), 4.25 (dd,J= 11.6, 9.0 Hz, 1H), 4.19 (t,J= 4.8 Hz, 2H), 4.17 (s, 2H), 3.88 (t,J= 4.8 Hz, 2H), 3.76 - 3.68 (m, 13H), 3.48 (s, 3H), 3.19 (dd,J= 14.1, 4.6 Hz, 1H), 2.93 (dt,J= 9.3, 4.7 Hz, 1H), 2.67 (dd,J= 14.2, 9.8 Hz, 1H), 1.52 (s, 9H). ESI-MS m / z 766.1 (M+H) +

[0279] 단계 10) Methyl 2-(2-(2-(2-(5-((6-((2-((tert-butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)ethoxy)ethoxy)ethoxy)acetate (화합물 9-10)의 제조

[0280] To a solution of compound 9-9 (291 mg, 0.3805 mmol) in 1,4-dioxane / H2O (10:1, 5.5 mL) at room temperature were added Cs2CO3 (248 mg, 0.761 mmol) and Pd(amphos)Cl2 (27 mg, 0.0381 mmol). After 10 min, (1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)boronic acid (119 mg, 0.5708 mmol) was added, and the reaction mixture was heated for 2 h. After cooling to room temperature, 1,4-dioxane was removed under reduced pressure, and the resulting residue was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, 2% to 10%) to give compound 9-10 (241 mg, 75%).

[0281] 1H NMR (400 MHz, CDCl3) δ 7.82 (d,J= 2.3 Hz, 1H), 7.52 (s, 1H), 7.39 (d,J= 2.3 Hz, 1H), 6.99 (dd,J= 11.1, 8.2 Hz, 1H), 6.85 (dd,J= 8.0, 2.0 Hz, 1H), 6.73 (ddd,J= 8.3, 4.1, 2.0 Hz, 1H), 6.52 (d,J= 2.4 Hz, 1H), 6.44 (d,J= 2.5 Hz, 1H), 5.01 (s, 2H), 4.35 (dd,J= 11.7, 4.4 Hz, 1H), 4.24 (q,J= 7.4 Hz, 2H), 4.17 (d,J= 5.1 Hz, 5H), 3.87 (t,J= 4.8 Hz, 2H), 3.78 - 3.63 (m, 13H), 3.46 (d,J= 1.7 Hz, 3H), 3.18 (dd,J= 14.0, 4.4 Hz, 1H), 2.88 (td,J= 8.9, 4.3 Hz, 1H), 2.68 (dd,J= 14.0, 10.1 Hz, 1H), 1.55 (t,J= 7.4 Hz, 3H), 1.49 (s, 9H). ESI-MS m / z 848.3 (M+H) +

[0282] 단계 11) 2-(2-(2-(2-(5-((6-((2-((tert-Butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)ethoxy)ethoxy)ethoxy)acetic acid (화합물 9-11)의 제조

[0283] To a solution of compound 9-10 (92.9 mg, 0.1095 mmol) in MeOH / H2O (1 mL / 0.1 mL) was added LiOH (5.2 mg, 0.219 mmol). The reaction mixture was stirred at room temperature for 15 h and evaporated. The reaction mixture was cooled to 0°C and the pH was adjusted to 3-4 by adding 1 N HCl solution. The reaction mixture was diluted with ethyl acetate and water, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was used in the next step without further purification (36.6 mg, 40%).

[0284] 1 H NMR (400 MHz, MeOD) δ 7.97 - 7.83 (m, 2H), 7.57 (dd,J= 9.8, 2.4 Hz, 2H), 7.48 (d,J= 2.3 Hz, 1H), 7.05 - 6.96 (m, 2H), 6.79 (ddd,J= 8.3, 4.2, 2.0 Hz, 1H), 5.29 (d,J= 28.9 Hz, 2H), 4.45 (dd,J= 11.7, 4.4 Hz, 1H), 4.29 (q,J= 7.1 Hz, 2H), 4.17 (d,J= 4.6 Hz, 3H), 4.04 (d,J= 4.6 Hz, 2H), 3.85 (d,J= 4.4 Hz, 2H), 3.78 - 3.67 (m, 10H), 3.33 (s, 3H), 3.14 (dd,J= 13.9, 5.2 Hz, 1H), 3.03 (dt,J= 8.6, 4.1 Hz, 1H), 2.79 (dd,J= 13.9, 8.7 Hz, 1H), 1.53 (t,J= 7.3 Hz, 3H), 1.44 (d,J= 2.3 Hz, 9H). ESI-MS m / z 834.2 (M+H) +

[0285] Step 12) tert-Butyl (1-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(4-fluoro-3-(((S)-13-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1 -carbonyl)-14,14-dimethyl-11-oxo-3,6,9-trioxa-12-azapentadecyl)oxy)benzyl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate Preparation of (Compound 9-12)

[0286] To a solution of compound 9-11 (17.6 mg, 0.021 mmol) in DMF (1 mL) were added HATU (16 mg, 0.105 mmol) and DIEA (36 μL, 0.21 mmol) at room temperature. After stirring for 30 min, the reaction mixture was added (S,R,S)-AHPC (10 mg, 0.023 mmol) in DMF (0.5 mL), and the mixture was stirred at room temperature for 15 h. The reaction mixture was quenched with H2O, brine, and ethyl acetate at 0 °C, extracted with ethyl acetate (x3), washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2: = 1:50 to 1:10) to give compounds 9-12 (7.6 mg, 36%).

[0287] 1H NMR (400 MHz, CDCl3) δ 8.67 (d,J= 1.7 Hz, 1H), 7.82 (d,J= 2.4 Hz, 1H), 7.53 (s, 1H), 7.42 - 7.34 (m, 5H), 7.30 (d,J= 8.2 Hz, 1H), 6.97 (dd,J= 11.1, 8.2 Hz, 1H), 6.87 (dd,J= 10.8, 8.3 Hz, 1H), 6.77 - 6.69 (m, 1H), 6.57 - 6.50 (m, 1H), 6.45 (d,J= 2.6 Hz, 1H), 5.00 (s, 2H), 4.73 - 4.67 (m, 1H), 4.53 (td,J= 14.9, 7.7 Hz, 3H), 4.39 - 4.31 (m, 2H), 4.23 (d,J= 7.3 Hz, 1H), 4.16 (t,J= 4.7 Hz, 2H), 4.09 - 4.02 (m, 2H), 4.00 - 3.95 (m, 1H), 3.87 - 3.80 (m, 2H), 3.73 - 3.61 (m, 10H), 3.63 - 3.49 (m, 2H), 3.46 (d,J= 2.9 Hz, 3H), 3.28 (d,J= 1.9 Hz, 1H), 3.17 (dd,J= 14.0, 4.6 Hz, 1H), 2.92 - 2.84 (m, 1H), 2.67 (ddd,J= 14.1, 10.0, 4.3 Hz, 1H), 2.51 (d,J= 1.3 Hz, 4H), 2.13 - 2.07 (m, 1H), 1.55 (t,J= 7.3 Hz, 3H), 1.49 (s, 9H), 0.94 (s, 9H). ESI-MS m / z 1246.4 (M+H) +

[0288] Step 13) (2S,4R)-1-((2S)-2-(tert-butyl)-14-(5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-o xochroman-3-yl)methyl)-2-fluorophenoxy)-4-oxo-6,9,12-trioxa-3-azatetradecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide Preparation of hydrochloride (compound 9)

[0289] To a solution of compound 9-12 (7.6 mg, 0.006 mmol) in anhydrous CH2Cl2 (1 mL) at 0°C was added dropwise 4 N-HCl in dioxane (0.5 mL). The resulting mixture was stirred at room temperature for 2 h and concentrated under reduced pressure. The resulting solid was filtered, rinsed with diethyl ether (2 mL x 8), and concentrated in vacuo to obtain compound 9 HCl salt product (7.0 mg, 97%).

[0290] 1H NMR (400 MHz, MeOD) δ 9.74 (s, 1H), 7.97 - 7.86 (m, 1H), 7.85 - 7.77 (m, 1H), 7.63 (d,J= 8.8 Hz, 1H), 7.56 - 7.49 (m, 5H), 7.05 - 6.90 (m, 3H), 6.92 - 6.65 (m, 2H), 5.12 (s, 2H), 4.70 (d,J= 6.7 Hz, 1H), 4.63 - 4.54 (m, 2H), 4.51 (d,J= 10.5 Hz, 2H), 4.43 - 4.35 (m, 2H), 4.28 (t,J= 7.4 Hz, 2H), 4.14 (d,J= 5.5 Hz, 1H), 4.03 (d,J= 5.3 Hz, 2H), 3.87 - 3.79 (m, 3H), 3.68 (d,J= 11.4 Hz, 10H), 3.61 - 3.58 (m, 1H), 3.55 (d,J= 1.7 Hz, 3H), 3.31 - 3.28 (m, 1H), 3.16 (d,J= 13.6 Hz, 1H), 3.02 (s, 1H), 2.82 - 2.67 (m, 1H), 2.58 (d,J= 6.2 Hz, 4H), 2.25 (d,J= 14.1 Hz, 1H), 1.51 (t,J= 7.3 Hz, 3H), 1.03 (t,J= 2.7 Hz, 9H). ESI-MS m / z 1146.3 (M+H) +

[0291] Compound 10. N-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)-2-(2-(2-(5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)ethoxy)ethoxy)ethoxy)acetamide hydrochloride

[0292]

[0293] Step 1) 2-(2-(2-(2-(5-((6-((2-((tert-butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-8-(1-ethyl -3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)ethoxy)ethoxy)ethoxy)acetic Preparation of acid (compound 10-1)

[0294] To a solution of compound 9-10 (48 mg, 0.0566 mmol) in THF / H2O (2 / 0.2 mL) at room temperature was added LiOH (7 mg, 0.283 mmol). The reaction mixture was stirred at room temperature for 1 h and evaporated. The reaction mixture was cooled to 0°C and the pH was adjusted to 3-4 by adding 1 N-HCl solution. The reaction mixture was diluted with ethyl acetate and water, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was used in the next step without further purification (27.4 mg, 58%).

[0295] 1H NMR (400 MHz, MeOD) δ 7.97 - 7.83 (m, 2H), 7.57 (dd,J= 9.8, 2.4 Hz, 2H), 7.48 (d,J= 2.3 Hz, 1H), 7.05 - 6.96 (m, 2H), 6.79 (ddd,J= 8.3, 4.2, 2.0 Hz, 1H), 5.29 (d,J= 28.9 Hz, 2H), 4.45 (dd,J= 11.7, 4.4 Hz, 1H), 4.29 (q,J= 7.1 Hz, 2H), 4.17 (d,J= 4.6 Hz, 3H), 4.04 (d,J= 4.6 Hz, 2H), 3.85 (d,J= 4.4 Hz, 2H), 3.78 - 3.67 (m, 10H), 3.33 (s, 3H), 3.14 (dd,J= 13.9, 5.2 Hz, 1H), 3.03 (dt,J= 8.6, 4.1 Hz, 1H), 2.79 (dd,J= 13.9, 8.7 Hz, 1H), 1.53 (t,J= 7.3 Hz, 3H), 1.44 (d,J= 2.3 Hz, 9H). ESI-MS m / z 834.2 (M+H) +

[0296] 단계 2) tert-Butyl (1-((3-(3-(2-(2-(2-(2-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)amino)-2-oxoethoxy)ethoxy)ethoxy)ethoxy)-4-fluorobenzyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate (화합물 10-2)의 제조

[0297] To a solution of compound 10-1 (27.4 mg, 0.0328 mmol) in DMF (1 mL) at room temperature were added HATU (19 mg, 0.0492 mmol) and DIEA (58 μL, 0.33 mmol). After stirring for 30 min, 5-(4-aminopiperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (17 mg, 0.0492 mmol) in DMF (1 mL) was added to the mixture, and the reaction mixture was stirred at room temperature for 20 h. The reaction mixture was quenched with H2O, brine, and ethyl acetate at 0 °C, extracted with ethyl acetate (x3), washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2: = 1:50 to 1:10) to obtain compound 10-2 (6.1 mg, 16%).

[0298] 1H NMR (400 MHz, MeOD) δ 7.87 (s, 2H), 7.61 (d,J= 8.6 Hz, 1H), 7.47 (d,J= 2.6 Hz, 1H), 7.38 - 7.27 (m, 3H), 7.19 (d,J= 8.9 Hz, 1H), 7.05 - 6.93 (m, 2H), 6.78 (s, 1H), 5.21 (s, 2H), 5.11 - 5.04 (m, 1H), 4.40 (d,J= 10.3 Hz, 1H), 4.28 (t,J= 7.1 Hz, 2H), 4.19 (d,J= 8.9 Hz, 1H), 4.11 (s, 2H), 4.01 (s, 1H), 3.97 (s, 2H), 3.78 (d,J= 4.7 Hz, 2H), 3.68 (d,J= 7.8 Hz, 8H), 3.63 (s, 3H), 3.10 (q,J= 12.8 Hz, 3H), 3.01 (s, 1H), 2.88 - 2.81 (m, 1H), 2.72 (t,J= 13.2 Hz, 3H), 2.05 (d,J= 10.4 Hz, 3H), 1.94 (d,J= 12.7 Hz, 2H), 1.65 (d,J= 12.3 Hz, 2H), 1.52 (t,J= 7.2 Hz, 3H), 1.44 (s, 9H). ESI-MS m / z 1172 (M+H) +

[0299] 단계 7) N-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)-2-(2-(2-(2-(5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)ethoxy)ethoxy)ethoxy)acetamide hydrochloride (화합물 10)의 제조

[0300] To a solution of compound 10-2 (6.1 mg, 0.0052 mmol) in anhydrous CH2Cl2 (2 mL) at 0°C was added dropwise 4 N-HCl in dioxane (0.5 mL). The resulting mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure. The resulting solid was filtered, rinsed with diethyl ether (2 mL x 8), and concentrated in vacuo to give compound 10 HCl salt product (3.6 mg, 62%).

[0301] 1 H NMR (400 MHz, MeOD) δ 7.91 (s, 1H), 7.83 (s, 1H), 7.61 (d,J= 8.6 Hz, 1H), 7.43 (s, 1H), 7.30 (s, 1H), 7.18 (d,J= 8.5 Hz, 1H), 7.05 - 6.92 (m, 4H), 6.78 (s, 1H), 5.12 (s, 2H), 5.07 (d,J= 9.9 Hz, 1H), 4.43 (d,J= 10.9 Hz, 1H), 4.28 (d,J= 7.4 Hz, 2H), 4.22 (d,J= 12.3 Hz, 1H), 4.10 (d,J= 4.7 Hz, 2H), 4.01 (s, 1H), 3.97 (s, 3H), 3.77 (s, 2H), 3.68 (d,J= 5.7 Hz, 8H), 3.56 (s, 3H), 3.10 (dd,J= 26.2, 13.9 Hz, 4H), 2.86 (s, 1H), 2.74 (d,J= 15.3 Hz, 3H), 2.08 (d,J= 19.6 Hz, 2H), 1.94 (d,J= 12.4 Hz, 2H), 1.64 (d,J= 12.5 Hz, 2H), 1.52 (t,J= 6.8 Hz, 3H). ESI-MS m / z 1072.4 (M+H) +

[0302] Compound 11. (2S,4R)-1-((S)-2-(2-(2-fluoro-5-(((S)-8-(4-fluoro-2-methylphenyl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride

[0303]

[0304]

[0305] Step 1) Preparation of Methyl 2-(2-fluoro-5-formylphenoxy)acetate (Compound 11-1)

[0306] To a solution of 4-fluoro-3-hydroxybenzaldehyde (CAS NO. 56962-12-0) (8.0 g, 57.1 mmol) in DMF (60 mL) at room temperature were added K2CO3 (15.784 g, 114.2 mmol) and methyl bromoacetate (CAS NO. 96-32-2) (5.96 mL, 62.81 mmol). The resulting mixture was stirred at 50°C for 2 h. The reaction mixture was diluted with ethyl acetate, and the organic phase was washed with water, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by MPLC (ethyl acetate:n-heptane = 1:10 to 1:2) to obtain compound 11-1 (11.651 g, 96%).

[0307] 1 H NMR (400 MHz, CDCl3) δ 9.92 (s, 1H), 7.54 (ddd,J= 8.2, 4.4, 1.9 Hz, 1H), 7.46 (dd,J= 8.0, 1.9 Hz, 1H), 7.31 - 7.26 (m, 1H), 4.80 (s, 2H), 3.84 (s, 3H).

[0308] Step 2) Preparation of Methyl (E)-2-(5-((8-bromo-6-methyl-4-oxochroman-3-ylidene)methyl)-2-fluorophenoxy)acetate (Compound 11-2)

[0309] To a solution of 8-bromo-6-methylchroman-4-one (CAS NO. 1026982-77-3) (15.276 g, 63.45 mmol) in toluene (110 mL) were added compound 11-1 (11.219 g, 52.875 mmol) and p-toluene sulfonic acid (910 mg, 5.287 mmol). The reaction mixture was refluxed for 20 h. After cooling to ambient temperature, the resulting residue was diluted with CH2Cl2, brine, and H2O, extracted with CH2Cl2 (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (CH2Cl2:n-heptane = 1:10 to 1:1) to obtain compound 11-2 (8.491 g, 37%, BORSM 64%).

[0310] 1 H NMR (400 MHz, CDCl3) δ 7.79 (dd,J= 2.2, 1.0 Hz, 2H), 7.61 (d,J= 2.2 Hz, 1H), 7.20 (dd,J= 10.8, 8.3 Hz, 1H), 6.93 (ddd,J= 12.4, 7.2, 2.1 Hz, 2H), 5.40 (d,J= 1.8 Hz, 2H), 4.77 (s, 2H), 3.86 (s, 3H), 2.36 (s, 3H).

[0311] Step 3) Preparation of Methyl 2-(5-(((3S,4S)-8-bromo-4-hydroxy-6-methylchroman-3-yl)methyl)-2-fluorophenoxy)acetate (Compound 11-3)

[0312] To a solution of compound 11-2 (4.228 g, 9.713 mmol) in acetonitrile (10 mL) was added a solution of DBU / formic acid (3.6 mL:1.8 mL) in acetonitrile (50 mL) at ambient temperature. After stirring for 20 min, RuCl(p-cymene)[(S,S)-Ts-DPEN] (32 mg, 48 μmol) was added. The reaction mixture was stirred at 50°C for 16 h and then quenched with saturated aqueous NaHCO3 at ambient temperature. After extraction with CH2Cl2, the organic layer was washed with an additional portion of NH4Cl, dried over MgSO4, and concentrated under reduced pressure. The residue was purified by MPLC (ethyl acetate / n-hexane = 1:4 to 1:1) to give compound 11-3 (3.75 g, 91%).

[0313] 1 H NMR (400 MHz, CDCl3) δ 7.32 (d,J= 2.1 Hz, 1H), 7.06 (dd,J= 11.3, 8.1 Hz, 1H), 6.98 (d,J= 2.1 Hz, 1H), 6.92 - 6.84 (m, 2H), 4.73 (s, 2H), 4.44 (d,J= 3.1 Hz, 1H), 4.26 - 4.14 (m, 2H), 3.83 (s, 3H), 2.83 (dd,J= 13.7, 8.8 Hz, 1H), 2.63 (dd,J= 13.7, 7.1 Hz, 1H), 2.26 (s, 4H).

[0314] Step 4) Preparation of Methyl (S)-2-(5-((8-bromo-6-methyl-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetate (Compound 11-4)

[0315] A solution of compound 11-3 (3.385 g, 7.705 mmol) and 4Å molecular sieves (300 mg) in CH2Cl2 (60 mL) was stirred for 10 min. N-Methylmorpholine-N-oxide (NMO, 903 mg, 7.705 mmol) and tetrapropylammonium perruthenate (TPAP, 271 mg, 0.771 mmol) were added at 0°C, and stirring was continued at room temperature for 3 h. The dark mixture was filtered over Celite using diethyl ether as the eluent. After concentration in vacuo, the residue was purified by MPLC (ethyl acetate:n-heptane, 20%) to give compound 11-4 (2.828 g, 84%).

[0316] 1 H NMR (400 MHz, CDCl3) δ 7.69 (dd,J= 2.3, 0.9 Hz, 1H), 7.59 (dd,J= 2.2, 0.7 Hz, 1H), 7.11 - 7.02 (m, 1H), 6.88 - 6.80 (m, 2H), 4.73 (s, 2H), 4.48 (dd,J= 11.6, 4.4 Hz, 1H), 4.24 (dd,J= 11.6, 8.7 Hz, 1H), 3.85 (s, 3H), 3.20 (dd,J= 14.1, 4.7 Hz, 1H), 2.96 - 2.87 (m, 1H), 2.71 (dd,J= 14.1, 9.8 Hz, 1H), 2.33 (d,J= 0.7 Hz, 3H).

[0317] Step 5) Preparation of Methyl (S)-2-(5-((8-bromo-6-(bromomethyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetate (Compound 11-5)

[0318] A solution of compound 11-4 (2.828 g, 6.467 mmol), NBS (1.266 g, 7.114 mmol), AIBN (319 mg, 1.94 mmol), and EtOAc (50 mL) was refluxed at 70°C for 4 h. After cooling to ambient temperature, the reaction mixture was diluted with ethyl acetate and water, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate:n-hexane = 1:10) to give compound 11-5 (1.459 g, 44%).

[0319] 1 H NMR (400 MHz, CDCl3) δ 7.91 (d,J= 2.3 Hz, 1H), 7.82 (d,J= 2.3 Hz, 1H), 7.09 - 7.04 (m, 1H), 6.87 - 6.80 (m, 2H), 4.74 (s, 2H), 4.53 (dd,J= 5.0, 2.3 Hz, 1H), 4.45 (s, 2H), 4.28 (dd,J= 11.6, 8.9 Hz, 1H), 3.85 (s, 3H), 3.22 (dd,J= 14.1, 4.8 Hz, 1H), 2.95 (tt,J= 9.2, 4.6 Hz, 1H), 2.72 (dd,J= 14.1, 9.7 Hz, 1H).

[0320] Step 6) Preparation of Methyl (S)-2-(5-((8-bromo-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetate (Compound 11-6)

[0321] To a solution of compound 11-5 (1.459 g, 1.991 mmol), 1-methyl-1,3-dihydro-2H-imidazol-2-imine (387 mg, 3.982 mmol), and KI (330 mg, 1.991 mmol) in MeCN (20 mL) was added DIEA (695 uL, 3.982 mmol) at 0°C, and the mixture was stirred at 60°C for 3 h. After cooling to ambient temperature, the reaction mixture was diluted with ethyl acetate, and the organic phase was washed with water, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, 2% to 10%) to give compound 11-6 (448 mg, 30%).

[0322] 1 H NMR (400 MHz, CDCl3) δ 7.94 (d,J= 2.3 Hz, 1H), 7.88 (s, 1H), 7.83 (d,J= 2.3 Hz, 1H), 7.06 (dd,J= 11.1, 8.8 Hz, 1H), 6.89 - 6.78 (m, 2H), 6.61 (d,J= 2.5 Hz, 1H), 6.56 (d,J= 2.5 Hz, 1H), 5.48 (s, 2H), 4.74 (s, 2H), 4.53 (dd,J= 11.7, 4.5 Hz, 1H), 4.29 (dd,J= 11.7, 8.9 Hz, 1H), 3.84 (s, 6H), 3.18 (dd,J= 14.2, 5.0 Hz, 1H), 2.96 (dt,J= 9.1, 4.5 Hz, 1H), 2.70 (dd,J= 14.2, 9.5 Hz, 1H).

[0323] Step 7) Preparation of Methyl (S)-2-(5-((8-bromo-6-((2-((tert-butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetate (Compound 11-7)

[0324] A solution of compound 11-6 (445 mg, 0.835 mmol) and Boc2O (1.27 mL, 1.671 mmol) in THF (15 mL) was stirred at room temperature. After 10 min, DMAP (51 mg, 0.417 mmol) was added and stirred for 2 h. The reaction mixture was diluted with CH2Cl2, and the organic layer was washed with water, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2 = 1:50 to 1:10) to give protected compound 11-7 (350 mg, 66%).

[0325] 1 H NMR (400 MHz, CDCl3) δ 7.85 - 7.74 (m, 2H), 7.06 (dd,J= 11.2, 8.3 Hz, 1H), 6.83 (dd,J= 7.7, 5.6 Hz, 2H), 6.71 (d,J= 39.5 Hz, 2H), 5.19 (s, 2H), 4.73 (s, 2H), 4.52 (dd,J= 11.7, 4.4 Hz, 1H), 4.28 (dd,J= 11.7, 8.8 Hz, 1H), 3.85 (s, 3H), 3.63 (s, 3H), 3.20 (dd,J= 14.2, 4.8 Hz, 1H), 2.94 (dq,J= 9.2, 4.6 Hz, 1H), 2.71 (dd,J= 14.1, 9.7 Hz, 1H), 1.55 (s, 9H).

[0326] Step 8) Methyl (S)-2-(5-((6-((2-((tert-butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-8-(4-fluoro-2-methylphenyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetate (Compound 11-8) Manufacturing

[0327] To compound 11-7 (250 mg, 0.395 mmol) in 1,4-dioxane / H2O (10:1, 5.5 mL) was added Cs2CO3 (257 mg, 0.79 mmol) and Pd(amphos)Cl2 (28 mg, 0.039 mmol) at room temperature. After 10 min, (4-fluoro-2-methylphenyl)boronic acid (140 mg, 0.593 mmol) was added and heated at 100 °C for 2 h. After cooling to room temperature, 1,4-dioxane was removed under reduced pressure, and the resulting residue was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, 2% to 10%) to give compound 11-8 (64.4 mg, 25%).

[0328] 1 H NMR (400 MHz, CDCl3) δ 7.86 (d,J= 2.4 Hz, 1H), 7.34 (d,J= 2.4 Hz, 1H), 7.10 (dd,J= 8.4, 5.9 Hz, 1H), 7.05 - 6.90 (m, 3H), 6.84 - 6.75 (m, 2H), 6.59 (d,J= 21.4 Hz, 2H), 5.12 (s, 2H), 4.70 (s, 2H), 4.36 (dd,J= 11.6, 4.4 Hz, 1H), 4.17 - 4.09 (m, 1H), 3.80 (s, 3H), 3.53 (s, 3H), 3.20 (dd,J= 14.0, 4.6 Hz, 1H), 2.90 (dt,J= 9.2, 4.6 Hz, 1H), 2.70 (dd,J= 14.1, 9.7 Hz, 1H), 2.14 (s, 3H), 1.49 (s, 9H).

[0329] Step 9) Preparation of (S)-2-(5-((6-((2-((tert-Butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-8-(4-fluoro-2-methylphenyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetic acid (Compound 11-9)

[0330] A mixture of compound 11-8 (64.4 mg, 0.0973 mmol) and LiOH (3.5 mg, 0.145 mmol) in MeOH / H2O (2 mL / 0.2 mL) was stirred at room temperature for 1 h and evaporated. The reaction mixture was cooled to 0°C and the pH was adjusted to 3–4 by adding 1 N-HCl solution. The reaction mixture was diluted with ethyl acetate and water, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was used in the next step without further purification (63.8 mg, 99%).

[0331] 1H NMR (400 MHz, MeOD) δ 7.92 (d,J= 2.4 Hz, 1H), 7.67 (d,J= 2.4 Hz, 1H), 7.59 (d,J= 2.4 Hz, 1H), 7.34 (d,J= 2.4 Hz, 1H), 7.13 (dd,J= 8.4, 5.9 Hz, 1H), 7.05 - 6.99 (m, 2H), 6.96 (td,J= 8.7, 3.0 Hz, 1H), 6.88 (dd,J= 8.1, 2.0 Hz, 1H), 6.85 - 6.77 (m, 1H), 5.36 (s, 2H), 4.64 (s, 2H), 4.41 (dd,J= 11.7, 4.4 Hz, 1H), 4.19 (dd,J= 11.7, 8.8 Hz, 1H), 3.76 (s, 3H), 3.14 (dd,J= 13.9, 5.3 Hz, 1H), 3.05 - 2.98 (m, 1H), 2.79 (dd,J= 13.9, 8.6 Hz, 1H), 2.14 (s, 3H), 1.43 (s, 9H).

[0332] 단계 10) tert-Butyl (1-(((S)-8-(4-fluoro-2-methylphenyl)-3-(4-fluoro-3-(2-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)benzyl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate (화합물 11-10)의 제조

[0333] To a solution of compound 11-9 (15 mg, 0.0234 mmol) in DMF (1 mL) were added EDCI (5.4 mg, 0.0346 mmol), HOBt (4.7 mg, 0.0346 mmol), (S,R,S)-AHPC-Me·HCl (11.3 mg, 0.0254 mmol), and DIEA (41 uL, 0.231 mmol) at 0 °C. The mixture was stirred at room temperature for 20 h. The reaction mixture was quenched with H2O, brine, and ethyl acetate at 0 °C, extracted with ethyl acetate (x3), washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2:=1:20) to obtain compound 11-10 (7.5 mg, 30%).

[0334] 1 H NMR (400 MHz, CDCl3) δ 8.69 (s, 1H), 7.84 (t,J= 2.7 Hz, 1H), 7.50 - 7.31 (m, 7H), 7.05 (ddt,J= 19.2, 10.8, 4.5 Hz, 2H), 7.00 - 6.89 (m, 2H), 6.81 (d,J= 8.1 Hz, 2H), 6.57 (d,J= 18.0 Hz, 2H), 5.09 (d,J= 6.8 Hz, 2H), 4.74 (dt,J= 23.1, 7.9 Hz, 1H), 4.60 (t,J= 7.7 Hz, 1H), 4.58 - 4.50 (m, 2H), 4.37 (dd,J= 11.6, 4.3 Hz, 1H), 4.19 - 4.05 (m, 2H), 3.65 (dt,J= 11.1, 4.2 Hz, 1H), 3.50 (s, 3H), 3.19 (d,J= 15.1 Hz, 1H), 2.92 (dt,J= 9.0, 4.6 Hz, 1H), 2.72 (d,J= 13.2 Hz, 1H), 2.54 (s, 4H), 2.15 - 2.05 (m, 4H), 1.78 (d,J= 23.8 Hz, 1H), 1.56 - 1.42 (m, 12H), 1.08 (s, 9H).

[0335] Step 11) (2S,4R)-1-((S)-2-(2-(2-fluoro-5-(((S)-8-(4-fluoro-2-methylphenyl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman -3-yl)methyl)phenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide Preparation of hydrochloride (compound 11)

[0336] To a solution of compound 11-10 (7.5 mg, 6.98 μmol) in anhydrous CH2Cl2 (1 mL) at 0°C was added dropwise 4 N-HCl in dioxane (0.5 mL). The resulting mixture was stirred at room temperature for 5 h. The reaction mixture was concentrated under reduced pressure. The resulting solid was filtered, rinsed with diethyl ether (2 mL x 8), and concentrated in vacuo to give compound 11 HCl salt product (5.8 mg, 82%).

[0337] 1H NMR (400 MHz, MeOD) δ 9.68 (s, 1H), 7.84 (d,J= 2.2 Hz, 1H), 7.53 (q,J= 8.2 Hz, 4H), 7.39 (d,J= 2.3 Hz, 1H), 7.20 - 6.92 (m, 7H), 6.89 (d,J= 6.0 Hz, 1H), 5.14 (s, 2H), 5.03 (q,J= 6.9 Hz, 1H), 4.74 - 4.69 (m, 1H), 4.67 - 4.57 (m, 3H), 4.45 (s, 1H), 4.23 (dd,J= 11.5, 8.5 Hz, 1H), 3.88 (d,J= 11.0 Hz, 1H), 3.80 - 3.72 (m, 1H), 3.56 (s, 3H), 3.54 - 3.46 (m, 1H), 3.25 - 3.14 (m, 1H), 3.11 - 2.99 (m, 1H), 2.77 (ddd,J= 13.4, 8.7, 4.4 Hz, 1H), 2.58 (d,J= 8.9 Hz, 3H), 2.22 (q,J= 8.9, 6.1 Hz, 1H), 2.14 (d,J= 10.7 Hz, 3H), 2.01 - 1.91 (m, 1H), 1.53 (dd,J= 7.0, 1.6 Hz, 3H), 1.09 - 0.96 (m, 9H). ESI-MS m / z 974.6 (M+H) +

[0338] Compound 12. (2S,4R)-1-((S)-2-(2-(5-(((S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride

[0339]

[0340] Step 1) Methyl (S)-2-(5-((6-((2-((tert-butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetate (Compound 12-1) Manufacturing

[0341] To a solution of compound 11-7 (82.2 mg, 0.1299 mmol) in 1,4-dioxane / H2O (10:1, 2.2 mL) at room temperature were added Cs2CO3 (85 mg, 0.26 mmol) and Pd(amphos)Cl2 (9.2 mg, 0.013 mmol). After 10 min, (1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)boronic acid (CAS NO. 2287228-20-8) (41 mg, 0.1949 mmol) was added and heated for 2 h. After cooling to room temperature, 1,4-dioxane was removed under reduced pressure, and the resulting residue was diluted with EtOAc, brine, and H2O, and extracted with ethyl acetate (x3). The extract was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The concentrate was purified by silica gel flash column chromatography (MeOH:CH2Cl2, 2% to 10%) to obtain compound 12-1 (37 mg, 40%).

[0342] 1H NMR (400 MHz, CDCl3) δ 7.84 (d,J= 2.4 Hz, 1H), 7.60 (s, 1H), 7.47 (s, 1H), 7.07 - 7.02 (m, 1H), 6.82 (dt,J= 8.1, 2.2 Hz, 2H), 6.67 - 6.52 (m, 2H), 5.10 (s, 2H), 4.72 (s, 2H), 4.37 (dd,J= 11.7, 4.3 Hz, 1H), 4.26 (q,J= 7.3 Hz, 2H), 4.18 (dd,J= 11.9, 8.2 Hz, 1H), 3.81 (s, 3H), 3.53 (d,J= 11.3 Hz, 3H), 3.18 (dd,J= 14.0, 4.4 Hz, 1H), 2.90 - 2.85 (m, 1H), 2.71 (ddd,J= 13.0, 9.9, 2.9 Hz, 1H), 1.57 (d,J= 7.4 Hz, 3H), 1.51 (s, 9H).

[0343] 단계 2) (S)-2-(5-((6-((2-((tert-butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetic acid (화합물 12-2)의 제조

[0344] To a solution of compound 12-1 (33.6 mg, 0.0469 mmol) in MeOH / H2O (1 mL / 0.1 mL) at 0°C was added LiOH (1.7 mg, 0.07 mmol). After stirring at room temperature for 1 h, the reaction was quenched with NH4Cl and evaporated. The reaction mixture was cooled to 0°C and the pH was adjusted to 3–4 by adding 1 N-HCl solution. The reaction mixture was diluted with ethyl acetate and water, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was used in the next step without further purification (31.4 mg, 95%).

[0345] 1 H NMR (400 MHz, MeOD) δ 7.91 - 7.84 (m, 2H), 7.61 (dd,J= 13.5, 2.4 Hz, 2H), 7.48 (d,J= 2.3 Hz, 1H), 7.03 (dd,J= 11.3, 8.2 Hz, 1H), 6.88 (dd,J= 8.1, 2.1 Hz, 1H), 6.82 (ddd,J= 8.3, 4.2, 2.0 Hz, 1H), 5.34 (s, 2H), 4.63 (s, 2H), 4.44 (dd,J= 11.7, 4.4 Hz, 1H), 4.34 - 4.27 (m, 2H), 4.27 - 4.21 (m, 1H), 3.76 (s, 3H), 3.13 (dd,J= 13.9, 5.5 Hz, 1H), 3.00 (tt,J= 8.6, 4.8 Hz, 1H), 2.85 - 2.75 (m, 1H), 1.53 (t,J= 7.3 Hz, 3H), 1.45 (s, 9H).

[0346] Step 3) tert-Butyl (1-(((S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(4-fluoro-3-(2-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbam oyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)benzyl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate Preparation of (Compound 12-3)

[0347] To a solution of compound 12-2 (15.1 mg, 0.0215 mmol) in DMF (1 mL) at 0 °C were added EDCI (5 mg, 0.0258 mmol), (S,R,S)-AHPC-Me (11.5 mg, 0.0258 mmol), and DIEA (38 μL, 0.215 mmol). The mixture was stirred at room temperature for 20 h. The reaction mixture was quenched with H2O, brine, and ethyl acetate at 0 °C, extracted with ethyl acetate (x3), washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2:=1:20) to give compound 12-3 (10.4 mg, 43%).

[0348] 1H NMR (400 MHz, CDCl3) δ 8.69 (s, 1H), 7.82 (d,J= 2.3 Hz, 1H), 7.56 (d,J= 2.5 Hz, 1H), 7.49 (t,J= 7.4 Hz, 1H), 7.44 - 7.35 (m, 6H), 7.10 - 7.00 (m, 1H), 6.82 (ddt,J= 13.7, 7.5, 3.1 Hz, 2H), 6.54 (d,J= 26.0 Hz, 2H), 5.10 (dd,J= 7.3, 3.4 Hz, 1H), 5.04 (d,J= 6.4 Hz, 2H), 4.75 (q,J= 7.6 Hz, 1H), 4.67 - 4.46 (m, 4H), 4.43 - 4.34 (m, 1H), 4.30 - 4.16 (m, 3H), 4.10 (dd,J= 10.2, 4.1 Hz, 1H), 3.65 (dt,J= 11.3, 3.5 Hz, 1H), 3.49 (s, 3H), 3.17 (ddd,J= 14.4, 9.9, 4.8 Hz, 1H), 2.90 (q,J= 6.5, 3.4 Hz, 1H), 2.74 (ddd,J= 13.9, 9.5, 2.5 Hz, 1H), 2.54 (s, 4H), 2.12 - 2.06 (m, 1H), 1.56 (td,J= 7.3, 1.3 Hz, 3H), 1.50 (d,J= 4.4 Hz, 12H), 1.08 (d,J= 2.2 Hz, 9H).

[0349] 단계 4) (2S,4R)-1-((S)-2-(2-(5-(((S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (화합물 12)의 제조

[0350] To a solution of compound 12-3 (9.9 mg, 8.77 μmol) in anhydrous CH2Cl2 (1 mL) at 0°C was added dropwise 4 N-HCl in dioxane (0.5 mL). The resulting mixture was stirred at room temperature for 5 h and concentrated under reduced pressure. The concentrated solid was filtered, rinsed with diethyl ether (2 mL x 8), and concentrated in vacuo to give compound 12 HCl salt product (7.9 mg, 84%).

[0351] 1 H NMR (400 MHz, MeOD) δ 9.78 (s, 1H), 7.92 (s, 1H), 7.83 (d,J= 1.9 Hz, 1H), 7.52 (t,J= 8.4 Hz, 4H), 7.46 - 7.42 (m, 1H), 7.10 (dd,J= 11.2, 8.1 Hz, 1H), 7.02 (d,J= 8.2 Hz, 1H), 6.99 - 6.93 (m, 2H), 6.91 (s, 1H), 5.14 (s, 2H), 5.03 (q,J= 6.9 Hz, 1H), 4.72 (t,J= 4.8 Hz, 1H), 4.63 (d,J= 5.6 Hz, 2H), 4.59 (d,J= 8.9 Hz, 1H), 4.45 (d,J= 7.1 Hz, 2H), 4.34 - 4.24 (m, 3H), 3.89 (d,J= 11.0 Hz, 1H), 3.81 - 3.72 (m, 1H), 3.56 (s, 3H), 3.20 (d,J= 14.5 Hz, 1H), 3.06 (s, 1H), 2.78 (dt,J= 13.9, 6.5 Hz, 1H), 2.60 (s, 3H), 2.23 (dd,J= 13.1, 7.8 Hz, 1H), 1.97 (d,J= 9.6 Hz, 1H), 1.53 (dt,J= 7.4, 3.8 Hz, 6H), 1.03 (s, 9H). ESI-MS m / z 1028.6 (M+H) +

[0352] Compound 13. (2S,4R)-N-(2-(3-(2-(2-fluoro-5-(((S)-8-(4-fluoro-2-methylphenyl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)acetamido)propoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide hydrochloride

[0353]

[0354]

[0355] Step 1) Preparation of tert-Butyl (3-(2-(((2S,4R)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)propyl)carbamate (Compound 13-1)

[0356] (2S,4R)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide (CAS NO. 1448188-69-9) (VHL ligand, 20 mg, 0.036 mmol, 1 equiv), tert-butyl (3-iodopropyl)carbamate (CAS NO. 167479-01-8) (20.5 mg, 0.072 mmol, 2 equiv) and Cs2CO3 (23.5 mg, 0.072 mmol, 2 equiv) were dissolved in DMF (1.5 mL). The reaction mixture was stirred at room temperature. After 3 h, the reaction mixture was diluted with EA and washed three times with H2O. The organic layers were combined, dried over Na2SO4, and concentrated. The crude material was purified by MPLC to obtain compound 13-1 (31 mg, 99%).

[0357] 1H NMR (400 MHz, CDCl3) δ 8.71 (s, 1H), 7.73 - 7.67 (m, 1H), 7.46 (td,J= 7.4, 1.2 Hz, 2H), 7.37 (d,J= 7.2 Hz, 2H), 7.32 (d,J= 7.7 Hz, 1H), 6.95 (dd,J= 7.6, 1.6 Hz, 1H), 6.87 (d,J= 1.7 Hz, 1H), 5.44 (t,J= 6.1 Hz, 1H), 4.73 (d,J= 10.9 Hz, 1H), 4.68 - 4.58 (m, 2H), 4.50 (tt,J= 5.7, 2.8 Hz, 1H), 4.48 - 4.34 (m, 3H), 4.29 (d,J= 11.4 Hz, 1H), 4.09 (td,J= 6.5, 5.8, 3.9 Hz, 2H), 3.67 (dd,J= 11.2, 3.7 Hz, 1H), 3.45 - 3.33 (m, 2H), 2.52 (s, 3H), 2.50 - 2.41 (m, 1H), 2.35 (t,J= 8.6 Hz, 1H), 2.10 - 1.98 (m, 3H), 0.82 (t,J= 6.7 Hz, 6H).

[0358] Step 2) Preparation of (2S,4R)-N-(2-(3-aminopropoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide (Compound 13-2)

[0359] TFA (5 eq) was added dropwise to a solution of compound 13-1 (31 mg, 0.043 mmol, 1.0 eq). The resulting mixture was stirred at room temperature for 3 hours. The solvent was then removed under reduced pressure to obtain compound 13-2 (30 mg, 99%).

[0360] 1H NMR (400 MHz, CDCl3) δ 9.13 (s, 1H), 7.92 (s, 2H), 7.73 (d,J= 7.4 Hz, 1H), 7.63 (s, 1H), 7.54 (t,J= 7.2 Hz, 1H), 7.43 (d,J= 7.1 Hz, 2H), 7.31 (d,J= 7.5 Hz, 1H), 6.96 (d,J= 6.8 Hz, 1H), 6.84 (s, 1H), 4.73 (d,J= 10.6 Hz, 1H), 4.64 (d,J= 17.3 Hz, 1H), 4.51 (d,J= 12.2 Hz, 1H), 4.39 (d,J= 16.9 Hz, 1H), 4.32 - 4.12 (m, 5H), 3.66 (s, 1H), 3.32 (s, 1H), 3.19 (s, 1H), 2.52 (s, 3H), 2.25 (d,J= 58.5 Hz, 3H), 1.83 (s, 2H), 1.25 (dd,J= 4.4, 2.7 Hz, 1H), 1.00 (d,J= 6.1 Hz, 3H), 0.89 (dd,J= 12.5, 4.7 Hz, 1H), 0.84 (d,J= 6.5 Hz, 3H).

[0361] 단계 3) tert-Butyl (1-(((S)-8-(4-fluoro-2-methylphenyl)-3-(4-fluoro-3-(2-((3-(2-(((2S,4R)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)propyl)amino)-2-oxoethoxy)benzyl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate (화합물 13-3)의 제조

[0362] To a solution of compound 11-9 (15 mg, 0.021 mmol, 1.0 equiv) in CH2Cl2-DMF (1 mL / 1 mL) at room temperature were added DIEA (36 μL, 0.21 mmol, 10.0 equiv), EDCI (6.0 mg, 0.031 mmol, 1.5 equiv), HOBt (4.7 mg, 0.031 mmol, 1.5 equiv), and compound 13-2 (15 mg, 0.021 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature overnight. Upon completion of the reaction, the solvent was removed, and the residue was partitioned between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. Compound 13-3 (17 mg, 64%) was purified by MPLC.

[0363] 1H NMR (400 MHz, CDCl3) δ 8.60 (s, 1H), 7.77 (t,J= 2.4 Hz, 1H), 7.65 (d,J= 7.7 Hz, 2H), 7.52 - 7.45 (m, 2H), 7.41 (t,J= 7.4 Hz, 1H), 7.30 (dd,J= 7.6, 3.2 Hz, 2H), 7.27 - 7.22 (m, 2H), 7.17 (d,J= 8.1 Hz, 1H), 7.00 (q,J= 7.5, 6.4 Hz, 1H), 6.94 (dd,J= 8.4, 5.8 Hz, 1H), 6.91 - 6.87 (m, 1H), 6.87 - 6.80 (m, 2H), 6.80 - 6.76 (m, 3H), 6.70 (dd,J= 9.5, 2.9 Hz, 1H), 6.63 (ddd,J= 8.5, 4.3, 2.1 Hz, 1H), 5.12 (d,J= 2.7 Hz, 2H), 4.69 (d,J= 11.1 Hz, 2H), 4.64 (d,J= 3.4 Hz, 1H), 4.57 (td,J= 7.9, 3.1 Hz, 1H), 4.44 - 4.27 (m, 6H), 4.26 - 4.18 (m, 2H), 3.98 (dt,J= 12.6, 5.2 Hz, 2H), 3.67 - 3.59 (m, 2H), 3.51 (s, 3H), 3.02 (d,J= 12.9 Hz, 1H), 2.77 (td,J= 10.8, 10.1, 5.7 Hz, 1H), 2.63 - 2.52 (m, 1H), 2.44 (s, 3H), 2.35 - 2.23 (m, 2H), 2.09 - 2.02 (m, 2H), 2.00 - 1.94 (m, 3H), 1.30 (d,J= 2.3 Hz, 9H), 0.85 (dd,J= 6.5, 1.6 Hz, 3H), 0.77 (d,J= 6.7 Hz, 3H). ESI-MS m / z 1235.3 (M+H) +

[0364] Step 4) (2S,4R)-N-(2-(3-(2-(2-fluoro-5-(((S)-8-(4-fluoro-2-methylphenyl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)meth yl)phenoxy)acetamido)propoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide Preparation of hydrochloride (compound 13)

[0365] To a solution of compound 13-3 (10 mg, 0.008 mmol) dissolved in CH2Cl2 (3 mL) at 0°C was added 4 N-HCl in 1,4-dioxane (1 mL). The reaction was stirred at room temperature for 3.5 h. Upon completion of the reaction, the solvent was removed to obtain compound 13 as an HCl salt (11.3 mg, 90%).

[0366] 1H NMR (400 MHz, MeOD) δ 9.88 (s, 1H), 7.89 (d,J= 8.4 Hz, 1H), 7.81 (d,J= 2.0 Hz, 1H), 7.76 (dd,J= 7.9, 3.5 Hz, 2H), 7.63 - 7.54 (m, 3H), 7.53 - 7.48 (m, 2H), 7.35 (d,J= 2.1 Hz, 1H), 7.12 (d,J= 7.6 Hz, 2H), 7.06 (s, 1H), 7.00 (d,J= 9.7 Hz, 2H), 6.94 (dt,J= 9.2, 4.6 Hz, 3H), 6.89 - 6.83 (m, 1H), 6.81 (d,J= 6.1 Hz, 1H), 5.11 (s, 2H), 4.54 (t,J= 15.3 Hz, 4H), 4.46 (d,J= 5.8 Hz, 2H), 4.36 (d,J= 9.1 Hz, 1H), 4.22 - 4.13 (m, 2H), 3.95 (d,J= 10.9 Hz, 1H), 3.86 (dd,J= 11.2, 3.9 Hz, 1H), 3.74 (dd,J= 6.5, 5.2 Hz, 2H), 3.66 (dd,J= 6.0, 4.9 Hz, 4H), 3.58 (dd,J= 5.6, 4.1 Hz, 2H), 3.53 (s, 3H), 3.11 (d,J= 14.5 Hz, 1H), 2.98 (s, 1H), 2.70 (t,J= 11.4 Hz, 1H), 2.60 (s, 3H), 2.42 (d,J= 7.2 Hz, 1H), 2.11 (s, 3H), 1.29 (s, 3H), 1.01 (d,J= 6.4 Hz, 3H), 0.81 (d,J= 6.5 Hz, 3H).

[0367] Compound 14. (2S,4R)-1-((S)-2-(2-fluoro-5-(((S)-8-(4-fluoro-2-methylphenyl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)benzamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride

[0368]

[0369]

[0370] Step 1) Preparation of Methyl (E)-5-((8-bromo-6-methyl-4-oxochroman-3-ylidene)methyl)-2-fluorobenzoate (Compound 14-1)

[0371] To a solution of 8-bromo-6-methylchroman-4-one (CAS NO. 1026982-77-3) (15.0 g, 62.2 mmol, 1.0 equiv) and methyl 2-fluoro-5-formylbenzoate (CAS NO. 165803-94-1) (17.0 g, 93.3 mmol, 1.5 equiv) in toluene (186 mL) was added TsOH (1.0 g, 6.2 mmol, 0.1 equiv). The reaction mixture was stirred at 110 °C overnight. The solvent was removed, and the product was filtered through a short silica pad with EtOAc. The residue was evaporated, and the crude product was purified by recrystallization from EA and heptane to give compound 14-1 (13.8 g, 55%).

[0372] 1 H NMR (400 MHz, DMSO) δ 7.98 - 7.92 (m, 1H), 7.80 (dq, J = 6.9, 4.5, 3.7 Hz, 3H), 7.71 (s, 1H), 7.50 (dd, J = 10.7, 8.7 Hz, 1H), 5.50 (d, J) = 2.0 Hz, 2H), 3.90 (s, 3H), 2.33 (s, 3H).

[0373] Step 2) Preparation of Methyl 5-(((3S,4S)-8-bromo-4-hydroxy-6-methylchroman-3-yl)methyl)-2-fluorobenzoate (Compound 14-2)

[0374] To a solution of compound 14-1 (2.47 g, 6.0 mmol, 1.0 equiv) in acetonitrile (50 mL) at room temperature was added DBU-formic acid (0.89 mL:0.23 mL). After stirring for 20 min, RuCl(p-cymene)[(S,S)-Ts-DPEN (190 mg, 0.3 equiv) was added. The reaction mixture was stirred at 60°C for 5 h and then quenched with saturated aqueous NaHCO3 at ambient temperature. After extraction with CH2Cl2, the organic layer was washed with an additional portion of NH4Cl, dried over MgSO4, and concentrated under reduced pressure. The residue was purified by MPLC to give compound 14-2 (1.6 g, 67%).

[0375] 1 H NMR (400 MHz, CDCl3) δ 7.82 (dd,J= 6.9, 2.4 Hz, 1H), 7.41 (ddd,J= 8.4, 4.5, 2.4 Hz, 1H), 7.30 (d,J= 2.1 Hz, 1H), 7.10 (dd,J= 10.5, 8.5 Hz, 1H), 6.95 (d,J= 2.1 Hz, 1H), 4.42 (d,J= 3.4 Hz, 1H), 4.21 (ddd,J= 10.8, 4.2, 1.2 Hz, 1H), 4.15 (t,J= 10.9 Hz, 1H), 3.93 (s, 3H), 2.90 (dd,J= 13.8, 8.6 Hz, 1H), 2.68 (dd,J= 13.8, 7.1 Hz, 1H), 2.34 - 2.25 (m, 1H), 2.23 (s, 3H).

[0376] Step 3) Preparation of Methyl (S)-5-((8-bromo-6-methyl-4-oxochroman-3-yl)methyl)-2-fluorobenzoate (Compound 14-3)

[0377] To a solution of compound 14-2 (1.6 g, 4.0 mmol, 1 equiv) in CH2Cl2 (30 mL) was added 4 Å molecular sieves. The mixture was stirred at room temperature for 1 h. NMO (562 mg, 4.8 mmol, 1.2 equiv) and TPAP (210 mg, 0.6 mmol, 0.15 equiv) were added to the reaction mixture at 0 °C, and the reaction mixture was stirred at room temperature for 2 h. Upon completion of the reaction, the reaction was filtered through Celite. The residue was concentrated under reduced pressure. After purification by MPLC, compound 14-3 was obtained (1.3 g, 79.8%).

[0378] 1 H NMR (400 MHz, CDCl3) δ 7.79 (dd,J= 6.8, 2.5 Hz, 1H), 7.66 (dd,J= 2.1, 1.0 Hz, 1H), 7.57 (d,J= 2.2 Hz, 1H), 7.39 (ddd,J= 8.4, 4.5, 2.5 Hz, 1H), 7.09 (dd,J= 10.4, 8.5 Hz, 1H), 4.49 (dd,J= 11.5, 4.5 Hz, 1H), 4.23 (dd,J= 11.6, 9.2 Hz, 1H), 3.93 (s, 3H), 3.28 (dd,J= 14.3, 4.9 Hz, 1H), 2.97 (tt,J= 9.4, 4.7 Hz, 1H), 2.75 (dd,J= 14.3, 9.5 Hz, 1H), 2.31 (s, 3H).

[0379] Step 4) Preparation of Methyl (S)-5-((8-bromo-6-(bromomethyl)-4-oxochroman-3-yl)methyl)-2-fluorobenzoate (Compound 14-4)

[0380] To a solution of compound 14-3 (2.6 g, 6.38 mmol, 1.0 equiv) in MeOAc (30 mL) at room temperature were added NBS (1.25 g, 7.0 mmol, 1.1 equiv) and AIBN (105 mg, 0.64 mmol, 0.1 equiv). The reaction mixture was stirred at 50°C overnight. The solvent was removed, and the residue was partitioned between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. The crude product was purified by recrystallization from EtOAc and heptane to give compound 14-4 (1.2 g, 40%).

[0381] 1 H NMR (400 MHz, CDCl3) δ 7.99 (d,J= 2.2 Hz, 1H), 7.88 (d,J= 2.2 Hz, 1H), 7.84 (s, 1H), 7.82 (d,J= 2.3 Hz, 1H), 7.79 (d,J= 2.3 Hz, 1H), 5.45 (d,J= 1.9 Hz, 2H), 4.57 - 4.50 (m, 1H), 4.27 (d,J= 2.2 Hz, 1H), 3.27 (d,J= 4.9 Hz, 1H), 2.79 - 2.72 (m, 1H), 2.32 (s, 3H).

[0382] Step 5) Preparation of Methyl (S)-5-((8-bromo-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorobenzoate (Compound 14-5)

[0383] To a solution of compound 14-4 (3.8 g, 6.4 mmol, 1.0 equiv) in MeCN (20 mL) at room temperature were added 1-methyl-1H-imidazol-2-amine (738 mg, 7.6 mmol, 1.2 equiv), DIEA (1.3 mL, 7.6 mmol, 1.2 mmol), and KI (738 mg, 7.69 mmol, 1.2 equiv). The reaction mixture was stirred at 60 °C for 2 h and diluted with EtOAc. The mixture was washed three times with water and extracted twice with EtOAc. The combined organic layers were dried over Na2SO4 and concentrated. The crude product was used without further purification for the next step.

[0384] Step 6) Preparation of Methyl (S)-5-((8-bromo-6-((2-((tert-butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorobenzoate (Compound 14-6)

[0385] A solution of compound 14-5 (2.0 g, 4.1 mmol, 1 equiv) and (Boc)2O (3.7 mL, 4.9 mmol, 1.2 equiv) in THF (50 mL) was stirred at room temperature. After 10 min, DMAP (250 mg, 2.0 mmol, 0.5 equiv) was added, and the reaction mixture was stirred at room temperature for 15 h. The resulting mixture was diluted with CH2Cl2, and the organic phase was washed with water, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, 2% to 10%) to give protected compound 14-6 (1.14 g, 46%).

[0386] 1H NMR (400 MHz, CDCl3) δ 7.96 (dd,J= 37.3, 2.2 Hz, 1H), 7.86 - 7.81 (m, 1H), 7.80 (dd,J= 6.8, 2.4 Hz, 1H), 7.45 (dddd,J= 36.6, 8.3, 4.5, 2.4 Hz, 1H), 7.12 (dd,J= 10.4, 8.5 Hz, 1H), 6.67 - 6.61 (m, 1H), 6.52 (dd,J= 7.4, 2.5 Hz, 1H), 5.08 (s, 2H), 4.54 (dd,J= 11.7, 4.6 Hz, 1H), 4.27 (dd,J= 11.7, 9.3 Hz, 1H), 3.95 (s, 3H), 3.54 (d,J= 2.8 Hz, 3H), 3.29 (dd,J= 14.3, 4.9 Hz, 1H), 3.00 (dq,J= 9.7, 4.7 Hz, 1H), 2.76 (dd,J= 14.3, 9.4 Hz, 1H), 1.54 (s, 9H).

[0387] 단계 7) Methyl (S)-5-((6-((2-((tert-butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-8-(4-fluoro-2-methylphenyl)-4-oxochroman-3-yl)methyl)-2-fluorobenzoate (화합물 14-7)의 제조

[0388] To a solution of compound 14-6 (300 mg, 0.496 mmol, 1.0 equiv) in 1,4-dioxane / H2O (10:1, 5 mL) at room temperature were added Cs2CO3 (323 mg, 0.992 mmol, 2.0 equiv), Pd(amphos)Cl2 (35 mg, 0.049 mmol, 10 mol%), (4-fluoro-2-methylphenyl)boronic acid (114 mg, 0.74 mmol), and the reaction mixture was heated at 90 °C for 2 h. After cooling to RT, 1,4-dioxane was removed under reduced pressure, and the resulting residue was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, 2% to 10%) to give compound 14-7 (143 mg, 45%).

[0389] 1 H NMR (400 MHz, CDCl3) δ 7.85 - 7.27 (m, 5H), 7.12 - 6.85 (m, 3H), 6.52 (t,J= 2.1 Hz, 1H), 6.44 (dd,J= 14.8, 2.6 Hz, 1H), 5.00 (d,J= 17.8 Hz, 2H), 4.55 - 4.30 (m, 1H), 4.16 (ddd,J= 54.1, 11.6, 9.2 Hz, 1H), 3.90 (d,J= 6.6 Hz, 3H), 3.44 (d,J= 3.3 Hz, 3H), 3.25 (dt,J=14.4, 4.3 Hz, 1H), 2.95 (ddd,J= 20.7, 9.2, 4.4 Hz, 1H), 2.71 (ddd,J= 14.2, 9.4, 6.9 Hz, 1H), 2.22 - 1.94 (m, 2H), 1.47 (d,J= 21.9 Hz, 9H), 1.27 - 1.20 (m, 1H).

[0390] Step 8) Preparation of (S)-5-((6-((2-((tert-butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-8-(4-fluoro-2-methylphenyl)-4-oxochroman-3-yl)methyl)-2-fluorobenzoic acid (Compound 14-8)

[0391] To a solution of compound 14-7 (146 mg, 0.22 mmol, 1.0 equiv) in H2O:MeOH=1:3 (5 mL) was added NaHCO3 (95.2 mg, 1.13 mmol, 5.0 equiv). The reaction mixture was stirred at 110°C for 4 h using a microwave. The reaction solution was evaporated under reduced pressure, diluted with water, and washed three times with EtOAc. The aqueous layer was acidified to pH 4–5 with 1 N-HCl in H2O at 0°C and extracted with EtOAc. The combined organic layers were dried over Na2SO4 and concentrated to obtain compound 14-8 (74 mg, 54.5%).

[0392] 1 H NMR (400 MHz, MeOD) δ 7.88 (d,J= 2.4 Hz, 1H), 7.58 - 7.53 (m, 1H), 7.46 (d,J= 2.4 Hz, 1H), 7.39 (d,J= 2.3 Hz, 1H), 7.31 (d,J= 2.4 Hz, 1H), 7.14 - 7.09 (m, 1H), 7.08 - 6.97 (m, 3H), 6.93 (td,J= 8.4, 2.8 Hz, 1H), 5.25 (s, 2H), 4.20 (dd,J= 11.6, 8.3 Hz, 1H), 3.66 (s, 3H), 3.16 (dd,J= 13.9, 5.5 Hz, 1H), 3.07 (q,J= 6.6 Hz, 1H), 3.04 - 2.96 (m, 1H), 2.81 (dd,J= 14.4, 8.7 Hz, 1H), 2.12 (d,J= 4.7 Hz, 3H), 1.41 (s, 9H). ESI-MS m / z 168 (M+H) +

[0393] Step 9) tert-Butyl (1-(((S)-8-(4-fluoro-2-methylphenyl)-3-(4-fluoro-3-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyr rolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamoyl)benzyl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate Preparation of (Compound 14-9)

[0394] To a solution of compound 14-8 (30 mg, 0.048 mmol, 1.0 equiv) in DMF (1.5 mL) were added DIEA (26 μL, 0.144 mmol, 3.0 equiv) and HATU (37 mg, 0.096 mmol, 2.0 equiv) and stirred at room temperature for 1 h. (S,R,S)-AHPC-Me (23.5 mg, 0.048 mmol, 1.0 equiv) was added to the mixture. The reaction mixture was stirred at room temperature overnight. Upon completion of the reaction, the solvent was removed, and the residue was partitioned between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. Compound 14-9 was obtained (15.5 mg, 31%) after purification by MPLC.

[0395] 1H NMR (400 MHz, MeOD) δ 9.01 (s, 1H), 7.90 (d,J= 2.4 Hz, 1H), 7.64 (p,J= 5.6 Hz, 2H), 7.57 (d,J= 2.4 Hz, 1H), 7.48 - 7.38 (m, 5H), 7.32 (d,J= 2.4 Hz, 1H), 7.21 - 7.15 (m, 1H), 7.15 - 7.10 (m, 1H), 7.01 (dd,J= 9.8, 2.6 Hz, 1H), 6.94 (td,J= 8.4, 2.7 Hz, 1H), 5.33 (s, 2H), 5.01 (q,J= 7.0 Hz, 1H), 4.60 (t,J= 8.4 Hz, 1H), 4.50 - 4.35 (m, 2H), 4.25 - 4.16 (m, 1H), 3.94 (d,J= 11.1 Hz, 1H), 3.80 (dd,J= 11.1, 3.9 Hz, 1H), 3.74 (s, 3H), 3.21 (dd,J= 14.0, 5.7 Hz, 1H), 3.07 (dq,J= 8.7, 4.5, 4.0 Hz, 1H), 2.87 - 2.80 (m, 1H), 2.49 (s, 3H), 2.23 (dd,J= 13.3, 7.8 Hz, 1H), 2.12 (s, 3H), 2.00 - 1.93 (m, 1H), 1.60 (dd,J= 7.0, 3.0 Hz, 1H), 1.51 (d,J= 7.0 Hz, 3H), 1.42 (s, 9H), 1.11 (s, 9H). ESI-MS m / z 1045 (M+H) +

[0396] Step 10) (2S,4R)-1-((S)-2-(2-fluoro-5-(((S)-8-(4-fluoro-2-methylphenyl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochro man-3-yl)methyl)benzamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide Preparation of hydrochloride (compound 14)

[0397] To a solution of compound 14-9 (15.6 mg, 14.9 μmol) in anhydrous CH2Cl2 (1 mL) at 0°C was added dropwise 4 N-HCl in 1,4-dioxane (0.5 mL). The resulting mixture was stirred at room temperature for 4 h. The reaction mixture was concentrated under reduced pressure. The resulting solid was filtered, rinsed with diethyl ether (2 mL x 8), and concentrated in vacuo to give compound 14 as the HCl salt (10 mg, 64%).

[0398] 1H NMR (400 MHz, MeOD) δ 9.70 (s, 1H), 7.84 (d,J= 2.3 Hz, 1H), 7.68 (s, 1H), 7.54 (dd,J= 9.1, 6.6 Hz, 4H), 7.47 - 7.43 (m, 1H), 7.38 (d,J= 2.5 Hz, 1H), 7.22 - 7.12 (m, 2H), 7.04 (d,J= 9.9 Hz, 1H), 7.00 - 6.92 (m, 3H), 5.13 (s, 2H), 5.04 (d,J= 7.0 Hz, 1H), 4.62 (t,J=8.4 Hz, 1H), 4.49 (s, 1H), 4.44 (dd,J= 11.5, 4.4 Hz, 1H), 4.24 (t,J= 10.2 Hz, 1H), 3.97 (d,J= 11.1 Hz, 1H), 3.82 (dd,J= 11.2, 3.9 Hz, 1H), 3.56 (s, 3H), 3.24 (dd,J= 14.0, 5.7 Hz, 1H), 3.08 (s, 1H), 2.86 (s, 1H), 2.60 (s, 3H), 2.29 - 2.20 (m, 1H), 2.16 (s, 3H), 2.03 - 1.95 (m, 1H), 1.62 (d,J= 7.2 Hz, 1H), 1.53 (d,J= 7.1 Hz, 3H), 1.13 (s, 9H). ESI-MS m / z 944.4 (M+H) +

[0399] Compound 15. (2S,4R)-1-((S)-2-(3-(2-fluoro-5-(((S)-8-(4-fluoro-2-methylphenyl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)benzamido)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride

[0400]

[0401] Step 1) tert-Butyl (3-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)carbamate (compound 15-1) Manufacturing

[0402] To a solution of (S,R,S)-AHPC-Me (CAS NO. 1948273-02-6) (300 mg, 0.623 mmol) in DMF (5 mL) at 0 °C was added HATU (350 mg, 0.935 mmol) and DIEA (0.45 mL, 2.494 mmol). After stirring at room temperature for 30 min, 3-((tert-butoxycarbonyl)amino)propanoic acid (CAS NO. 3303-84-2) (130 mg, 0.686 mmol) in DMF (2 mL) was added to the reaction mixture at room temperature. The reaction mixture was stirred at room temperature for 30 min. The reaction mixture was quenched with H2O, brine, and ethyl acetate at 0 °C, extracted with ethyl acetate, washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MC: MeOH= 10:1) to obtain compound 15-1 (296 mg, 77%).

[0403] 1H NMR (400 MHz, CDCl3) δ 8.79 (s, 1H), 7.50 (d,J= 7.8 Hz, 1H), 7.44 - 7.33 (m, 4H), 6.43 (d,J= 8.6 Hz, 1H), 5.18 (s, 1H), 5.08 (t,J= 7.2 Hz, 1H), 4.77 (t,J= 7.9 Hz, 1H), 4.53 (d,J= 11.2 Hz, 2H), 4.11 (d,J= 11.3 Hz, 1H), 3.59 (dd,J= 11.5, 3.6 Hz, 1H), 3.47 - 3.27 (m, 2H), 2.56 (s, 3H), 2.46 (q,J= 7.4, 5.6 Hz, 1H), 2.41 - 2.33 (m, 1H), 2.08 (dd,J= 19.8, 8.8 Hz, 1H), 1.56 - 1.44 (m, 5H), 1.43 (s, 9H), 1.04 (s, 9H).

[0404] Step 2) Preparation of (2S,4R)-1-((S)-2-(3-aminopropanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-Methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 15-2)

[0405] To a solution of compound 15-1 (290 mg, 0.471 mmol) in CH2Cl2 (4 mL) at 0°C was slowly added 4 N-HCl in 1,4-dioxane (2 mL). The mixture was stirred at room temperature overnight, and the solvent was removed under pressure. The mixture was solidified using MeOH / diethyl ether. The solid was filtered, washed with Et2O, and dried under vacuum to give compound 15-2 (260 mg, quant.).

[0406] ESI-MS m / z 516 (M+H) +

[0407] Step 3) tert-butyl (1-(((S)-8-(4-fluoro-2-methylphenyl)-3-(4-fluoro-3-((3-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin -1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)carbamoyl)benzyl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate Preparation of (Compound 15-3)

[0408] To a solution of compound 14-8 (30 mg, 0.048 mmol, 1.0 equiv) in CH2Cl2:DMF (1 mL / 1 mL) at room temperature were added DIEA (26 μL, 0.144 mmol, 3.0 equiv) and HATU (37 mg, 0.096 mmol, 2.0 equiv). After stirring at room temperature for 1 h, compound 15-2 (23.5 mg, 0.048 mmol, 1.0 equiv) was added. The reaction mixture was stirred at room temperature overnight. Upon completion of the reaction, the solvent was removed, and the residue was partitioned between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After purification by MPLC, compound 15-3 (5 mg, 9.3%) was obtained.

[0409] 1H NMR (400 MHz, MeOD) δ 8.87 (s, 1H), 8.02 - 7.68 (m, 2H), 7.61 (t,J= 7.6 Hz, 1H), 7.50 - 7.34 (m, 5H), 7.34 - 7.27 (m, 1H), 7.16 (dd,J= 5.9, 2.4 Hz, 1H), 7.13 - 7.07 (m, 1H), 7.01 (q,J= 3.9, 3.0 Hz, 2H), 6.98 - 6.92 (m, 1H), 5.08 - 4.95 (m, 2H), 4.66 - 4.59 (m, 1H), 4.55 (t,J= 8.5 Hz, 1H), 4.47 - 4.30 (m, 2H), 4.22 (d,J= 10.4 Hz, 1H), 3.89 (d,J= 11.8 Hz, 1H), 3.77 - 3.72 (m, 1H), 3.64 (dd,J= 10.8, 5.4 Hz, 2H), 3.35 (s, 3H), 3.27 - 3.18 (m, 1H), 3.12 (d,J= 3.8 Hz, 1H), 3.08 - 3.00 (m, 1H), 2.70 - 2.51 (m, 2H), 2.48 (s, 3H), 2.14 (d,J= 15.1 Hz, 4H), 1.99 - 1.89 (m, 1H), 1.64 - 1.43 (m, 4H), 1.36 (d,J= 52.2 Hz, 9H), 1.14 - 0.94 (m, 9H). ESI-MS m / z 1113 (M-H) -

[0410] Step 4) (2S,4R)-1-((S)-2-(3-(2-fluoro-5-(((S)-8-(4-fluoro-2-methylphenyl)-6-((2-imino-3-methyl-2,3-dihydro Preparation of -1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)benzamido)propanamido)-3,3-dimethyl butanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (Compound 15)

[0411] To a solution of compound 15-3 (5.2 mg, 4.6 μmol) in anhydrous CH2Cl2 (1 mL) at 0°C was added dropwise 4 N-HCl in dioxane (0.5 mL). The resulting mixture was stirred at room temperature for 5 h. The reaction mixture was concentrated under reduced pressure. The resulting solid was filtered, rinsed with diethyl ether (2 mL x 8), and concentrated in vacuo to give compound 15 HCl salt product (3.9 mg, 80%).

[0412] 1H NMR (400 MHz, MeOD) δ 9.73 (s, 1H), 7.94 - 7.87 (m, 1H), 7.61 (t,J= 7.8 Hz, 1H), 7.51 (q,J= 8.2 Hz, 4H), 7.41 (d,J= 11.5 Hz, 2H), 7.18 (d,J= 2.3 Hz, 1H), 7.12 (q,J= 9.1, 7.5 Hz, 2H), 7.03 (d,J= 2.5 Hz, 2H), 6.99 - 6.91 (m, 1H), 5.06 - 4.98 (m, 3H), 4.62 (d,J=4.1 Hz, 1H), 4.56 (t,J= 8.3 Hz, 1H), 4.41 (s, 2H), 4.21 (d,J= 8.7 Hz, 1H), 3.89 (d,J= 11.1 Hz, 1H), 3.73 (d,J= 10.6 Hz, 2H), 3.65 (s, 2H), 3.36 (s, 3H), 3.22 (dd,J= 14.5, 5.4 Hz, 1H), 3.13 (s, 1H), 3.07 (s, 2H), 2.58 (s, 5H), 2.15 (d,J= 25.6 Hz, 4H), 1.94 (d,J= 10.8 Hz, 1H), 1.62 - 1.41 (m, 4H), 1.02 (d,J= 4.8 Hz, 9H). ESI-MS m / z 1015.5 (M+H) +

[0413] Compound 16. (2S,4R)-N-(2-((2-(1-(6-(((R)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-4-oxo-8,11-dioxa-2,5-diazatridecan-13-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide

[0414]

[0415]

[0416] Step 1) Preparation of Methyl 6-(3-((tert-butoxycarbonyl)(methyl)amino)azetidin-1-yl)-4-methylpicolinate (Compound 16-1)

[0417] A solution of methyl 6-chloro-4-methylpicolinate (CAS NO. 1186605-87-7) (5 g, 26.9 mmol), tert-butyl azetidin-3-yl(methyl)carbamate hydrochloride (CAS NO. 943060-59-1) (6 g, 26.9 mmol), CS2CO3 (26 g, 80.7 mmol), Pd2(dba)3 (739 g, 0.807 mmol), and Xantphos (933 g, 1.6 mmol) in 1,4-dioxane (50 mL) was stirred at 90°C for 17 h. After cooling to ambient temperature, the reaction mixture was filtered and concentrated. The residue was purified by MPLC (ethyl acetate:CH2Cl2=1:1) to give compound 16-1 (3.5 g, 55%).

[0418] 1 H NMR (400 MHz, CDCl3) δ 7.31 (d,J= 1.3 Hz, 1H), 6.29 (t,J= 1.1 Hz, 1H), 5.07 (s, 1H), 4.27 (t,J= 8.4 Hz, 2H), 4.05 (dd,J= 8.8, 5.7 Hz, 2H), 3.92 (s, 3H), 2.94 (s, 3H), 2.31 (s, 3H), 1.47 (s, 9H).

[0419] Step 2) Preparation of tert-Butyl (1-(6-(hydroxymethyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)carbamate (Compound 16-2)

[0420] To a solution of compound 16-1 (3.5 g, 14.8 mmol) in anhydrous CH2Cl2 (44 mL) at -78°C was added DIBAL (1 M solution in THF, 44 mL, 44 mmol). After stirring at 0°C for 3 h, the reaction mixture was quenched with K·Na·tartratein H2O (30 mL) at -78°C, and the slurry was stirred at room temperature for 1 h. The mixture was extracted with ethyl acetate (x 3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate:n-hexane = 1:2) to give compound 16-2 (2.6 mg, 84.7%).

[0421] 1 H NMR (400 MHz, CDCl3) δ 6.40 (s, 1H), 6.06 (s, 1H), 5.07 (s, 1H), 4.67 - 4.55 (m, 2H), 4.19 (d,J= 84.0 Hz, 5H), 2.97 (s, 3H), 2.29 (s, 3H), 1.49 (s, 9H). ESI-MS m / z 208.3 (M+H) +

[0422] Step 3) Preparation of tert-Butyl (1-(6-formyl-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)carbamate (Compound 16-3)

[0423] A solution of compound 16-2 (800 mg, 2.602 mmol) and 4 Å molecular sieves (100 mg) in CH2Cl2 (10 mL) was stirred for 10 min. N-methyl morpholine-N-oxide (NMO, 362 mg, 3.903 mmol) and tetrapropylammoniumperruthenate (TPAP, 91 mg, 0.26 mmol) were then added to the mixture at 0°C, and the reaction mixture was stirred at room temperature for 3 h. The dark mixture was filtered over Celite using diethyl ether as the eluent. After concentration in vacuo, the residue was purified by MPLC (ethyl acetate:n-heptane, 20%) to give compound 16-3 (386 mg, 49%).

[0424] 1 H NMR (400 MHz, CDCl3) δ 9.94 (s, 1H), 7.17 (d,J= 1.3 Hz, 1H), 6.36 (t,J= 1.1 Hz, 1H), 5.08 (s, 1H), 4.31 (t,J= 8.4 Hz, 2H), 4.10 (dd,J= 8.8, 5.7 Hz, 2H), 2.98 (s, 3H), 2.36 (s, 3H), 1.50 (s, 9H).

[0425] Step 4) tert-Butyl (E)-(1-(6-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-ylidene)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)carbamate Preparation of (Compound 16-4)

[0426] To a solution of compound 20-1 (565 mg, 1.3 mmol, 1.0 equiv) in MeOH (10 mL) at room temperature was added pyrrolidine (0.17 mL, 2.08 mmol, 1.5 equiv). The reaction mixture was stirred for 1 h, and compound 16-3 (287 mg, 1.39 mmol) was added to the mixture. After stirring at room temperature for 17 h, the solvent was removed under reduced pressure, and the resulting residue was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by MPLC (MeOH:CH2Cl2= 1:50 to 1:10) to obtain compound 16-4 (486 mg, 75%).

[0427] 1 H NMR (400 MHz, CDCl3) δ 7.82 (d,J= 2.3 Hz, 1H), 7.51 (d,J= 2.3 Hz, 1H), 7.47 (s, 1H), 7.10 (d,J= 2.4 Hz, 1H), 6.92 (d,J= 1.4 Hz, 1H), 6.84 (d,J= 1.3 Hz, 1H), 6.71 (s, 1H), 6.10 (s, 1H), 5.93 (d,J= 2.1 Hz, 2H), 5.01 (s, 2H), 4.28 - 4.14 (m, 5H), 3.99 (dd,J= 8.7, 5.8 Hz, 2H), 2.93 (s, 3H), 2.34 (d,J= 8.6 Hz, 4H), 2.25 (s, 3H), 1.53 (t,J= 7.3 Hz, 4H), 1.44 (s, 9H).

[0428] Step 5) tert-butyl (1-(6-(((3R,4R)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-hydroxy-6-((2-methyl-1H-imidazol-1-yl)methyl)chroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)carbamate Preparation of (Compound 16-5)

[0429] To a solution of compound 16-4 (486 mg, 0.7 mmol, 1.0 equiv) in acetonitrile (10 mL) was added a solution of DBU / formic acid (0.2 mL:0.33 mL) at ambient temperature. After stirring for 20 min, RuCl(p-cymene)[(R,R)-Ts-DPEN (44 mg, 0.07 mmol, 0.1 equiv) was added to the mixture. The reaction mixture was stirred at 60°C for 5 h and then quenched with saturated aqueous NaHCO3 at ambient temperature. After extraction with CH2Cl2, the organic layer was washed with an additional portion of NH4Cl, dried over MgSO4, and concentrated under reduced pressure. The residue was purified by MPLC (MeOH / CH2Cl2 = 1:30 to 1:10) to give compound 16-5 (361 mg, 74%).

[0430] 1H NMR (400 MHz, CDCl3) δ 7.47 (s, 1H), 7.11 (d,J= 2.4 Hz, 1H), 6.89 (d,J= 1.3 Hz, 1H), 6.85 (d,J= 2.3 Hz, 1H), 6.81 (d,J= 1.3 Hz, 1H), 6.37 (s, 1H), 6.02 (s, 1H), 4.99 (s, 1H), 4.94 (d,J= 9.5 Hz, 2H), 4.45 (d,J= 3.7 Hz, 1H), 4.22 (p,J= 7.7 Hz, 4H), 4.12 - 3.97 (m, 5H), 2.96 (s, 3H), 2.69 (qd,J= 13.3, 7.8 Hz, 2H), 2.33 (s, 3H), 2.32 - 2.27 (m, 1H), 2.23 (s, 3H), 1.53 (t,J= 7.3 Hz, 3H), 1.47 (s, 9H).

[0431] 단계 6) tert-Butyl (R)-(1-(6-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)carbamate (화합물 16-6)의 제조

[0432] A solution of compound 16-5 (361 mg, 0.51 mmol, 1.0 equiv) and 4 Å molecular sieves (100 mg) in CH2Cl2 (10 mL) was stirred at room temperature for 30 min. Then, N-methylmorpholine-N-oxide (NMO, 120 mg, 1.03 mmol) and tetrapropylammonium perruthenate (TPAP, 91 mg, 0.25 mmol) were added to the mixture at 0 °C. After stirring at ambient temperature for 17 h, the dark mixture was filtered through Celite using diethyl ether as the eluent and concentrated in vacuo. The residue was purified by MPLC (MeOH / CH2Cl2 = 1:30 to 1:10) to give compound 16-6 (162 mg, 46%).

[0433] 1 H NMR (400 MHz, CDCl3) δ 7.76 (d,J= 2.4 Hz, 1H), 7.49 (s, 1H), 7.12 (d,J= 2.4 Hz, 1H), 6.94 (d,J= 1.4 Hz, 1H), 6.84 (d,J= 1.4 Hz, 1H), 6.38 (s, 1H), 5.97 (s, 1H), 5.01 (s, 2H), 4.83 (s, 1H), 4.57 (dd,J= 11.4, 5.1 Hz, 1H), 4.32 - 4.26 (m, 1H), 4.26 - 4.19 (m, 2H), 4.13 (td,J=8.4, 3.0 Hz, 2H), 3.91 (ddd,J= 8.7, 5.9, 3.0 Hz, 2H), 3.39 (tt,J= 9.5, 4.6 Hz, 1H), 3.29 (dd,J= 14.7, 4.1 Hz, 1H), 2.93 (s, 3H), 2.66 (dd,J= 14.7, 9.4 Hz, 1H), 2.36 (s, 3H), 2.21 (s, 3H), 1.55 (t,J= 7.4 Hz, 3H), 1.46 (s, 9H).

[0434] Step 7) (R)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-3-((4-methyl-6-(3-(methylamino)azetidin-1-yl)pyridin-2-yl)methyl)chroman-4-one hydrochloride (Compound 16-7) manufacturing

[0435] To a solution of compound 16-6 (139 mg, 0.2 mmol) dissolved in CH2Cl2 (3 mL) was added dropwise 4 N-HCl in dioxane (1 mL) at 0 °C. The reaction mixture was stirred at room temperature for 4 h. Upon completion of the reaction, the solvent was removed to obtain compound 16-7 as a salt (126 mg, 99%).

[0436] 1 H NMR (400 MHz, MeOD) δ 7.97 (d,J= 1.0 Hz, 1H), 7.90 (d,J= 2.4 Hz, 1H), 7.55 (d,J= 2.1 Hz, 1H), 7.51 (q,J= 3.1, 2.7 Hz, 2H), 6.83 (d,J= 1.3 Hz, 1H), 6.67 (s, 1H), 5.44 (s, 2H), 4.71 (dd,J= 10.5, 7.7 Hz, 2H), 4.65 (dd,J= 11.5, 4.8 Hz, 1H), 4.52 (d,J= 10.7 Hz, 2H), 4.42 - 4.33 (m, 2H), 4.30 (q,J= 7.4 Hz, 2H), 3.52 - 3.37 (m, 2H), 2.93 (dd,J= 14.3, 6.7 Hz, 1H), 2.81 (s, 3H), 2.67 (s, 3H), 2.50 - 2.39 (m, 3H), 1.53 (t,J= 7.3 Hz, 3H). ESI-MS m / z 631 (M+H) +

[0437] Step 8) tert-butyl (R)-N-(1-(6-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N-methylglycinate Preparation of (Compound 16-8)

[0438] To a solution of compound 16-7 (100 mg, 0.15 mmol, 1.0 equiv) in DMF (2 mL) at room temperature was added Cs2CO3 (146 mg, 0.45 mmol, 3.0 equiv). t-Butyl bromoacetate (46 mg, 0.23 mmol, 1.5 equiv) was added to the mixture, and the reaction mixture was stirred at 60°C for 3 h. Upon completion of the reaction, the solvent was removed and diluted with EA. The residue was washed twice with H2O and extracted with EA. The combined organic layers were dried over Na2SO4 and concentrated. The crude product was purified by MPLC to give compound 16-8 (9 mg, 8.4%).

[0439] 1H NMR (400 MHz, CDCl3) δ 7.78 (dd, J = 11.6, 2.4 Hz, 1H), 7.49 (d, J = 16.2 Hz, 1H), 7.11 (dd, J = 12.3, 2.4 Hz, 1H), 6.94 (t, J = 1.6 Hz, 1H), 6.84 (t, J = 1.2 Hz, 1H), 6.31 (d, J = 26.0 Hz, 1H), 5.99 (d,J= 22.0 Hz, 1H), 5.01 (d,J= 2.8 Hz, 2H), 4.54 (dt,J= 9.4, 4.7 Hz, 1H), 4.27 - 4.22 (m, 2H), 4.20 (d,J= 6.1 Hz, 1H), 4.07 - 3.96 (m, 2H), 3.90 - 3.76 (m, 2H), 3.68 (dt,J= 19.5, 6.2 Hz, 1H), 3.39 (d,J= 10.2 Hz, 1H), 3.29 (dd,J= 14.5, 4.0 Hz, 1H), 2.63 (dd,J= 14.6, 9.5 Hz, 1H), 2.36 (t,J= 2.8 Hz, 6H), 2.20 (d,J= 3.3 Hz, 3H), 1.55 (td,J= 7.3, 3.7 Hz, 3H), 1.46 (d,J= 3.4 Hz, 9H). ESI-MS m / z 708 (M+H) +

[0440] 단계 9) (R)-N-(1-(6-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N-methylglycine (화합물 16-9)의 제조

[0441] To a solution of compound 16-8 (30 mg, 42 μmol) in anhydrous CH2Cl2 (1 mL) at 0°C was added TFA (0.5 mL) dropwise. The resulting mixture was stirred at room temperature for 15 h. The reaction mixture was concentrated under reduced pressure. The resulting solid was filtered, rinsed with diethyl ether (2 mL x 8), and concentrated in vacuo to give compound 16-9 TFA salt product (25 mg, 78%).

[0442] 1 H NMR (400 MHz, MeOD) δ 7.93 (dd,J= 20.9, 14.3 Hz, 2H), 7.51 (q,J= 15.3, 11.1 Hz, 3H), 6.79 - 6.39 (m, 2H), 5.43 (d,J= 8.5 Hz, 2H), 5.09 (s, 1H), 4.63 (d,J= 27.6 Hz, 1H), 4.35 (d,J= 42.5 Hz, 7H), 4.12 (s, 1H), 3.61 (s, 1H), 3.13 (d,J= 18.3 Hz, 1H), 2.91 (d,J= 33.5 Hz, 1H), 2.64 (d,J= 18.0 Hz, 6H), 2.50 - 2.14 (m, 4H), 1.63 - 1.42 (m, 3H). ESI-MS m / z 652.2 (M+H) +

[0443] Step 10) (2S,4R)-N-(2-((2-(1-(6-(((R)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidi n-3-yl)-4-oxo-8,11-dioxa-2,5-diazatridecan-13-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide Preparation of (Compound 16)

[0444] To a solution of (2S,4R)-N-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide hydrochloride ((S,R,S)-VL285 Phenol-PEG2-NH2hydrochloride, aldrich) (14 mg, 0.0196 mmol) in DMF (1 mL) were added compound 16-9 (15 mg, 0.0196 mmol), HATU (15 mg, 0.0392 mmol), and DIEA (17 uL, 0.098 mmol) at 0 °C. The mixture was stirred at room temperature for 20 h. The mixture was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by MPLC (MeOH:CH2Cl2=1:50 to 1:10) to give compound 16 (9.5 mg, 37%).

[0445] 1H NMR (400 MHz, CDCl3) δ 8.69 (s, 1H), 7.78 (dd,J= 14.9, 5.2 Hz, 2H), 7.54 (q,J= 6.8, 6.2 Hz, 2H), 7.48 - 7.31 (m, 5H), 7.15 (d,J= 2.1 Hz, 1H), 7.03 - 6.94 (m, 2H), 6.88 (d,J= 12.6 Hz, 2H), 5.03 (s, 2H), 4.85 - 4.73 (m, 2H), 4.61 - 4.54 (m, 2H), 4.46 (d,J= 17.1 Hz, 2H), 4.40 (t,J= 6.1 Hz, 1H), 4.34 (d,J= 10.3 Hz, 1H), 4.30 - 4.09 (m, 6H), 3.97 (t,J= 7.7 Hz, 1H), 3.90 (dd,J= 16.3, 9.7 Hz, 3H), 3.78 - 3.65 (m, 5H), 3.61 (td,J= 9.3, 8.8, 4.1 Hz, 2H), 3.46 (d,J= 7.1 Hz, 3H), 3.38 (s, 3H), 3.31 - 3.22 (m, 1H), 3.08 - 2.87 (m, 3H), 2.54 (s, 3H), 2.40 (s, 3H), 2.22 (d,J= 6.8 Hz, 6H), 2.07 (q,J= 9.0, 7.7 Hz, 3H), 1.56 (t,J= 6.2 Hz, 3H), 1.28 (s, 6H). ESI-MS m / z 1313.5 (M+H) +

[0446] Compound 17. (2S,4R)-1-((S)-2-(2-((1-(6-(((R)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)amino)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0447]

[0448] To a solution of compound 16-9 (10.3 mg, 0.0134 mmol) in DMF (1 mL) at room temperature were added HATU (6.1 mg, 0.0161 mmol) and DIEA (12 μL, 0.067 mmol). After stirring at room temperature for 30 min, a solution of (S,R,S)-AHPC-Me (6.8 mg, 0.0141 mmol) in DMF (0.5 mL) was added to the mixture, and the reaction mixture was stirred at room temperature for 19 h. The resulting mixture was quenched with H2O (5 mL) in an ice bath, extracted three times with ethyl acetate, and the extracts were washed with saturated NaCl, dried over Na2SO4, filtered, and concentrated. The concentrate was purified by flash column chromatography to give PROTAC compound 17 (6.7 mg, 46%).

[0449] 1H NMR (400 MHz, CDCl3) δ 8.68 (d,J= 2.8 Hz, 1H), 7.77 (t,J= 2.5 Hz, 1H), 7.54 (s, 1H), 7.48 - 7.32 (m, 6H), 7.18 (d,J= 2.4 Hz, 1H), 6.97 (s, 1H), 6.89 (s, 1H), 5.09 (d,J= 7.3 Hz, 1H), 5.05 (d,J= 9.2 Hz, 2H), 4.75 (t,J= 7.9 Hz, 1H), 4.54 (d,J= 14.2 Hz, 3H), 4.37 - 4.18 (m, 3H), 4.14 (d,J= 11.2 Hz, 1H), 4.08 - 3.92 (m, 2H), 3.77 (q,J= 8.1, 7.7 Hz, 2H), 3.60 (dd,J= 19.4, 9.8 Hz, 2H), 3.38 (s, 1H), 3.26 (ddd,J= 19.9, 9.3, 5.7 Hz, 1H), 3.17 - 2.85 (m, 3H), 2.54 (s, 3H), 2.41 - 2.38 (m, 3H), 2.35 (d,J= 2.3 Hz, 1H), 2.32 (d,J= 3.3 Hz, 3H), 2.22 (s, 3H), 2.11 (d,J= 9.2 Hz, 2H), 1.58 - 1.53 (m, 3H), 1.48 (dd,J= 7.0, 3.6 Hz, 3H), 1.06 (dd,J= 6.4, 2.5 Hz, 9H). ESI-MS m / z 1076.4(MH) -

[0450] Compound 18. N-1-((R)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N4-methyl-N4-(1-(4-methyl-6-(((R)-6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)pyridin-2-yl)azetidin-3-yl)succinimide

[0451]

[0452] Step 1) Preparation of 8-Bromo-6-(bromomethyl)-2,3-dihydrochromen-4-one (Compound 18-1)

[0453] To a solution of 8-bromo-6-methylchroman-4-one (CAS NO. 1026982-77-3) (32 g, 0.133 mol, 1 eq) in methyl acetate (640 mL) at room temperature were added NBS (28.35 g, 0.159 mol, 1.2 eq) and AIBN (4.36 g, 26.54 mmol, 0.2 eq). The reaction mixture was stirred at 70°C for 3 h and quenched with H2O in an ice bath. The mixture was extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated. The residue was solidified using MC / MeOH / heptane to give compound 18-1 (30.85 g, 70.4%).

[0454] 1 H NMR (400 MHz, CDCl3) δ 7.89 (d,J= 2.2 Hz, 1H), 7.81 (d,J= 2.2 Hz, 1H), 4.68 (t,J= 6.5 Hz, 2H), 4.44 (s, 2H), 2.88 (t,J= 6.5 Hz, 2H).

[0455] Step 2) Preparation of 8-Bromo-2,3-dihydro-6-((2-methyl-1H-imidazol-1-yl)methyl)chromen-4-one (Compound 18-2)

[0456] To a solution of compound 18-1 (20 g, 62.5 mmol, 1 eq.) in DMF (100 mL) was added 2-methyl imidazole (10.26 g, 125.0 mmol, 2 eq.). The reaction mixture was stirred at 50°C for 3.5 h and then cooled to ambient temperature. The mixture was poured into CH2Cl2 (700 ml), washed with H2O (500 ml), dried over MgSO4, and concentrated. The residue was purified by silica gel column chromatography (CH2Cl2 to CH2Cl2:MeOH=20:1) to obtain compound 18-2 (12.42 g, 61.9%).

[0457] 1 H NMR (400 MHz, CDCl3) δ 7.69 (d,J= 2.3 Hz, 1H), 7.43 (d,J= 2.3 Hz, 1H), 6.99 (d,J= 1.3 Hz, 1H), 6.85 (d,J= 1.3 Hz, 1H), 5.00 (s, 2H), 4.68 (m, 2H), 2.92 - 2.82 (m, 2H).

[0458] Step 3) Preparation of 8-(3-(Trifluoromethyl)-1-methyl-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)chroman-4-one (Compound 18-3)

[0459] To a solution of compound 18-2 (5 g, 15.57 mmol, 1 eq.) in 1,4-dioxane / H2O (6:1, 87.5 mL) at room temperature were added 3-(trifluoromethyl)-1-methyl-1H-pyrazol-4-yl-4-boronic acid (CAS NO. 1138450-30-2) (3.6 g, 18.68 mmol, 1.2 eq.), Cs2CO3 (10.1 g, 31.14 mmol, 2 eq.), and Pd(amphos)Cl2 (330 mg, 0.466 mmol, 0.03 eq.). The mixture was stirred at 100°C for 1 h. After cooling to room temperature, 1,4-dioxane was removed under reduced pressure, and the resulting residue was diluted with MC, brine, and H2O, extracted with CH2Cl2 (x2), dried over MgSO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (MC:MeOH=40:1) to obtain compound 18-3 (4.13 g, 68% yield).

[0460] 1 H NMR (400 MHz, CDCl3) δ 7.75 (d,J= 2.4 Hz, 1H), 7.50 (s, 1H), 7.14 (d,J= 2.4 Hz, 1H), 6.94 (d,J= 1.3 Hz, 1H), 6.84 (d,J= 1.3 Hz, 1H), 5.02 (s, 2H), 4.54 (m, 2H), 3.99 (s, 3H), 2.83 (m, 2H), 2.36 (s, 3H).

[0461] Step 4) tert-Butyl (E)-methyl(1-(4-methyl-6-((6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-ylidene)methyl)pyridin-2-yl)azetidin-3-yl)carbamate (Compound 18-4) Manufacturing

[0462] To a solution of compound 18-3 (12 mg, 0.030 mmol) in MeOH (1 mL) at room temperature was added pyrrolidine (5 μL, 0.06 mmol). After stirring at room temperature for 1 h, compound 16-3 (9.4 mg, 0.030 mmol) was added to the mixture, and the reaction mixture was stirred for 17 h. MeOH was removed under reduced pressure, and the resulting residue was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by MPLC (MeOH:CH2Cl2 = 1:50 to 1:10) to obtain compound 18-4 (16 mg, 80%).

[0463] 1 H NMR (400 MHz, CDCl3) δ 7.88 (d,J= 2.4 Hz, 1H), 7.56 (t,J= 2.1 Hz, 1H), 7.48 (s, 1H), 7.12 (d,J= 2.4 Hz, 1H), 6.98 (d,J= 1.4 Hz, 1H), 6.89 (d,J= 1.4 Hz, 1H), 6.76 (d,J= 1.1 Hz, 1H), 6.15 (t,J= 1.1 Hz, 1H), 5.98 (d,J= 2.1 Hz, 2H), 5.06 (s, 3H), 4.26 (q,J= 8.1 Hz, 2H), 4.04 (dd,J= 8.7, 5.7 Hz, 2H), 4.01 (s, 3H), 2.97 (d,J= 1.4 Hz, 3H), 2.41 (s, 3H), 2.30 (s, 3H), 1.49 (s, 9H).

[0464] Step 5) tert-butyl (1-(6-(((3R,4R)-4-hydroxy-6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)chroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)carbamate Preparation of (Compound 18-5)

[0465] To a solution of compound 18-4 (210 mg, 0.309 mmol, 1.0 equiv) in acetonitrile (5 mL) at room temperature was added DBU / formic acid solution (98 μL:58 μL). After stirring for 20 min, RuCl(p-cymene)[(R,R)-Ts-DPEN (19.7 mg, 0.03 mmol, 0.1 equiv) was added. The reaction mixture was stirred at 60°C for 5 h and then quenched with saturated aqueous NaHCO3 at ambient temperature. After extraction with CH2Cl2, the organic layer was washed with an additional portion of NH4Cl, dried over MgSO4, and concentrated under reduced pressure. The residue was purified by MPLC (MeOH / CH2Cl2 = 1:30 to 1:10) to give compound 18-5 (165 mg, 78%).

[0466] 1 H NMR (400 MHz, CDCl3) δ 7.46 (d,J= 1.0 Hz, 1H), 7.15 (d,J= 2.3 Hz, 1H), 7.00 (d,J= 1.5 Hz, 1H), 6.86 (t,J= 1.8 Hz, 2H), 6.38 (d,J= 1.2 Hz, 1H), 6.03 (t,J= 1.0 Hz, 1H), 4.99 (d,J= 41.0 Hz, 3H), 4.47 (d,J= 3.8 Hz, 1H), 4.26 (t,J= 8.2 Hz, 2H), 4.10 - 3.99 (m, 4H), 3.97 (s, 3H), 2.97 (s, 3H), 2.79 - 2.64 (m, 2H), 2.46 (s, 3H), 2.31 (td,J= 11.0, 10.1, 4.1 Hz, 1H), 2.24 (s, 3H), 1.48 (s, 9H). ESI-MS m / z 682 (M+H) +

[0467] Step 6) tert-butyl (R)-methyl(1-(4-methyl-6-((6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)pyridin-2-yl)azetidin-3-yl)carbamate (compound 18-6) Manufacturing

[0468] Compound 18-5 (164 mg, 0.4 mmol, 1.0 equiv) and 4 Å molecular sieves (100 mg) were added to CH2Cl2 (5 mL) and stirred for 30 min. At 0°C, N-methylmorpholine N-oxide (NMO, 70 mg, 0.6 mmol) and tetrapropylammonium perruthenate (TPAP, 28 mg, 0.08 mmol) were added, and stirring was continued at room temperature for 17 h. The dark mixture was filtered over Celite using diethyl ether as the eluent. After concentration in vacuo, the residue was purified by MPLC (MeOH / CH2Cl2 = 1:30 to 1:10) to give compound 18-6 (35 mg, 13%).

[0469] 1H NMR (400 MHz, CDCl3) δ 7.77 (d,J= 2.4 Hz, 1H), 7.49 (d,J= 1.1 Hz, 1H), 7.12 (d,J= 2.4 Hz, 1H), 7.01 (d,J= 1.5 Hz, 1H), 6.87 (d,J= 1.5 Hz, 1H), 6.38 (s, 1H), 5.98 (s, 1H), 5.04 (s, 3H), 4.59 (dd,J= 11.4, 5.1 Hz, 1H), 4.29 (t,J= 11.2 Hz, 1H), 4.17 - 4.11 (m, 2H), 3.98 (s, 3H), 3.92 (ddd,J= 8.4, 5.8, 2.0 Hz, 2H), 3.45 - 3.35 (m, 1H), 3.29 (dd,J= 14.7, 4.2 Hz, 1H), 2.92 (s, 3H), 2.69 (dd,J= 14.8, 9.1 Hz, 1H), 2.44 (s, 3H), 2.21 (s, 3H), 1.45 (s, 9H).

[0470] Step 7) Preparation of (R)-6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-3-((4-methyl-6-(3-(methylamino)azetidin-1-yl)pyridin-2-yl)methyl)chroman-4-one hydrochloride (Compound 18-7)

[0471] Compound 18-6 (27 mg, 0.039 mmol, 1.0 equiv) dissolved in CH2Cl2 (2 mL) at 0°C was treated with 4 N-HCl in 1,4-dioxane (1.0 mL). The reaction was stirred at room temperature, and upon completion of the reaction, the solvent was removed to obtain compound 18-7 as a salt (24 mg, 99%).

[0472] 1H NMR (400 MHz, MeOD) δ 7.95 - 7.85 (m, 2H), 7.57 - 7.46 (m, 3H), 7.01 - 6.64 (m, 2H), 5.42 (s, 2H), 4.74 - 4.58 (m, 2H), 4.50 (d,J= 9.6 Hz, 1H), 4.35 (dd,J= 23.3, 12.0 Hz, 2H), 4.17 (t,J= 8.7 Hz, 1H), 4.12 - 4.01 (m, 2H), 3.99 (s, 3H), 3.80 - 3.71 (m, 2H), 3.16 (td,J= 12.1, 3.6 Hz, 1H), 2.91 (s, 3H), 2.65 (d,J= 2.1 Hz, 3H), 2.43 (d,J= 4.7 Hz, 3H).

[0473] 단계 8) N-1-((R)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N4-methyl-N4-(1-(4-methyl-6-(((R)-6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)pyridin-2-yl)azetidin-3-yl)succinimide (화합물 18)의 제조

[0474] To a solution of compound 27-2 (9.7 mg, 0.017 mmol, 1.1 eq) in MC / DMF (1 mL / 1 mL) were added DIEA (21 mg, 0.16 mmol, 10.0 eq), EDCI (4.6 mg, 0.024 mmol, 1.5 eq), HOBt (3.6 mg, 0.024 mmol, 1.5 eq), and compound 18-7 (10 mg, 0.016 mmol, 1 eq). The reaction mixture was stirred at room temperature overnight. Upon completion of the reaction, the solvent was removed, and the residue was partitioned between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After purification by MPLC, compound 18 (4.2 mg, 26%) was obtained.

[0475] 1H NMR (400 MHz, MeOD) δ 8.88 (s, 1H), 7.96 - 7.82 (m, 4H), 7.77 (s, 1H), 7.55 - 7.40 (m, 8H), 6.52 (s, 1H), 6.23 (s, 1H), 5.39 (s, 2H), 5.19 (s, 1H), 5.01 (t,J= 6.9 Hz, 1H), 4.63 - 4.48 (m, 3H), 4.41 (s, 1H), 4.39 - 4.26 (m, 2H), 4.20 (d,J= 14.8 Hz, 2H), 4.06 - 4.01 (m, 1H), 3.98 (s, 3H), 3.84 (d,J= 11.2 Hz, 1H), 3.73 (d,J= 11.1 Hz, 1H), 3.26 - 3.18 (m, 1H), 3.14 (s, 2H), 3.04 (s, 1H), 2.77 (s, 1H), 2.69 (t,J= 8.5 Hz, 1H), 2.62 (s, 3H), 2.56 (t,J= 6.9 Hz, 1H), 2.48 (s, 3H), 2.27 (s, 2H), 2.23 - 2.15 (m, 1H), 2.01 (s, 2H), 1.95 (t,J= 13.0 Hz, 1H), 1.50 (d,J= 7.0 Hz, 3H), 1.29 (s, 4H), 1.03 (d,J= 5.9 Hz, 9H). ESI-MS m / z 1107

[0476] Compound 19. 2-(4-(2,6-dioxopiperidin-3-yl)phenoxy)-N-methyl-N-(1-(4-methyl-6-(((R)-6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)pyridin-2-yl)azetidin-3-yl)acetamide

[0477]

[0478] DIEA (8 μL, 0.048 mmol, 3.0 equiv) and HATU (12.1 mg, 0.048 mmol, 2.0 equiv) were added to a solution of 2-(4-(2,6-dioxopiperidin-3-yl)phenoxy)acetic acid (synthesized according to the synthetic method of the following paper. Angew. Chem. Int. Ed. 2021, 60, 26663-26670; https: / onlinelibrary.wiley.com / doi / full / 10.1002 / anie.202108848) (4.5 mg, 0.017 mmol, 1.1 equiv) in DMF (1 mL) at RT. After stirring at room temperature for 1 h, compound 18-7 (8 mg, 0.013 mmol, 1.0 equiv) was added to the mixture. The reaction mixture was stirred at room temperature overnight. Upon completion of the reaction, the solvent was removed, and the residue was partitioned between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After purification by MPLC, compound 19 was obtained (1.6 mg, 15%).

[0479] 1H NMR (400 MHz, MeOD) δ 7.83 (s, 1H), 7.75 (s, 1H), 7.32 (s, 1H), 7.23 (d,J= 8.7 Hz, 1H), 7.16 (dd,J= 8.7, 1.9 Hz, 2H), 7.10 (d,J= 7.4 Hz, 1H), 7.01 - 6.92 (m, 2H), 6.47 (s, 1H), 6.13 (s, 1H), 5.24 (s, 2H), 5.14 (s, 1H), 5.01 (s, 1H), 4.47 (s, 1H), 4.34 (d,J= 9.4 Hz, 1H), 4.23 (t,J= 8.6 Hz, 1H), 4.14 (t,J= 8.2 Hz, 1H), 4.04 (s, 1H), 3.96 (s, 4H), 3.80 (s, 1H), 3.16 (s, 3H), 3.09 (s, 1H), 2.85 (s, 2H), 2.71 - 2.58 (m, 2H), 2.43 (d,J= 3.5 Hz, 3H), 2.23 (s, 3H), 2.16 (s, 2H), 2.03 (d,J= 10.0 Hz, 1H). ESI-MS m / z 825 (M+H) +

[0480] Compound 20. (2S,4R)-1-((S)-2-(2-(5-(((S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0481]

[0482] Step 1) Preparation of Methyl 2-(2-fluoro-5-formylphenoxy)acetate (Compound A)

[0483] To a solution of 4-fluoro-3-hydroxybenzaldehyde (CAS NO. 103438-85-3) (3 g, 21.413 mmol) in DMF (15 mL) at room temperature were added K2CO3 (5.919 g, 42.826 mmol) and methyl bromoacetate (CAS NO. 96-32-2) (2.24 mL, 23.554 mmol). The reaction mixture was stirred at 50°C for 15 h and cooled to room temperature. The mixture was diluted with ethyl acetate, and the organic phase was washed with water, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by MPLC (ethyl acetate:n-heptane = 1:10 to 1:2) to give compound A (3.559 g, 78%).

[0484] 1 H NMR (400 MHz, CDCl3) δ 9.92 (s, 1H), 7.54 (ddd,J= 8.2, 4.4, 1.9 Hz, 1H), 7.46 (dd,J= 8.0, 1.9 Hz, 1H), 7.31 - 7.26 (m, 1H), 4.80 (s, 2H), 3.84 (s, 3H).

[0485] Step 2) Preparation of 8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)chroman-4-one (Compound 20-1)

[0486] To a solution of compound 18-2 (5.5 g, 16.41 mmol, 1 equiv) in 1,4-dioxane / H2O (6:1, 96.3 mL) at room temperature were added 3-(trifluoromethyl)-1-ethyl-1H-pyrazol-4-yl-4-boronic acid (CAS NO. 2287228-20-8) (4.1 g, 19.72 mmol, 1.2 equiv), Cs2CO3 (10.69 g, 32.81 mmol, 2 equiv), and Pd(amphos)Cl2 (232 mg, 0.328 mmol, 0.02 equiv). The mixture was stirred at 100°C for 1 h. After cooling to room temperature, 1,4-dioxane was removed under reduced pressure, and the resulting residue was diluted with MC, brine, and H2O, MC(x2) was extracted, dried over MgSO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (CH2Cl2:MeOH=40:1) to obtain compound 20-1 (6.18 g, 76.2% yield).

[0487] 1 H NMR (400 MHz, CDCl3) δ 7.76 (d,J= 2.4 Hz, 1H), 7.52 (d,J= 0.8 Hz, 1H), 7.15 (d,J= 2.4 Hz, 1H), 6.95 (d,J= 1.4 Hz, 1H), 6.85 (d,J= 1.4 Hz, 1H), 5.02 (s, 2H), 4.55 (m, 2H), 4.26 (q,J= 7.4 Hz, 2H), 2.84 (m, 2H), 2.36 (s, 3H), 1.57 (t,J= 7.4 Hz, 3H).

[0488] Step 3) Preparation of Methyl (E)-2-(5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-ylidene)methyl)-2-fluorophenoxy)acetate (Compound 20-2)

[0489] To a solution of compound 20-1 (500 mg, 1.236 mmol) in MeOH (7 mL) were added pyrrolidine (150 uL, 1.854 mmol) and compound A (393 mg, 1.854 mmol). After stirring at room temperature for 17 h, MeOH was removed under reduced pressure, and the resulting residue was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by MPLC (ethyl acetate:n-heptane = 1:10 to 1:2) to give compound 20-2 (248 mg, 34%).

[0490] 1 H NMR (400 MHz, CDCl3) δ 7.92 - 7.86 (m, 1H), 7.81 (s, 1H), 7.52 - 7.48 (m, 1H), 7.18 (dt,J= 6.0, 3.1 Hz, 2H), 7.03 - 7.00 (m, 1H), 6.92 - 6.87 (m, 3H), 5.32 (s, 2H), 5.09 (s, 2H), 4.75 (s, 2H), 4.26 (d,J= 7.4 Hz, 2H), 3.83 (s, 3H), 2.45 (s, 3H), 1.57 (d,J= 7.3 Hz, 3H). ESI-MS m / z 599.5 (M+H) +

[0491] Step 4) Preparation of methyl 2-(5-(((3S,4S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-hydroxy-6-((2-methyl-1H-imidazol-1-yl)methyl)chroman-3-yl)methyl)-2-fluorophenoxy)acetate (Compound 20-3)

[0492] A solution of DBU / formic acid (0.15 mL:0.077 mL) was added to a solution of compound 20-2 (245 mg, 0.409 mmol) in acetonitrile (7 mL) at room temperature. After stirring for 20 min, RuCl(p-cymene)[(S,S)-Ts-DPEN] (26 mg, 41 μmol) was added to the mixture. The reaction mixture was stirred at 70°C for 2 h and then quenched with saturated aqueous NaHCO3 at ambient temperature. After extraction with CH2Cl2, the organic layer was washed with saturated NH4Cl solution, dried over MgSO4, and concentrated under reduced pressure. The residue was purified by MPLC (MeOH / CH2Cl2 = 1:30 to 1:10) to give compound 20-3 (99 mg, 40%).

[0493] 1 H NMR (400 MHz, CDCl3) δ 7.54 (s, 1H), 7.13 (s, 1H), 7.05 (d,J= 3.2 Hz, 1H), 7.03 (s, 1H), 6.97 (d,J= 2.3 Hz, 1H), 6.87 (s, 1H), 6.85 (s, 2H), 4.97 (s, 2H), 4.72 (s, 2H), 4.50 (d,J= 3.3 Hz, 1H), 4.28 - 4.20 (m, 3H), 4.09 (s, 1H), 3.80 (s, 3H), 2.86 (dd,J= 13.7, 8.5 Hz, 1H), 2.62 (dd,J= 13.7, 7.3 Hz, 1H), 2.35 (d,J= 4.4 Hz, 1H), 2.33 (s, 3H), 1.57 (s, 3H). ESI-MS m / z 603.1 (M+H) +

[0494] Step 5) Preparation of Methyl (S)-2-(5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetate (Compound 20-4)

[0495] To a solution of compound 20-3 (95 mg, 0.158 mmol) in CH2Cl2 (10 mL) were added N-methylmorpholine-N-oxide (NMO, 37 mg, 0.316 mmol), TPAP (30 mg, 0.079 mmol), and 4 Å molecular sieves (40 mg). After stirring at room temperature for 2 h, the dark mixture was filtered over Celite using diethyl ether as the eluent. After concentration in vacuo, the residue was purified by MPLC (MeOH / CH2Cl2 = 1:30 to 1:10) to give compound 20-4 (44 mg, 46%).

[0496] 1 H NMR (400 MHz, CDCl3) δ 7.80 - 7.76 (m, 1H), 7.51 (d,J= 1.0 Hz, 1H), 7.17 (d,J= 2.4 Hz, 1H), 7.08 - 7.03 (m, 1H), 7.01 (s, 1H), 6.89 (s, 1H), 6.85 - 6.80 (m, 2H), 5.06 (s, 2H), 4.71 (s, 2H), 4.39 (dd,J= 11.6, 4.4 Hz, 1H), 4.26 (t,J= 7.4 Hz, 2H), 4.18 (dd,J= 11.6, 8.6 Hz, 1H), 3.81 (s, 3H), 3.24 - 3.18 (m, 1H), 2.91 (dt,J= 9.2, 4.4 Hz, 1H), 2.70 (dd,J= 14.1, 9.9 Hz, 1H), 2.43 (s, 3H), 1.57 (d,J= 7.3 Hz, 3H).

[0497] Step 6) Preparation of (S)-2-(5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetic acid (Compound 20-5)

[0498] To a solution of compound 20-4 (39 mg, 0.065 mmol) in MeOH / H2O (2 / 0.2 mL) at 0°C was added LiOH (2.3 mg, 0.097 mmol). The reaction mixture was stirred at room temperature for 2 h, quenched with saturated NH4Cl solution, and evaporated. The mixture was diluted with water (1.5 mL), cooled to 0°C, and adjusted to pH 4 by adding 1 N aqueous HCl solution. The mixture was diluted with ethyl acetate and water, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was used in the next step without further purification (26 mg, 68%).

[0499] 1 H NMR (400 MHz, MeOD) δ 7.93 (d,J= 1.1 Hz, 1H), 7.84 (d,J= 2.4 Hz, 1H), 7.51 - 7.46 (m, 1H), 7.45 (d,J= 2.4 Hz, 1H), 7.44 - 7.39 (m, 1H), 7.01 - 6.95 (m, 1H), 6.87 (dd,J= 8.1, 2.1 Hz, 1H), 6.78 (ddd,J= 8.3, 4.2, 2.1 Hz, 1H), 5.39 (s, 2H), 4.55 (s, 2H), 4.44 (dd,J= 11.7, 4.5 Hz, 1H), 4.31 - 4.24 (m, 3H), 3.19 - 3.11 (m, 1H), 3.01 (dt,J= 8.7, 4.4 Hz, 1H), 2.73 (dd,J= 13.9, 9.1 Hz, 1H), 2.61 (d,J= 1.1 Hz, 3H), 1.53 (d,J= 7.3 Hz, 3H). ESI-MS m / z 587.2 (M+H) +

[0500] Step 7) (2S,4R)-1-((S)-2-(2-(5-(((S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)met hyl)-2-fluorophenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide Preparation of (Compound 20)

[0501] To a solution of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (11 mg, 0.022 mmol) in DMF (1 mL) at 0 °C were added compound 20-5 (13.1 mg, 0.022 mmol), HATU (17 mg, 0.044 mmol), and DIEA (20 uL, 0.112 mmol). The reaction mixture was stirred at room temperature for 20 h and diluted with EtOAc, brine, and H2O. The mixture was extracted with ethyl acetate (x3), and the extracts were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by MPLC (MeOH:CH2Cl2=1:50 to 1:10) to obtain compound 20 (12 mg, 54%).

[0502] 1H NMR (400 MHz, CDCl3) δ 8.67 (s, 1H), 7.72 (dd,J= 6.2, 2.2 Hz, 1H), 7.56 (dd,J= 19.4, 5.2 Hz, 2H), 7.39 - 7.36 (m, 4H), 7.20 (s, 1H), 7.08 - 6.97 (m, 1H), 6.96 (d,J= 3.6 Hz, 1H), 6.89 (s, 1H), 6.83 (s, 1H), 5.12 - 4.99 (m, 3H), 4.76 (q,J= 7.7 Hz, 1H), 4.61 - 4.48 (m, 4H), 4.40 (dd,J= 11.9, 4.4 Hz, 1H), 4.25 (q,J= 7.4 Hz, 2H), 4.20 - 4.12 (m, 1H), 4.09 (d,J= 11.3 Hz, 1H), 3.67 (dd,J= 11.3, 3.9 Hz, 1H), 3.17 (dd,J= 14.0, 5.2 Hz, 1H), 3.06 (s, 3H), 2.94 (s, 1H), 2.77 (q,J= 12.2, 11.2 Hz, 1H), 2.52 (s, 3H), 2.47 - 2.41 (m, 1H), 2.38 (d,J= 3.3 Hz, 3H), 2.11 (d,J= 11.7 Hz, 1H), 1.55 (t,J= 7.3 Hz, 3H), 1.49 (d,J= 6.7 Hz, 3H), 1.08 (s, 9H). ESI-MS m / z 1013.2 (M+H) +

[0503] Compound 21. 5-((8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenyl 2-(3-(2,6-dioxopiperidin-3-yl)phenoxy)acetate

[0504]

[0505]

[0506] Step 1) Preparation of 3-(2,6-bis(benzyloxy)pyridin-3-yl)phenol (Compound 21-1)

[0507] To a mixture of 2,6-bis(benzyloxy)-3-bromopyridine (CAS NO. 16727-47-2) (1 g, 2.701 mmol), (3-hydroxyphenyl)boronic acid (CAS NO. 87199-18-6) (745 mg, 5.402 mmol), and potassium phosphate (1.25 g, 5.81 mmol) in 1,4-dioxane / H2O (6:1, 30 mL:5 mL) was added 1,1-bis(diphenylphosphino)ferrocenedichloropalladium (221 mg, 0.270 mmol) at room temperature. After stirring overnight at 110°C, the reaction mixture was cooled to room temperature and filtered through a pad of Celite. The mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (EtOAc:heptane = 1:4) to obtain compound 21-1 (980 mg, 95%).

[0508] 1 H NMR (400 MHz, CDCl3) δ 7.80 (d,J= 8.1 Hz, 1H), 7.65 - 7.43 (m, 12H), 7.33 (d,J= 7.8 Hz, 1H), 6.99 - 6.95 (m, 1H), 6.67 (d,J= 8.1 Hz, 1H), 5.64 (s, 2H), 5.56 (s, 2H), 4.90 (s, 1H).

[0509] Step 2) Preparation of tert-Butyl 2-(3-(2,6-bis(benzyloxy)pyridin-3-yl)phenoxy)acetate (Compound 21-2)

[0510] To a solution of compound 21-1 (950 mg, 2.48 mmol) in DMF (25 mL) at room temperature were added potassium carbonate (515 mg, 3.72 mmol) and tert-butyl 2-bromoacetate (0.39 mL, 2.600 mmol). After stirring overnight at room temperature, the reaction mixture was quenched with H2O, extracted with ethyl acetate, washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (EtOAc:Hep = 0-20%) to give compound 21-2 (1.1 g, 92%).

[0511] 1 H NMR (400 MHz, CDCl3) δ 7.63 (d,J= 8.0 Hz, 1H), 7.48 - 7.44 (m, 2H), 7.44 - 7.28 (m, 9H), 7.24 - 7.19 (m, 1H), 7.16 (dd,J= 2.6, 1.5 Hz, 1H), 6.89 - 6.83 (m, 1H), 6.49 (d,J= 8.1 Hz, 1H), 5.45 (s, 2H), 5.39 (s, 2H), 4.49 (s, 2H), 1.52 (s, 9H).

[0512] Step 3) Preparation of tert-Butyl 2-(3-(2,6-dioxopiperidin-3-yl)phenoxy)acetate (Compound 21-3)

[0513] To a solution of compound 21-2 (1.1 g, 2.211 mmol) in EtOH (20 mL) was added 10% palladium on carbon (100 mg, 0.928 mmol) at room temperature. After evacuating the reaction flask, a hydrogen balloon was attached to the reaction flask. After stirring overnight at room temperature, the reaction mixture was filtered through a pad of Celite. The mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (EtOAc:Hep = 1:1) to give compound 21-3 (690 mg, 98%).

[0514] 1 H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.29 (t,J= 7.9 Hz, 1H), 6.87 - 6.77 (m, 3H), 4.51 (s, 2H), 3.76 (dd,J= 9.3, 5.2 Hz, 1H), 2.77 - 2.59 (m, 2H), 2.34 - 2.17 (m, 2H), 1.49 (s, 9H).

[0515] Step 4) Preparation of 2-(3-(2,6-dioxopiperidin-3-yl)phenoxy)acetic acid (compound 21-4)

[0516] To a solution of compound 21-3 (690 mg, 2.16 mmol) in THF (0.5 mL) at room temperature was added trifluoroacetic acid (6.6 mL, 86.42 mmol). The reaction mixture was stirred at room temperature overnight and concentrated under reduced pressure to obtain compound 21-4 (530 mg, 93%).

[0517] 1 H NMR (400 MHz, MeOD) δ 7.31 - 7.25 (m, 1H), 6.90 - 6.85 (m, 3H), 4.66 (s, 2H), 3.85 (dd,J= 9.9, 5.9 Hz, 1H), 2.76 - 2.57 (m, 2H), 2.29 - 2.19 (m, 2H).

[0518] Step 5) Preparation of 8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-methylchroman-4-one (Compound 21-5)

[0519] To a solution of 8-bromo-6-methylchroman-4-one (CAS NO. 1026982-77-3) (1.5 g, 6.2 mmol, 1.0 equiv) in 1,4-dioxane / H2O (10:1, 50 mL) at room temperature were added Cs2CO3 (4.0 g, 12.44 mmol, 2.0 equiv) and Pd(amphos)Cl2 (446 mg, 0.63 mmol, 0.1 equiv). After 10 min, (1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)boronic acid (1.94 g, 9.33 mmol, 1.5 equiv) was added to the mixture, and the reaction mixture was stirred at 100 °C for 2 h. After cooling to room temperature, 1,4-dioxane was removed under reduced pressure, and the resulting residue was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, from 2% to 10%) to give compound 21-5 (1.069 g, 53%).

[0520] 1 H NMR (400 MHz, CDCl3) δ 7.70 (dd,J= 2.3, 1.0 Hz, 1H), 7.53 (d,J= 1.1 Hz, 1H), 7.28 (d,J= 2.3 Hz, 1H), 4.52 - 4.44 (m, 2H), 4.25 (q,J= 7.3 Hz, 2H), 2.78 (dd,J= 6.9, 6.0 Hz, 2H), 2.31 (s, 3H), 1.56 (t,J= 7.4 Hz, 3H).

[0521] Step 6) Preparation of 6-(Bromomethyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)chroman-4-one (Compound 21-6)

[0522] To a solution of compound 21-5 (1.0 g, 3.3 mol, 1 equiv) in methyl acetate (30 mL) at room temperature were added NBS (640 mg, 3.6 mmol, 1.1 equiv) and AIBN (50 mg, 0.3 mmol, 0.1 equiv). The reaction mixture was stirred at 70°C for 3 h, quenched with H2O in an ice bath, extracted with ethyl acetate, washed with brine, dried over MgSO4, and concentrated. The residue was solidified using CH2Cl2 / MeOH / heptane to give compound 21-6 (512 mg, 44%).

[0523] ESI-MS m / z 403.0 (M+H) +

[0524] Step 7) Preparation of 8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)chroman-4-one (Compound 21-7)

[0525] To a solution of compound 21-6 (100 mg, 0.28 mmol, 1.0 equiv) and 1-methyl-1,3-dihydro-2H-imidazol-2-imine (32.6 mg, 0.34 mmol, 1.2 equiv) in MeCN (2 mL) were added DIEA (59 μL, 0.336 mmol, 1.2 equiv) and KI (46 mg, 0.28 mmol, 1.0 equiv). The reaction mixture was stirred at 60 °C for 2 h. After cooling to ambient temperature, the reaction mixture was diluted with ethyl acetate, and the organic phase was washed with water, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, 2% to 10%) to give compound 21-7 (54.5 mg, 43.7%).

[0526] 1H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 2.4 Hz, 1H), 7.81 (s, 1H), 7.58 (d, J = 2.4 Hz, 1H), 6.67 (d,J= 2.5 Hz, 1H), 6.65 (d,J= 2.5 Hz, 1H), 5.41 (s, 2H), 4.50 (t,J= 6.4 Hz, 2H), 4.22 (q,J= 7.3 Hz, 2H), 3.76 (s, 3H), 2.77 (t,J= 6.5 Hz, 2H), 1.51 (t,J= 7.3 Hz, 3H).

[0527] Step 8) Preparation of tert-Butyl (1-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate (Compound 21-8)

[0528] A solution of compound 21-7 (2.0 g, 4.7 mmol, 1.0 equiv), Boc2O (4.4 mL, 5.7 mmol, 1.2 equiv), and THF (50 mL) was stirred at room temperature. After 10 min, DMAP (287 mg, 2.35 mmol, 0.5 equiv) was added and stirred for 15 h. The reaction mixture was diluted with CH2Cl2, and the organic phase was washed with water, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, from 2% to 10%) to give protected compound 21-8 (1.87 g, 77.8%).

[0529] 1H NMR (400 MHz, CDCl3) δ 7.78 (d,J= 2.4 Hz, 1H), 7.65 (d,J= 1.2 Hz, 1H), 7.45 (d,J= 2.4 Hz, 1H), 6.79 (d,J= 2.5 Hz, 1H), 6.68 (d,J= 2.5 Hz, 1H), 5.08 (s, 2H), 4.54 - 4.46 (m, 2H), 4.21 (q,J= 7.3 Hz, 2H), 3.55 (s, 3H), 2.82 - 2.71 (m, 2H), 1.52 (t,J= 7.4 Hz, 3H), 1.43 (s, 9H).

[0530] Step 9) tert-Butyl ((E)-1-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-3-((E)-4-fluoro-3-hydroxybenzylidene)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate Preparation of (Compound 21-9)

[0531] To a solution of compound 21-8 (100 mg, 0.192 mmol) in MeOH (5 mL) at room temperature were added 4-fluoro-3-hydroxybenzaldehyde (35 mg, 0.250 mmol) and pyrrolidine (18 mg, 0.250 mmol). The mixture was stirred for 23 h. MeOH was removed under reduced pressure, and the resulting residue was diluted with EA, brine, and H2O. EA was extracted, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by MPLC (MC: MeOH = 100:1 to 15:1) to give compound 21-9 (106 mg, 86%).

[0532] 1H NMR (400 MHz, CDCl3) δ 7.89 (d,J= 2.4 Hz, 1H), 7.67 (s, 1H), 7.62 (d,J= 2.1 Hz, 1H), 7.48 (d,J= 2.3 Hz, 1H), 7.04 - 6.90 (m, 4H), 6.66 (ddd,J= 8.6, 4.4, 2.2 Hz, 1H), 5.25 (d,J= 2.0 Hz, 2H), 5.19 (s, 2H), 4.20 (q,J= 7.3 Hz, 2H), 3.66 (s, 3H), 1.50 (t,J= 7.3 Hz, 3H), 1.44 (s, 9H). ESI-MS m / z 642 (M+H) +

[0533] Step 10) tert-butyl (E)-(1-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(4-fluoro-3-hydroxybenzyl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate (compound 21-10) Manufacturing

[0534] To a solution of compound 21-9 (106 mg, 0.165 mmol) in ethyl acetate (5 mL) at room temperature was added PtO2 (4 mg, 0.017 mmol). The reaction flask was evacuated and a hydrogen balloon was attached to the reaction flask. After stirring overnight at room temperature, the reaction mixture was filtered through a pad of Celite, and the filtrate was concentrated under reduced pressure. The residue was extracted with ethyl acetate, washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MC: MeOH = 0%–10%) to give compound 21-10 (30 mg, 28%).

[0535] 1H NMR (400 MHz, CDCl3) δ 7.76 (d,J= 2.3 Hz, 1H), 7.60 (s, 1H), 7.43 (d,J= 2.3 Hz, 1H), 6.89 (dd,J= 10.8, 8.2 Hz, 1H), 6.81 - 6.75 (m, 2H), 6.69 (dd,J= 8.4, 2.2 Hz, 1H), 6.62 - 6.58 (m, 1H), 5.13 (s, 2H), 4.45 - 4.37 (m, 1H), 4.25 - 4.22 (m, 2H), 4.11 (d,J= 7.1 Hz, 1H), 3.58 (s, 3H), 3.09 - 3.03 (m, 1H), 2.85 - 2.81 (m, 1H), 2.03 (s, 2H), 1.56 - 1.52 (m, 3H), 1.45 (s, 9H).

[0536] Step 11) 5-((6-((2-((tert-butoxycarbonyl)imino)-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-fluorophenyl Preparation of 2-(3-(2,6-dioxopiperidin-3-yl)phenoxy)acetate (Compound 21-11)

[0537] To a solution of compound 21-10 (36 mg, 0.056 mmol), compound 21-4 (20 mg, 0.073 mmol), and 4-(dimethylamino)pyridine in CH2Cl2 (5 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (9 mg, 0.056 mmol) at 0°C. The mixture was stirred at room temperature for 3 h. The reaction mixture was filtered through a pad of Celite, and the residue was concentrated under pressure. The residue was purified by MPLC (CH2Cl2:MeOH = 100%~5%) to give compound 21-11 (35 mg, 70%).

[0538] 1H NMR (400 MHz, CDCl3) δ 8.41 - 8.33 (m, 1H), 7.82 (dd,J= 6.8, 2.4 Hz, 1H), 7.69 (s, 1H), 7.53 (t,J= 3.1 Hz, 1H), 7.32 (t,J= 8.0 Hz, 1H), 7.12 - 7.01 (m, 3H), 6.92 - 6.84 (m, 2H), 6.84 - 6.73 (m, 3H), 5.18 (s, 2H), 4.91 (s, 2H), 4.36 (dd,J= 11.7, 4.2 Hz, 1H), 4.23 (q,J= 7.3 Hz, 2H), 3.81 - 3.73 (m, 1H), 3.69 (s, 2H), 3.62 (s, 3H), 3.15 (dt,J= 13.8, 4.0 Hz, 1H), 2.90 (dd,J= 8.9, 4.5 Hz, 1H), 2.84 - 2.57 (m, 4H), 2.25 (dq,J= 14.6, 5.0 Hz, 2H), 1.53 (t,J= 7.4 Hz, 3H), 1.46 (s, 9H). ESI-MS m / z 888 (M+H) +

[0539] 단계 12) 5-((8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenyl 2-(3-(2,6-dioxopiperidin-3-yl)phenoxy)acetate (화합물 21)의 제조

[0540] To a solution of compound 21-11 (18 mg, 0.020 mmol) in CH2Cl2 (1 mL) was slowly added 4 N-HCl in dioxane (0.5 mL) at 0°C. The mixture was stirred at room temperature overnight. The solvent was removed under pressure. The mixture was solidified using MeOH / diethyl ether. The solid was filtered and washed with Et2O. The solid was dried under vacuum to give compound 21 (5.1 mg, 33%).

[0541] 1 H NMR (400 MHz, MeOD) δ 7.90 (d,J= 7.4 Hz, 1H), 7.80 (d,J= 2.3 Hz, 1H), 7.41 (d,J= 2.3 Hz, 1H), 7.31 (t,J= 8.1 Hz, 1H), 7.22 - 7.11 (m, 3H), 6.93 (ddd,J= 9.8, 5.9, 2.3 Hz, 5H), 5.09 (d,J= 3.9 Hz, 2H), 5.04 (s, 2H), 4.45 (dd,J= 11.7, 4.4 Hz, 1H), 4.29 - 4.24 (m, 2H), 3.92 - 3.82 (m, 1H), 3.75 (q,J= 6.5, 5.4 Hz, 1H), 3.54 (d,J= 2.5 Hz, 3H), 3.19 (dd,J= 14.0, 5.2 Hz, 1H), 3.05 (dt,J= 8.6, 4.1 Hz, 1H), 2.82 (dt,J= 14.7, 7.4 Hz, 1H), 2.75 - 2.60 (m, 2H), 2.24 (dq,J= 16.3, 6.4, 5.4 Hz, 2H), 1.50 (t,J= 7.3 Hz, 3H). ESI-MS m / z 789.6 (M+H) +

[0542] Compound 22. N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethyl)-2-(5-(((S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamide

[0543]

[0544] To a solution of 4-(2-aminoethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (CRBN) (8 mg, 0.024 mmol) in DMF (1 mL) at 0°C were added compound 20-5 (13 mg, 0.022 mmol), HATU (10 mg, 0.0264 mmol), and DIEA (14 μL, 0.079 mmol). The mixture was stirred at room temperature for 5 h. The mixture was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography (MeOH:CH2Cl2 = 1:50 to 1:10) to give compound 22 (6.4 mg, 33%).

[0545] 1 H NMR (400 MHz, CDCl3) δ 7.70 (dd,J= 16.7, 8.0 Hz, 2H), 7.54 - 7.48 (m, 3H), 7.24 (d,J= 8.3 Hz, 1H), 7.18 (s, 1H), 7.05 - 6.94 (m, 2H), 6.88 (d,J= 7.8 Hz, 2H), 6.79 (t,J= 6.2 Hz, 1H), 5.05 (s, 2H), 5.01 - 4.94 (m, 1H), 4.57 (s, 2H), 4.38 (dd,J= 11.6, 4.4 Hz, 1H), 4.33 - 4.24 (m, 4H), 4.18 - 4.11 (m, 1H), 3.86 (dt,J= 10.7, 5.4 Hz, 2H), 3.17 (dt,J= 14.1, 7.3 Hz, 1H), 3.02 - 2.74 (m, 5H), 2.68 (ddt,J= 13.5, 9.6, 5.8 Hz, 1H), 2.38 (s, 3H), 1.55 (d,J= 7.4 Hz, 3H). ESI-MS m / z 886.3 (M+H) +

[0546] Compound 23. N1-(1-(6-(((R)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-3-fluoropyridin-2-yl)azetidin-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)succinamide

[0547]

[0548] Step 1) Preparation of tert-Butyl (1-(3-fluoro-6-(hydroxymethyl)pyridin-2-yl)azetidin-3-yl)carbamate (Compound 23-1)

[0549] A mixture of (6-bromo-5-fluoropyridin-2-yl)methanol (CAS NO. 1227599-50-9) (4.6 g, 22.3 mmol, 1.0 equiv), tert-butyl azetidin-3-ylcarbamate hydrochloride (CAS NO. 217806-26-3) (3.85 g, 22.3 mmol, 1.0 equiv), Cs2CO3 (21.7 g, 66.9 mmol, 3.0 equiv), Pd2(dba)3 (408 mg, 0.44 mmol, 5 mol%), and Xantphos (509 mg, 0.88 mmol, 10 mol%) in 1,4-dioxane (85 mL) was stirred at 90°C overnight. After cooling to room temperature, the reaction mixture was filtered through Celite with EtOAc, and the residual solvent was evaporated. The crude product was purified by MPLC to obtain compound 23-1 (2.9 g, 63%).

[0550] 1H NMR (400 MHz, CDCl3) δ 7.14 (dd,J= 11.5, 8.0 Hz, 1H), 6.50 (ddt,J= 8.0, 2.8, 0.8 Hz, 1H), 4.45 (t,J= 8.2 Hz, 2H), 3.97 - 3.87 (m, 2H), 3.43 (s, 1H), 1.45 (s, 9H).

[0551] Step 2) Preparation of tert-Butyl (1-(3-fluoro-6-formylpyridin-2-yl)azetidin-3-yl)carbamate (Compound 23-2)

[0552] Molecular sieve was added to a solution of compound 23-1 (2.9 g, 9.75 mmol) in CH2Cl2 (40 mL). The mixture was stirred at room temperature. After 1 h, NMO (2.28 g, 19.5 mmol, 2.0 eq) and TPAP (685.2 mg, 1.95 mmol, 0.2 eq) were added to the reaction mixture at 0 °C, and the reaction was stirred at room temperature for 4 h. Upon completion of the reaction, the solvent was removed, and the residue was partitioned between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After purification by MPLC, compound 23-2 (1.6 g, 56%) was obtained.

[0553] 1 H NMR (400 MHz, CDCl3) δ 9.84 (s, 1H), 7.32 (dd,J= 8.0, 3.5 Hz, 1H), 7.29 - 7.23 (m, 1H), 5.04 (s, 1H), 4.63 (s, 1H), 4.57 - 4.44 (m, 2H), 4.01 (ddd,J= 9.5, 5.4, 1.6 Hz, 2H), 1.45 (s, 9H). ESI-MS m / z 296.1 (M+H)+

[0554] Step 3) tert-butyl (E)-(1-(6-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-ylidene)methyl)-3-fluoropyridin-2-yl)azetidin-3-yl)carbamate Preparation of (Compound 23-3)

[0555] To a solution of compound 20-1 (1.0 g, 2.58 mmol, 1.0 equiv) dissolved in MeOH (10 mL) at 0°C was added pyrrolidine (0.3 mL, 3.87 mmol, 1.5 eq). The reaction was stirred at room temperature for 1 h. Compound 23-2 (800 mg, 2.71 mmol, 1.0 eq) dissolved in MeOH (6 mL) was added to the reaction mixture. After stirring overnight at room temperature, the solvent was removed, and the residue was purified via MPLC to obtain pure compound 23-3 (1.87 g, 85%).

[0556] 1 H NMR (400 MHz, CDCl3) δ 7.84 (d,J= 2.3 Hz, 1H), 7.52 (t,J= 2.1 Hz, 1H), 7.47 (s, 1H), 7.16 (dd,J= 11.3, 8.0 Hz, 1H), 7.11 (d,J= 2.4 Hz, 1H), 6.94 (d,J= 1.4 Hz, 1H), 6.89 - 6.84 (m, 2H), 5.87 (d,J= 2.2 Hz, 2H), 5.13 (s, 1H), 4.62 (s, 1H), 4.47 (t,J= 8.3 Hz, 2H), 4.25 (q,J= 7.3 Hz, 2H), 3.96 (ddd,J= 9.5, 5.6, 1.5 Hz, 2H), 2.36 (s, 3H), 1.94 (d,J= 15.9 Hz, 1H), 1.55 (t,J= 7.4 Hz, 3H), 1.45 (s, 9H).

[0557] Step 4) tert-Butyl (1-(6-(((3R,4R)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-hydroxy-6-((2-methyl-1H-imidazol-1-yl)methyl)chroman-3-yl)methyl)-3-fluoropyridin-2-yl)azetidin-3-yl)carbamate Preparation of (Compound 23-4)

[0558] To a solution of compound 23-3 (1.65 g, 2.4 mmol, 1.0 equiv) in MeCN (10 mL) at 0°C were added DBU (0.71 mL, 4.8 mmol, 2.0 equiv) and HCO2H (0.45 mL, 12.0 mmol, 5.0 equiv), and the mixture was degassed at room temperature for 1 h. RuCl(p-cymene)[(R,R)-Ts-DPEN] (154 mg, 0.24 mmol, 0.1 equiv) was added to the solution, and the resulting mixture was stirred at 70°C for 2 h. Upon completion of the reaction, the solvent was removed, and the crude material was purified via MPLC to obtain compound 23-4 (1.05 g, 57%).

[0559] 1H NMR (400 MHz, CDCl3) δ 7.46 (d,J= 1.0 Hz, 1H), 7.09 - 7.04 (m, 1H), 7.03 (d,J= 2.0 Hz, 1H), 6.86 (d,J= 2.3 Hz, 1H), 6.85 (d,J= 1.4 Hz, 1H), 6.79 (d,J= 1.4 Hz, 1H), 6.44 (dd,J= 7.9, 2.7 Hz, 1H), 5.44 (s, 1H), 4.91 (d,J= 6.2 Hz, 2H), 4.60 (s, 1H), 4.43 (t,J= 7.2 Hz, 3H), 4.19 (q,J= 7.4 Hz, 2H), 4.05 - 3.99 (m, 2H), 3.99 - 3.91 (m, 2H), 2.74 - 2.62 (m, 2H), 2.30 - 2.26 (m, 4H), 1.50 (t,J= 7.4 Hz, 3H), 1.43 (s, 9H). %) ESI-MS m / z 686.4 (M+H)+

[0560] 단계 5) tert-butyl (R)-(1-(6-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-3-fluoropyridin-2-yl)azetidin-3-yl)carbamate (화합물 23-5)의 제조

[0561] To a solution of compound 23-4 (960 mg, 1.4 mmol, 1.0 equiv) in CH2Cl2 (5.5 mL) at room temperature was added 4Å molecular sieves (140 mg). After stirring at room temperature for 1 h, NMO (328 mg, 2.0 equiv) and TPAP (98 mg, 0.28 mmol, 0.2 equiv) were added to the mixture at 0 °C, and the reaction mixture was stirred at room temperature for 2 h. After the reaction was completed, the solvent was removed, and the residue was partitioned between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After purification by MPLC, compound 23-5 (500 mg, 52%) was obtained.

[0562] 1 H NMR (400 MHz, CDCl3) δ 7.79 - 7.72 (m, 1H), 7.49 (d,J= 1.1 Hz, 1H), 7.13 (d,J= 2.4 Hz, 1H), 7.05 (dd,J= 11.6, 7.9 Hz, 1H), 6.95 (d,J= 1.4 Hz, 1H), 6.84 (d,J= 1.4 Hz, 1H), 6.48 (dd,J= 8.0, 2.7 Hz, 1H), 5.01 (s, 3H), 4.54 (dd,J= 11.4, 5.0 Hz, 2H), 4.36 (d,J= 8.9 Hz, 2H), 4.31 - 4.21 (m, 3H), 3.83 (ddd,J= 9.3, 5.6, 1.5 Hz, 2H), 3.34 (ddt,J= 10.6, 9.0, 4.7 Hz, 1H), 3.26 (dd,J= 14.7, 4.3 Hz, 1H), 2.72 (dd,J= 14.6, 8.9 Hz, 1H), 2.36 (s, 3H), 1.55 (t,J= 7.4 Hz, 3H), 1.44 (s, 9H). ESI-MS m / z 684.2 (M+H)+

[0563] Step 6) Preparation of (R)-3-((6-(3-aminoazetidin-1-yl)-5-fluoropyridin-2-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)chroman-4-one hydrochloride (Compound 23-6)

[0564] To a solution of compound 23-5 (488 mg, 0.71 mmol, 1.0 equiv) in CH2Cl2 (3 mL) at 0°C was added 4 N-HCl in dioxane (0.5 mL). The reaction was stirred at room temperature for 2 h. Upon completion of the reaction, the solvent was removed to obtain compound 23-6 (54 mg, 90%).

[0565] 1 H NMR (400 MHz, MeOD) δ 8.02 (s, 1H), 7.91 (dd,J= 7.0, 2.0 Hz, 1H), 7.73 (dd,J= 11.6, 8.0 Hz, 1H), 7.60 - 7.56 (m, 1H), 7.52 (d,J= 3.5 Hz, 2H), 6.89 - 6.77 (m, 1H), 5.47 (s, 2H), 4.80 - 4.57 (m, 3H), 4.48 - 4.34 (m, 2H), 4.29 (q,J= 7.2 Hz, 2H), 4.14 - 3.93 (m, 2H), 3.57 - 3.37 (m, 2H), 3.12 - 2.92 (m, 1H), 2.69 (d,J= 1.4 Hz, 3H), 1.52 (t,J= 7.2 Hz, 3H). ESI-MS m / z 584.2 (M+H)+

[0566] Step 7) N1-(1-(6-(((R)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-3-fluoropyridin-2-yl)azeti din-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)succinamide Preparation of (Compound 23)

[0567] To a solution of compound 27-2 (13.4 mg, 0.0216 mmol, 1.0 equiv) in DMF (40 mL) in an ice bath were added DIEA (10 μL, 0.054 mmol, 3.0 equiv) and HATU (14.0 mg, 0.036 mmol, 2.0 equiv). After stirring at room temperature for 1 h, compound 23-6 (10 mg, 0.018 mmol, 1.2 equiv) was added. The reaction mixture was stirred at room temperature overnight. Upon completion of the reaction, the solvent was removed and the residue was partitioned between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After purification by MPLC, compound 23 was obtained (4.8 mg, 36%).

[0568] 1H NMR (400 MHz, MeOD) δ 8.87 (s, 1H), 8.52 (dd,J= 4.3, 1.4 Hz, 1H), 8.20 (dd,J= 8.4, 1.4 Hz, 1H), 7.90 - 7.87 (m, 1H), 7.76 (d,J= 2.4 Hz, 1H), 7.42 (d,J= 3.1 Hz, 3H), 7.37 - 7.31 (m, 2H), 7.30 - 7.27 (m, 1H), 7.20 - 7.14 (m, 2H), 6.56 (dd,J= 8.0, 2.8 Hz, 1H), 5.28 (s, 2H), 5.03 - 4.96 (m, 1H), 4.65 - 4.48 (m, 5H), 4.41 (s, 1H), 4.26 (ddt,J= 10.0, 7.3, 4.0 Hz, 5H), 4.10 (q,J= 7.1 Hz, 2H), 3.91 - 3.82 (m, 3H), 3.77 - 3.69 (m, 2H), 3.35 (s, 1H), 3.26 - 3.15 (m, 2H), 2.81 (dd,J= 14.7, 8.6 Hz, 1H), 2.62 (dt,J= 10.1, 7.7 Hz, 1H), 2.56 - 2.49 (m, 3H), 2.46 - 2.44 (m, 1H), 2.22 - 2.16 (m, 1H), 2.01 (s, 2H), 1.94 (ddd,J= 13.3, 9.0, 4.5 Hz, 1H), 1.52 - 1.48 (m, 6H), 1.38 (dd,J= 7.0, 2.2 Hz, 6H).

[0569] Compound 24. N1-(1-(6-(((S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-3-fluoropyridin-2-yl)azetidin-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)succinamide

[0570]

[0571] Step 1) tert-butyl (1-(6-(((3S,4S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-hydroxy-6-((2-methyl-1H-imidazol-1-yl)methyl)chroman-3-yl)methyl)-3-fluoropyridin-2-yl)azetidin-3-yl)carbamate Preparation of (Compound 24-1)

[0572] To a solution of compound 23-3 (150 mg, 0.232 mmol, 1.0 equiv) in 1.5 mL of MeCN at 0°C were added DBU (65 μL, 0.44 mmol, 2.0 equiv) and HCO2H (41.5 μL, 1.1 mmol, 5.0 equiv). The mixture was degassed at room temperature for 1 h. RuCl(p-cymene)[(S,S)-Ts-DPEN] (14 mg, 0.022 mmol, 0.1 equiv) was added to the mixture, and the resulting mixture was stirred at 70°C for 2 h. After the reaction was completed, the solvent was removed, and the crude material was purified via MPLC to give compound 24-1 (110 mg, 73%).

[0573] 1H NMR (400 MHz, CDCl3) δ 7.47 (d,J= 1.0 Hz, 1H), 7.11 - 7.03 (m, 2H), 6.91 - 6.85 (m, 2H), 6.82 (d,J= 1.4 Hz, 1H), 6.46 (dd,J= 7.9, 2.8 Hz, 1H), 5.01 - 4.88 (m, 2H), 4.62 (s, 1H), 4.51 - 4.40 (m, 3H), 4.21 (q,J= 7.3 Hz, 2H), 4.13 - 4.01 (m, 2H), 3.97 (dq,J= 9.5, 5.8, 5.2 Hz, 2H), 2.77 - 2.64 (m, 2H), 2.32 (s, 3H), 2.29 - 2.23 (m, 1H), 1.53 (t,J= 7.3 Hz, 3H), 1.46 (s, 9H). ESI-MS m / z 686.4 (M+H) +

[0574] 단계 2) tert-Butyl (S)-(1-(6-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-3-fluoropyridin-2-yl)azetidin-3-yl)carbamate (화합물 24-2)의 제조

[0575] To a solution of compound 24-1 (110 mg, 0.16 mmol, 1.0 equiv) in CH2Cl2 (1.5 mL) at room temperature was added 4Å molecular sieves (30 mg). After stirring at room temperature for 1 h, NMO (37.4 mg, 0.32 mmol, 2.0 equiv) and TPAP (11.2 mg, 0.032 mmol, 0.2 equiv) were added to the reaction mixture at 0 °C, and the reaction mixture was stirred at room temperature for 2 h. After the reaction was completed, the solvent was removed, and the residue was partitioned between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After purification by MPLC, compound 24-2 (67 mg, 61%) was obtained.

[0576] 1 H NMR (400 MHz, CDCl3) δ 7.73 (d,J= 2.4 Hz, 1H), 7.52 - 7.46 (m, 1H), 7.12 (d,J= 2.4 Hz, 1H), 7.02 (dd,J= 11.6, 7.9 Hz, 1H), 6.93 (d,J= 1.4 Hz, 1H), 6.83 (d,J= 1.4 Hz, 1H), 6.46 (dd,J= 7.9, 2.7 Hz, 1H), 5.14 (d,J= 16.8 Hz, 1H), 5.00 (s, 2H), 4.52 (dd,J= 11.4, 5.0 Hz, 2H), 4.37 - 4.30 (m, 2H), 4.28 - 4.19 (m, 3H), 3.82 (ddd,J= 9.6, 5.5, 1.6 Hz, 2H), 3.38 - 3.28 (m, 1H), 3.24 (dd,J= 14.7, 4.3 Hz, 1H), 2.70 (dd,J= 14.7, 8.9 Hz, 1H), 2.34 (s, 3H), 1.53 (t,J= 7.4 Hz, 3H), 1.42 (s, 9H).

[0577] Step 3) Preparation of (S)-3-((6-(3-aminoazetidin-1-yl)-5-fluoropyridin-2-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)chroman-4-one hydrochloride (Compound 24-3)

[0578] To a solution of compound 24-2 (67 mg, 0.097 mmol, 1.0 equiv) dissolved in CH2Cl2 (1.5 mL) at 0°C was added 4 N-HCl in dioxane (0.3 mL). The reaction was stirred at room temperature for 2 h. Upon completion of the reaction, the solvent was removed to obtain compound 24-3 (54 mg, 90%).

[0579] 1 H NMR (400 MHz, MeOD) δ 7.87 (dd,J= 2.0, 1.0 Hz, 1H), 7.69 (d,J= 2.4 Hz, 1H), 7.31 (d,J= 2.2 Hz, 1H), 7.16 (dd,J= 11.1, 7.9 Hz, 1H), 7.10 (t,J= 1.5 Hz, 1H), 6.91 (s, 1H), 6.48 (dd,J= 7.9, 3.0 Hz, 1H), 5.20 (s, 2H), 4.50 (ddd,J= 11.7, 7.0, 4.8 Hz, 1H), 4.32 - 4.22 (m, 3H), 3.77 (ddd,J= 11.6, 4.1, 2.7 Hz, 1H), 3.72 - 3.50 (m, 5H), 3.24 - 3.14 (m, 1H), 2.85 - 2.74 (m, 1H), 2.33 (s, 3H), 1.51 (td,J= 7.3, 0.5 Hz, 3H). ESI-MS m / z 620.1 (M+H) +

[0580] Step 4) N1-(1-(6-(((S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-3-fluoropyridin-2-yl)azeti din-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)succinamide Preparation of (Compound 24)

[0581] To a solution of compound 27-2 (7.0 mg, 0.012 mmol, 1.0 equiv) in DMF (1.5 mL) at room temperature were added DIEA (6 μL, 0.036 mmol, 3.0 equiv) and HATU (9.0 mg, 0.024 mmol, 2.0 equiv). After stirring at room temperature for 1 h, compound 24-3 (8.0 mg, 0.012 mmol, 1.0 equiv) was added to the mixture. The reaction mixture was stirred at room temperature overnight. Upon completion of the reaction, the solvent was removed, and the residue was partitioned between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After purification by MPLC, compound 24 was obtained (4.8 mg, 36%).

[0582] 1H NMR (400 MHz, MeOD) δ 8.87 (s, 1H), 8.51 (d,J= 7.1 Hz, 1H), 7.92 (s, 1H), 7.86 (d,J= 10.2 Hz, 1H), 7.48 - 7.38 (m, 6H), 7.13 (dd,J= 11.2, 7.8 Hz, 1H), 6.45 (dt,J= 6.5, 3.1 Hz, 1H), 5.37 (s, 2H), 5.00 (t,J= 6.8 Hz, 1H), 4.56 (dd,J= 13.5, 5.8 Hz, 3H), 4.41 (s, 1H), 4.37 - 4.22 (m, 4H), 3.85 (d,J= 11.1 Hz, 1H), 3.73 (p,J= 6.6 Hz, 4H), 3.60 (dd,J= 9.1, 5.2 Hz, 2H), 3.52 (t,J= 5.5 Hz, 1H), 3.23 (q,J= 7.4 Hz, 4H), 2.85 - 2.73 (m, 1H), 2.60 (s, 3H), 2.55 (d,J= 2.4 Hz, 1H), 2.48 (s, 3H), 2.22 - 2.14 (m, 1H), 2.00 - 1.89 (m, 1H), 1.51 (dd,J=8.5, 6.6 Hz, 5H), 1.39 (d,J= 2.3 Hz, 9H).

[0583] Compound 25. (2S,4R)-1-((2S)-2-(3-(3,4-dichlorophenyl)-3-(6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0584]

[0585] Step 1) Preparation of (E)-3-(3,4-dichlorobenzylidene)-6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)chroman-4-one (Compound 25-1)

[0586] To a solution of compound 18-3 (1.0 g, 2.56 mmol, 1.0 equiv) dissolved in MeOH (9 mL) at 0 °C was added pyrrolidine (0.31 mL, 3.84 mmol, 1.5 eq). The reaction mixture was stirred at room temperature for 1 h, and then 3,4-dichlorobenzaldehyde (CAS NO. 6287-38-3) (448 mg, 2.56 mmol, 1 eq) dissolved in MeOH was added to the mixture. After stirring at room temperature for 2 h, the solvent was removed, and the concentrate was purified by MPLC to obtain compound 25-1 (350 mg, 24.9%).

[0587] 1 H NMR (400 MHz, CDCl3) δ 7.86 (d,J= 2.3 Hz, 1H), 7.75 (d,J= 2.1 Hz, 1H), 7.51 (d,J= 8.3 Hz, 1H), 7.45 (s, 1H), 7.37 (d,J= 2.1 Hz, 1H), 7.14 (dd,J= 7.1, 2.3 Hz, 2H), 6.97 (d,J= 1.4 Hz, 1H), 6.87 (d,J= 1.4 Hz, 1H), 5.28 (d,J= 1.9 Hz, 2H), 5.05 (s, 2H), 4.11 (q,J= 7.2 Hz, 2H), 3.97 (s, 3H), 3.26 (d,J= 17.9 Hz, 1H), 2.39 (s, 3H), 2.04 (s, 2H), 1.32 - 1.21 (m, 4H).

[0588] Step 2) 5-((3,4-dichlorophenyl)(6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2,2-dimethyl-1,3-dioxane-4,6-dione (Compound 25-2) Manufacturing

[0589] To a solution of Meldrum's acid (117.4 mg, 0.81 mmol, 1.0 equiv) in MeCN (3 mL) at 0 °C was added tert-BuOK (90 mg, 0.81 mmol, 1.0 equiv). After stirring at room temperature for 1 h, compound 25-1 (446 mg, 0.81 mmol, 1.0 equiv) in MeCN (1 mL) was added dropwise to the mixture at 0 °C. The reaction mixture was stirred at room temperature overnight, poured into H2O, and adjusted to pH 2 with 1 N aqueous HCl. The mixture was extracted three times with EtOAc, and the extracts were washed with saturated NaCl solution. The combined extracts were dried over anhydrous MgSO4, filtered, and concentrated. The crude material was purified by MPLC to give compound 25-2 (151 mg, 27%).

[0590] 1 H NMR (500 MHz, MeOD) δ 7.88 (s, 1H), 7.77 (d,J= 2.1 Hz, 1H), 7.73 (d,J= 2.4 Hz, 1H), 7.51 (d,J= 2.1 Hz, 1H), 7.48 (dd,J= 8.3, 2.0 Hz, 1H), 7.45 (d,J= 2.1 Hz, 1H), 7.42 (d,J= 2.2 Hz, 1H), 7.34 (d,J= 8.3 Hz, 1H), 5.38 (s, 2H), 4.42 - 4.30 (m, 2H), 4.15 (dd,J= 12.1, 2.7 Hz, 1H), 4.05 - 3.91 (m, 5H), 2.61 (s, 3H), 1.49 (s, 6H). ESI-MS m / z 692.7 (M+H)+

[0591] Step 3) Preparation of 3-(3,4-dichlorophenyl)-3-(6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)propanoicacid (Compound 25-3)

[0592] To a solution of compound 25-2 (100 mg, 0.144 mmol, 1.0 equiv) in DMF (1.5 mL) at room temperature, 1 N aqueous HCl was added to adjust the pH to 4. The reaction mixture was stirred at 80°C for 2 h and cooled to room temperature. The solvent was removed, and the concentrate was purified by MPLC to give compound 25-3 (30 mg, 34%).

[0593] 1 H NMR (400 MHz, MeOD) δ 7.80 (s, 1H), 7.72 (d,J= 2.3 Hz, 1H), 7.49 (d,J= 2.0 Hz, 1H), 7.41 (d,J= 8.3 Hz, 1H), 7.29 (d,J= 2.5 Hz, 1H), 7.24 (d,J= 2.3 Hz, 1H), 7.14 (s, 1H), 6.96 (s, 1H), 5.21 (s, 2H), 4.66 - 4.48 (m, 1H), 4.36 (d,J= 12.1 Hz, 1H), 4.05 (d,J= 12.1 Hz, 1H), 3.98 (s, 3H), 3.63 (dd,J= 10.1, 5.4 Hz, 1H), 2.74 - 2.59 (m, 2H), 2.36 (s, 3H). ESI-MS m / z 608.6 (M+H) +

[0594] Step 4) (2S,4R)-1-((2S)-2-(3-(3,4-dichlorophenyl)-3-(6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4 -oxochroman-3-yl)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide Preparation of (Compound 25)

[0595] To a solution of compound 25-3 (10 mg, 0.016 mmol, 1.0 equiv) in CH2Cl2 / DMF=1:1 (1 mL) at room temperature were added DIEA (8 μL, 0.048 mmol, 3.0 equiv) and HATU (12.5 mg, 0.033 mmol, 2.0 equiv). After stirring at room temperature for 1 h, (S,R,S)-AHPC-Me (7.69 mg, 0.016 mmol, 1.0 equiv) was added to the mixture. The reaction mixture was stirred at room temperature for 2 h. Upon completion of the reaction, the solvent was removed, and the residue was partitioned between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After purification by MPLC, compound 25 was obtained (3.7 mg, 23%).

[0596] 1H NMR (500 MHz, CDCl3) δ 11.08 (s, 1H), 8.71 (s, 1H), 8.58 (s, 2H), 8.28 (s, 2H), 7.33 (d,J= 20.1 Hz, 7H), 7.11 (s, 1H), 6.52 (s, 1H), 5.25 - 5.11 (m, 2H), 5.05 (t,J= 7.2 Hz, 1H), 4.73 (s, 1H), 4.51 (s, 1H), 4.40 (d,J= 8.9 Hz, 1H), 4.27 (d,J= 12.1 Hz, 1H), 4.05 (d,J= 12.1 Hz, 1H), 4.00 (s, 3H), 3.86 (d,J= 11.0 Hz, 1H), 3.66 (q,J= 6.8 Hz, 3H), 3.60 - 3.55 (m, 2H), 3.10 (q,J= 7.5 Hz, 2H), 2.71 (s, 2H), 2.68 (s, 1H), 2.62 (s, 1H), 2.50 (s, 3H), 2.39 - 2.32 (m, 1H), 2.20 (s, 1H), 1.52 (d,J= 6.6 Hz, 4H), 1.44 (d,J= 6.7 Hz, 5H). ESI-MS m / z 1033.1 (M+H) +

[0597] Compound 26. (2S,4R)-1-((S)-2-(2-((1-(6-(((S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)amino)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0598]

[0599] Step 1) tert-Butyl (1-(6-(((3S,4S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-hydroxy-6-((2-methyl-1H-imidazol-1-yl)methyl)chroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)carbamate Preparation of (Compound 26-2)

[0600] To a solution of compound 16-4 (1.05 g, 1.517 mmol, 1.0 eq) in MeCN at 0°C were added DBU (0.45 mL, 3.036 mmol, 2.0 eq) and HCO2H (0.29 mL, 7.589 mmol, 5.0 eq), and the mixture was degassed at room temperature for 1 h. RuCl(p-cymene)[(S,S)-Ts-DPEN] (100 mg, 0.152 mmol, 0.1 eq) was added to the solution, and the resulting mixture was stirred at 70°C for 2 h. Upon completion of the reaction, the solvent was removed, and the crude material was purified via MPLC to give compound 26-2 (877 mg, 84%).

[0601] ESI-MS m / z 696.4 (M+H) +

[0602] Step 2) tert-Butyl (S)-(1-(6-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)carbamate Preparation of (Compound 26-3)

[0603] Molecular sieves (200 mg) were added to a solution of compound 26-2 (830 mg, 1.193 mmol, 1.0 eq) in CH2Cl2 (5 mL) at room temperature. The mixture was stirred at room temperature. After 1 h, NMO (280 mg, 2.39 mmol, 2.0 eq) and TPAP (83 mg, 0.236 mmol, 0.2 eq) were added at 0 °C and stirred at room temperature for 2 h. Upon completion of the reaction, the solvent was removed and the residue was partitioned between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After purification by MPLC, compound 26-3 (478 mg, 58%) was obtained.

[0604] 1 H NMR (500 MHz, CDCl3) δ 7.77 (s, 1H), 7.57 (s, 1H), 7.18 (s, 2H), 6.96 (s, 1H), 6.41 (s, 1H), 6.01 (s, 1H), 5.11 (s, 2H), 4.68 (s, 1H), 4.33 (t,J= 11.2 Hz, 1H), 4.28 - 4.24 (m, 3H), 4.20 (s, 1H), 4.11 - 3.92 (m, 3H), 3.68 (dt,J= 17.3, 5.0 Hz, 1H), 3.46 (s, 1H), 3.29 (dd,J= 14.5, 4.8 Hz, 1H), 2.93 (s, 3H), 2.66 (s, 3H), 2.24 (s, 3H), 1.57 (d,J= 7.3 Hz, 3H), 1.46 (s, 9H).

[0605] Step 3) (S)-8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-3-((4-methyl-6-(3-(methylamino)azetidin-1-yl)pyridin-2-yl)methyl)chroman-4-one hydrochloride (compound 26-4) Manufacturing

[0606] To a solution of compound 26-3 (470 mg, 0.677 mmol, 1.0 equiv) in CH2Cl2 (4 mL) at 0°C was added 4 N-HCl in dioxane (1.5 mL). The reaction mixture was stirred at room temperature for 2 h. Upon completion of the reaction, the solvent was removed to obtain compound 26-4 (433 mg, 95%).

[0607] 1 H NMR (500 MHz, DMSO) δ 8.08 (s, 1H), 7.56 (d,J= 2.3 Hz, 1H), 7.30 (d,J= 2.3 Hz, 1H), 7.12 (s, 1H), 6.74 (s, 1H), 6.35 (s, 1H), 6.03 (s, 1H), 5.13 (s, 2H), 4.43 (dd,J= 11.3, 5.1 Hz, 1H), 4.32 (s, 1H), 4.22 (d,J= 7.3 Hz, 2H), 4.10 (s, 1H), 3.95 (d,J= 7.2 Hz, 2H), 3.65 - 3.57 (m, 3H), 3.14 (d,J= 2.7 Hz, 2H), 3.00 (dd,J= 14.8, 4.3 Hz, 1H), 2.65 (dd,J= 14.8, 8.9 Hz, 1H), 2.26 (s, 3H), 2.21 (s, 3H), 2.13 (s, 3H), 1.40 (t,J= 7.3 Hz, 3H).

[0608] Step 4) tert-butyl (S)-N-(1-(6-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N-methylglycinate Preparation of (Compound 26-5)

[0609] To a solution of compound 26-4 (250 mg, 0.397 mmol, 1.0 eq) in DMF (2.5 mL) at room temperature were added methyl tert-butyl bromoacetate (65 μL, 0.437 mmol, 1.1 eq) and Cs2CO3 (363 mg, 1.190 mmol, 2.0 eq). The reaction mixture was stirred at 60°C for 2 h. The reaction solution was diluted with EtOAc, washed three times with water, and extracted with EtOAc. The combined organic layers were dried over Na2SO4 and concentrated. The crude product was purified by MPLC to give pure compound 26-5 (56 mg, 22%).

[0610] 1 H NMR (400 MHz, CDCl3) δ 7.75 (d,J= 2.5 Hz, 1H), 7.55 - 7.50 (m, 1H), 7.12 (d,J= 2.4 Hz, 1H), 6.92 (dd,J= 7.7, 1.4 Hz, 2H), 6.82 (dd,J= 10.2, 1.4 Hz, 2H), 6.32 (s, 1H), 5.95 (s, 1H), 5.00 (s, 2H), 4.54 (dd,J= 11.4, 5.1 Hz, 1H), 4.47 (s, 2H), 4.26 - 4.20 (m, 2H), 3.98 (td,J= 7.5, 3.3 Hz, 2H), 3.78 (td,J= 5.4, 2.9 Hz, 2H), 3.68 - 3.61 (m, 1H), 3.39 (ddd,J= 10.1, 7.8, 4.5 Hz, 1H), 3.28 (dd,J= 14.6, 4.0 Hz, 1H), 3.12 (s, 2H), 2.62 (dd,J= 14.6, 9.6 Hz, 1H), 2.36 (s, 2H), 2.33 (d,J= 2.4 Hz, 4H), 1.53 (t,J= 7.4 Hz, 3H), 1.45 (s, 9H).

[0611] Step 5) (S)-N-(1-(6-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N-methylglycine (compound 26-6) Manufacturing

[0612] To a solution of compound 26-5 (50 mg, 0.071 mmol, 1.0 eq) in CH2Cl2 (1.5 mL) in an ice bath was added TFA (0.3 mL) dropwise. The resulting mixture was stirred at room temperature overnight. The solvent was then removed under reduced pressure, and the crude product was purified by MPLC to obtain compound 26-6 (55 mg, >99%).

[0613] ESI-MS m / z 652.2 (M+H) +

[0614] Step 6) (2S,4R)-1-((S)-2-(2-((1-(6-(((S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylp yridin-2-yl)azetidin-3-yl)(methyl)amino)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide Preparation of (Compound 26)

[0615] To a solution of compound 26-6 (25 mg, 0.038 mmol, 1.0 eq), (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (VHL ligand, 30 mg, 0.046 mmol, 1.1 eq), and HATU (30 mg, 0.079 mmol, 2.0 eq) in DMF (3 mL) was added DIEA (54 μL) at room temperature. The reaction mixture was stirred at the same temperature for 15 h. The reaction solution was diluted with EtOAc, washed three times with water, and then extracted with EtOAc. The combined organic layers were dried over Na2SO4 and concentrated. The crude product was purified by MPLC to obtain compound 26 (15 mg, 37%).

[0616] 1H NMR (500 MHz, DMSO) δ 8.96 (s, 1H), 8.44 - 8.37 (m, 1H), 8.07 (s, 1H), 7.73 (d,J= 9.6 Hz, 1H), 7.66 (s, 1H), 7.40 (d,J= 8.0 Hz, 2H), 7.34 (s, 4H), 7.03 (s, 1H), 6.36 (s, 1H), 6.04 (s, 1H), 5.21 (s, 2H), 5.10 (s, 1H), 4.89 - 4.84 (m, 1H), 4.51 - 4.39 (m, 3H), 4.32 (td,J=10.6, 6.4 Hz, 1H), 4.29 - 4.19 (m, 3H), 4.00 (q,J= 7.1 Hz, 2H), 3.89 (d,J= 8.3 Hz, 1H), 3.65 - 3.50 (m, 5H), 3.05 - 3.00 (m, 1H), 2.98 (s, 1H), 2.69 - 2.61 (m, 1H), 2.43 (s, 3H), 2.33 (s, 3H), 2.21 - 2.12 (m, 5H), 1.96 (s, 2H), 1.77 - 1.71 (m, 1H), 1.40 (d,J= 7.3 Hz, 2H), 1.34 (t,J= 6.8 Hz, 3H), 1.22 (d,J= 5.0 Hz, 2H), 1.16 (d,J= 7.2 Hz, 2H), 0.87 (s, 6H), 0.83 (s, 2H).

[0617] Compound 27. N-1-(1-(6-(((S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylsuccinamide

[0618]

[0619] Step 1) Preparation of tert-Butyl 4-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutanoate (Compound 27-1)

[0620] To a solution of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (=(S,R,S)-AHPC-Me HCl; CAS NO. 1948273-03-7) (VHL ligand, 200 mg, 0.415 mmol, 1.0 eq), 4-(tert-butoxy)-4-oxobutanoic acid (CAS NO. 15026-17-2)(80 mg, 0.457 mmol, 1.1 eq) in DMF (5 mL) at room temperature were added HATU (320 mg, 0.830 mmol, 2.0 eq) and DIEA (720 μL) was added. The reaction mixture was stirred at the same temperature for 15 h. The reaction solution was diluted with EtOAc, washed three times with water, and extracted with EtOAc. The combined organic layers were dried over Na2SO4 and concentrated. The concentrate was purified by MPLC to obtain pure compound 27-1 (197 mg, 80%).

[0621] 1H NMR (400 MHz, CDCl3) δ 8.85 (s, 1H), 7.57 (d,J= 7.8 Hz, 1H), 7.40 (s, 4H), 6.49 (d,J= 8.4 Hz, 1H), 5.07 (t,J= 7.2 Hz, 1H), 4.76 (t,J= 8.0 Hz, 1H), 4.52 - 4.47 (m, 2H), 4.14 - 4.06 (m, 1H), 3.55 (dd,J= 11.5, 3.6 Hz, 1H), 2.59 (s, 3H), 2.57 - 2.54 (m, 2H), 2.50 (dd,J= 7.1, 5.5 Hz, 1H), 2.47 - 2.42 (m, 1H), 2.10 - 2.05 (m, 1H), 1.44 (s, 12H), 1.26 (t,J= 7.2 Hz, 1H), 1.05 (s, 9H).

[0622] Step 2) Preparation of 4-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutanoic acid (Compound 27-2)

[0623] To a solution of compound 27-1 (190 mg, 0.316 mmol, 1.0 eq) in CH2Cl2 (2 mL) in an ice bath was added TFA (0.3 mL). The resulting mixture was stirred at room temperature overnight. The solvent was then removed under reduced pressure, and the crude product was purified by MPLC to obtain compound 27-2 (170 mg, 99%).

[0624] 1H NMR (400 MHz, MeOD) δ 8.88 (s, 1H), 7.96 - 7.82 (m, 4H), 7.77 (s, 1H), 7.55 - 7.40 (m, 8H), 6.52 (s, 1H), 6.23 (s, 1H), 5.39 (s, 2H), 5.19 (s, 1H), 5.01 (t,J= 6.9 Hz, 1H), 4.63 - 4.48 (m, 3H), 4.41 (s, 1H), 4.39 - 4.26 (m, 2H), 4.20 (d,J= 14.8 Hz, 2H), 4.06 - 4.01 (m, 1H), 3.98 (s, 3H), 3.84 (d,J= 11.2 Hz, 1H), 3.73 (d,J= 11.1 Hz, 1H), 3.26 - 3.18 (m, 1H), 3.14 (s, 2H), 3.04 (s, 1H), 2.77 (s, 1H), 2.69 (t,J= 8.5 Hz, 1H), 2.62 (s, 3H), 2.56 (t,J= 6.9 Hz, 1H), 2.48 (s, 3H), 2.27 (s, 2H), 2.23 - 2.15 (m, 1H), 2.01 (s, 2H), 1.95 (t,J= 13.0 Hz, 1H), 1.50 (d,J= 7.0 Hz, 3H), 1.29 (s, 4H), 1.03 (d,J= 5.9 Hz, 9H).

[0625] 단계 3) N-1-(1-(6-(((S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylsuccinamide (화합물 27)의 제조

[0626] To a solution of compound 26-4 (32 mg, 0.050 mmol, 1.0 equiv), compound 27-2 (30 mg, 0.055 mmol, 1.1 equiv), and HATU (38 mg, 0.100 mmol, 2.0 equiv) in DMF (3 mL) was added DIEA (90 μL) at room temperature. The reaction mixture was stirred at the same temperature for 15 h. The reaction solution was diluted with EtOAc, washed three times with water, and extracted with EtOAc. The combined organic layers were dried over Na2SO4 and concentrated. The crude product was purified by MPLC to give compound 27 (24.9 mg, 45%).

[0627] ESI-MS m / z 560.9 (M+H) + 1H NMR (500 MHz, DMSO) δ 8.98 (s, 1H), 8.37 (d,J= 7.7 Hz, 1H), 8.09 (s, 1H), 7.95 (s, 2H), 7.86 (d,J= 9.2 Hz, 1H), 7.65 (s, 1H), 7.42 (s, 2H), 7.38 (d,J= 8.2 Hz, 3H), 7.28 (s, 1H), 7.00 (s, 1H), 6.40 (s, 1H), 6.09 (d,J= 7.5 Hz, 1H), 5.22 (s, 2H), 5.18 (s, 1H), 5.10 (s, 1H), 4.97 - 4.90 (m, 1H), 4.47 (dd,J= 14.5, 7.8 Hz, 2H), 4.46 - 4.39 (m, 2H), 4.34 (t,J= 10.8 Hz, 1H), 4.24 (dd,J= 14.4, 7.1 Hz, 3H), 4.08 (dd,J= 16.6, 9.5 Hz, 1H), 4.04 - 3.98 (m, 1H), 3.90 (s, 1H), 3.78 (s, 1H), 3.60 (dd,J= 18.7, 11.4 Hz, 2H), 3.07 - 2.99 (m, 3H), 2.45 (s, 3H), 2.33 (s, 3H), 2.17 (s, 2H), 2.08 (s, 1H), 2.00 (d,J= 9.4 Hz, 2H), 1.82 - 1.76 (m, 1H), 1.42 (t,J= 7.3 Hz, 3H), 1.39 - 1.35 (m, 4H), 1.23 (s, 3H), 0.92 (s, 9H).

[0628] Compound 28. N1-(1-(6-(((R)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylsuccinamide

[0629]

[0630] Step 1) Preparation of 6-((1H-Imidazol-1-yl)methyl)-8-bromochroman-4-one (Compound 28-1)

[0631] To a solution of compound 18-1 (4.77 g, 14.91 mmol, 1 equiv) in DMF (38.0 mL) at room temperature was added 1H-imidazole (3.04 g, 44.72 mmol, 3 equiv). The reaction mixture was stirred at 50°C for 2 h and then cooled to ambient temperature. The resulting mixture was poured into CH2Cl2 (700 mL) and washed with H2O (500 mL). The mixture was extracted with 1 N HCl and basified with NaHCO3. The mixture was extracted with MC and dried over MgSO4. The MC layer was concentrated to give compound 28-1 (2.72 g, 59.3%).

[0632] 1 H NMR (400 MHz, CDCl3) δ 7.77 (d,J= 2.3 Hz, 1H), 7.59 (s, 1H), 7.54 (d,J= 2.3 Hz, 1H), 7.13 (d,J= 1.2 Hz, 1H), 6.91 (d,J= 1.2 Hz, 1H), 5.08 (s, 2H), 4.69 (m, 2H), 2.88 (m, 2H).

[0633] Step 2) Preparation of 6-((1H-Imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)chroman-4-one (Compound 28-2)

[0634] To a solution of compound 28-1 (3 g, 9.767 mmol) in 1,4-dioxane / H2O (10:1, 66 mL) at room temperature were added (1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)boronic acid (2.45 g, 11.721 mmol), Cs2CO3 (6.4 g, 19.534 mmol), and Pd(amphos)Cl2 (345 mg, 0.488 mmol). The reaction mixture was then heated to 100 °C and stirred at 100 °C for an additional 17 h. After cooling to room temperature, 1,4-dioxane was removed under reduced pressure, and the resulting residue was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, 2% to 10%) to give compound 28-2 (1.27 g, 33% yield).

[0635] 1 H NMR (400 MHz, CDCl3) δ 7.85 (dd,J= 5.5, 2.5 Hz, 1H), 7.72 (dd,J= 23.6, 1.7 Hz, 1H), 7.59 - 7.49 (m, 1H), 7.47 - 7.34 (m, 1H), 7.16 (s, 1H), 6.97 (s, 1H), 5.17 (d,J= 12.2 Hz, 2H), 4.61 - 4.52 (m, 1H), 4.27 (qd,J= 7.2, 5.1 Hz, 2H), 3.03 (d,J= 5.6 Hz, 2H), 2.86 (dd,J= 7.0, 6.0 Hz, 1H), 1.62 - 1.57 (m, 3H). ESI-MS m / z 391.1 (M+H) +

[0636] Step 3) tert-Butyl (E)-(1-(6-((6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-ylidene)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)carbamate (compound 28-3) Manufacturing

[0637] To a solution of compound 28-2 (1.276 g, 3.268 mmol) in MeOH (12 mL) was added pyrrolidine (0.4 mL, 4.902 mmol). The mixture was stirred at room temperature for 1 h. Then, compound 16-3 (1.097 g, 3.594 mmol) was added to the mixture, and the reaction mixture was stirred for 17 h. MeOH was removed under reduced pressure, and the resulting residue was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by MPLC (MeOH:CH2Cl2=1:50 to 1:10) to obtain compound 28-3 (1.71 g, 77%).

[0638] 1H NMR (400 MHz, CDCl3) δ 7.95 (d,J= 2.4 Hz, 1H), 7.82 (d,J= 1.3 Hz, 1H), 7.60 - 7.49 (m, 2H), 7.15 (t,J= 1.2 Hz, 1H), 6.98 (t,J= 1.4 Hz, 1H), 6.76 (s, 1H), 6.15 (t,J= 1.1 Hz, 1H), 6.00 (d,J= 2.1 Hz, 2H), 5.18 (s, 2H), 5.15 - 4.92 (m, 1H), 4.39 - 4.12 (m, 5H), 4.04 (dd,J= 8.7, 5.8 Hz, 2H), 3.03 (s, 1H), 2.97 (s, 3H), 2.30 (s, 3H), 1.58 (t,J= 7.4 Hz, 3H), 1.49 (s, 9H). ESI-MS m / z 678.7(M+H) +

[0639] 단계 4) tert-Butyl (1-(6-(((3R,4R)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-hydroxychroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)carbamate (화합물 28-4)의 제조

[0640] To a solution of compound 28-3 (807 mg, 1.19 mmol) in MeCN (50 mL) at room temperature was added a solution of DBU / formic acid (0.89 mL:0.23 mL). After stirring for 20 min, RuCl(p-cymene)[(R,R)-Ts-DPEN] (76 mg, 0.119 mmol) was added to the mixture. The reaction mixture was stirred at 60°C for 5 h and then quenched with saturated aqueous NaHCO3 in an ice bath. After extraction with CH2Cl2, the organic layer was washed with saturated NH4Cl solution, dried over MgSO4, and concentrated under reduced pressure. The residue was purified by MPLC (MeOH / CH2Cl2 = 1:30 to 1:10) to give compound 28-4 (459 mg, 57%).

[0641] 1 H NMR (400 MHz, CDCl3) δ 7.63 (d,J= 1.5 Hz, 1H), 7.50 (d,J= 1.0 Hz, 1H), 7.25 (d,J= 2.3 Hz, 1H), 7.10 (t,J= 1.2 Hz, 1H), 7.00 (d,J= 2.3 Hz, 1H), 6.94 (d,J= 1.4 Hz, 1H), 6.41 (d,J= 1.3 Hz, 1H), 6.06 (d,J= 1.4 Hz, 1H), 5.19 - 4.94 (m, 3H), 4.53 (d,J= 3.8 Hz, 1H), 4.34 - 4.21 (m, 4H), 4.16 - 4.03 (m, 4H), 2.99 (s, 3H), 2.82 (dd,J= 13.4, 10.8 Hz, 1H), 2.69 (dd,J= 13.5, 4.6 Hz, 1H), 2.36 (td,J= 10.3, 4.8 Hz, 1H), 2.27 (s, 3H), 1.57 (t,J= 7.3 Hz, 3H), 1.50 (s, 9H). ESI-MS m / z 682.4 (M+H) +

[0642] Step 5) tert-butyl (R)-(1-(6-((6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)carbamate (compound 28-5) Manufacturing

[0643] A solution of compound 28-4 (449 mg, 0.658 mmol) and 4 Å molecular sieves (100 mg) in CH2Cl2 (12 mL) was stirred for 30 min. Then, N-methylmorpholine-N-oxide (NMO, 154 mg, 1.317 mmol) and tetrapropylammonium perruthenate (TPAP, 90 mg, 0.264 mmol) were added at 0°C, and stirring was continued at room temperature for 17 h. The dark mixture was filtered over Celite using diethyl ether as the eluent. After concentration in vacuo, the residue was purified by MPLC (MeOH / CH2Cl2 = 1:30 to 1:10) to give compound 28-5 (178 mg, 40%).

[0644] 1H NMR (400 MHz, CDCl3) δ 7.83 (d,J= 2.4 Hz, 1H), 7.68 (t,J= 1.2 Hz, 1H), 7.55 (s, 1H), 7.27 (d,J= 4.8 Hz, 1H), 7.16 - 7.10 (m, 1H), 6.94 (t,J= 1.4 Hz, 1H), 6.42 (s, 1H), 6.02 (s, 1H), 5.13 (s, 3H), 4.66 (dd,J= 11.4, 5.0 Hz, 1H), 4.36 - 4.21 (m, 6H), 4.02 (t,J= 7.8 Hz, 2H), 3.49 - 3.42 (m, 1H), 3.31 (dd,J= 14.6, 4.8 Hz, 1H), 2.95 (s, 3H), 2.82 (t,J= 11.9 Hz, 1H), 2.26 (s, 3H), 1.56 (d,J= 7.3 Hz, 3H), 1.48 (s, 9H). ESI-MS m / z 680.4 (M+H) +

[0645] Step 6) Preparation of (R)-6-((1H-Imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-3-((4-methyl-6-(3-(methylamino)azetidin-1-yl)pyridin-2-yl)methyl)chroman-4-one hydrochloride (Compound 28-6)

[0646] To a solution of compound 28-5 (170 mg, 0.25 mmol) in anhydrous CH2Cl2 (2 mL) at 0°C was added dropwise 4 N-HCl in 1,4-dioxane (1 mL). The resulting mixture was stirred at room temperature for 4 h. The reaction mixture was concentrated under reduced pressure. The resulting solid was filtered, rinsed with diethyl ether (2 mL x 8), and concentrated in vacuo to give compound 28-6 HCl salt product (170 mg, 99%).

[0647] 1H NMR (400 MHz, DMSO) δ 9.91 (s, 1H), 9.34 (s, 1H), 8.14 (s, 1H), 7.96 (d,J= 2.3 Hz, 1H), 7.84 (t,J= 1.7 Hz, 1H), 7.75 - 7.66 (m, 2H), 6.66 (s, 2H), 5.46 (s, 2H), 4.58 - 4.19 (m, 7H), 4.13 (s, 1H), 3.57 (s, 6H), 3.44 (d,J= 19.1 Hz, 1H), 3.29 (s, 1H), 2.88 (s, 1H), 2.55 (s, 3H), 2.30 (s, 3H), 1.44 (t,J= 7.3 Hz, 3H). ESI-MS m / z 580.2(M+H) +

[0648] 단계 7) N1-(1-(6-(((R)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylsuccinamide (화합물 28)의 제조

[0649] To a solution of compound 27-2 (20 mg, 0.036 mmol) in DMF (0.5 mL) / CH2Cl2 (0.5 mL) at room temperature were added HATU (28 mg, 0.073 mmol) and DIEA (19 μL, 0.11 mmol). After stirring at room temperature for 30 min, compound 28-6 (27 mg, 0.044 mmol) was added to the mixture. The reaction mixture was stirred at room temperature for 17 h. The resulting mixture was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography (MeOH:CH2Cl2 = 1:50 to 1:10) to give compound 28 (30 mg, 74%).

[0650] 1H NMR (400 MHz, DMSO) δ 8.99 (s, 1H), 8.38 (d,J= 7.8 Hz, 1H), 8.10 (s, 1H), 7.96 (s, 1H), 7.86 (d,J= 9.1 Hz, 1H), 7.76 (d,J= 2.3 Hz, 1H), 7.50 (d,J= 2.3 Hz, 1H), 7.44 (d,J= 8.3 Hz, 2H), 7.38 (d,J= 8.2 Hz, 2H), 7.28 (s, 1H), 7.00 (s, 1H), 6.41 (s, 1H), 6.09 (s, 1H), 5.23 (s, 2H), 5.14 (d,J= 29.4 Hz, 1H), 4.92 (t,J= 7.2 Hz, 1H), 4.50 (d,J= 9.6 Hz, 1H), 4.47 - 4.39 (m, 2H), 4.33 (t,J= 10.8 Hz, 1H), 4.29 - 4.22 (m, 3H), 4.14 - 4.08 (m, 1H), 4.02 (q,J= 5.0, 3.0 Hz, 1H), 3.91 (s, 1H), 3.80 (s, 1H), 3.59 (q,J= 10.6, 9.2 Hz, 2H), 3.27 (d,J= 4.2 Hz, 3H), 3.02 (d,J= 11.1 Hz, 4H), 2.88 (s, 1H), 2.73 - 2.66 (m, 1H), 2.46 (s, 3H), 2.43 - 2.34 (m, 1H), 2.18 (s, 3H), 2.03 (d,J= 11.2 Hz, 1H), 1.79 (ddd,J= 12.9, 8.6, 4.7 Hz, 1H), 1.44 (d,J= 7.3 Hz, 3H), 1.38 (dd,J= 6.9, 2.5 Hz, 3H), 0.93 (s, 9H). ESI-MS m / z 1106.4(M+H) +

[0651] Compound 29. N1-(1-(6-(((S)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylsuccinamide

[0652]

[0653] Step 1) tert-Butyl (1-(6-(((3S,4S)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-hydroxychroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)carbamate (compound 29-1) Manufacturing

[0654] To a solution of compound 28-3 (861 mg, 1.27 mmol) in MeCN (50 mL) at room temperature was added a solution of DBU / formic acid (0.95 mL:0.24 mL). After stirring for 20 min, RuCl(p-cymene)[(S,S)-Ts-DPEN] (81 mg, 0.127 mmol) was added to the mixture. The reaction mixture was stirred at 60°C for 5 h and then quenched with saturated aqueous NaHCO3 at ambient temperature. After extraction with CH2Cl2, the organic layer was washed with saturated NH4Cl solution, dried over MgSO4, and concentrated under reduced pressure. The residue was purified by MPLC (MeOH / CH2Cl2 = 1:30 to 1:10) to give compound 29-1 (550 mg, 64%).

[0655] 1H NMR (400 MHz, CDCl3) δ 7.63 (d,J= 1.5 Hz, 1H), 7.50 (d,J= 1.0 Hz, 1H), 7.25 (d,J= 2.3 Hz, 1H), 7.10 (t,J= 1.2 Hz, 1H), 7.00 (d,J= 2.3 Hz, 1H), 6.94 (d,J= 1.4 Hz, 1H), 6.41 (d,J= 1.3 Hz, 1H), 6.06 (d,J= 1.4 Hz, 1H), 5.19 - 4.94 (m, 3H), 4.53 (d,J= 3.8 Hz, 1H), 4.34 - 4.21 (m, 4H), 4.16 - 4.03 (m, 4H), 2.99 (s, 3H), 2.82 (dd,J= 13.4, 10.8 Hz, 1H), 2.69 (dd,J= 13.5, 4.6 Hz, 1H), 2.36 (td,J= 10.3, 4.8 Hz, 1H), 2.27 (s, 3H), 1.57 (t,J= 7.3 Hz, 3H), 1.50 (s, 9H). ESI-MS m / z 682.4 (M+H) +

[0656] 단계 2) tert-Butyl (S)-(1-(6-((6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)carbamate (화합물 29-2)의 제조

[0657] A mixture of compound 29-1 (533 mg, 0.781 mmol) and 4 Å molecular sieves (100 mg) in CH2Cl2 (12 mL) was stirred at room temperature for 30 min. Then, N-methylmorpholine-N-oxide (NMO, 183 mg, 1.56 mmol) and tetrapropylammonium perruthenate (TPAP, 109 mg, 0.312 mmol) were added to the mixture at 0°C, and stirring was continued at room temperature for 17 h. The dark mixture was filtered over Celite using diethyl ether as the eluent. After concentration in vacuo, the residue was purified by MPLC (MeOH / CH2Cl2 = 1:30 to 1:10) to give compound 29-2 (245 mg, 46%).

[0658] 1 H NMR (400 MHz, CDCl3) δ 7.83 (d,J= 2.4 Hz, 1H), 7.68 (t,J= 1.2 Hz, 1H), 7.55 (s, 1H), 7.27 (d,J= 4.8 Hz, 1H), 7.16 - 7.10 (m, 1H), 6.94 (t,J= 1.4 Hz, 1H), 6.42 (s, 1H), 6.02 (s, 1H), 5.13 (s, 3H), 4.66 (dd,J= 11.4, 5.0 Hz, 1H), 4.36 - 4.21 (m, 6H), 4.02 (t,J= 7.8 Hz, 2H), 3.49 - 3.42 (m, 1H), 3.31 (dd,J= 14.6, 4.8 Hz, 1H), 2.95 (s, 3H), 2.82 (t,J= 11.9 Hz, 1H), 2.26 (s, 3H), 1.56 (d,J= 7.3 Hz, 3H), 1.48 (s, 9H). ESI-MS m / z 680.4 (M+H) +

[0659] Step 3) Preparation of (S)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-3-((4-methyl-6-(3-(methylamino)azetidin-1-yl)pyridin-2-yl)methyl)chroman-4-one hydrochloride (Compound 29-3)

[0660] To a solution of compound 29-2 (230 mg, 0.338 mmol) in anhydrous CH2Cl2 (2 mL) at 0°C was added dropwise 4 N-HCl in dioxane (1 mL). The resulting mixture was stirred at room temperature for 4 h. The reaction mixture was concentrated under reduced pressure. The resulting solid was filtered, rinsed with diethyl ether (2 mL x 8), and concentrated in vacuo to obtain compound 29-3HCl salt product (230 mg, 99%).

[0661] 1 H NMR (400 MHz, DMSO) δ 9.91 (s, 1H), 9.34 (s, 1H), 8.14 (s, 1H), 7.96 (d,J= 2.3 Hz, 1H), 7.84 (t,J= 1.7 Hz, 1H), 7.75 - 7.66 (m, 2H), 6.66 (s, 2H), 5.46 (s, 2H), 4.58 - 4.19 (m, 7H), 4.13 (s, 1H), 3.57 (s, 6H), 3.44 (d,J= 19.1 Hz, 1H), 3.29 (s, 1H), 2.88 (s, 1H), 2.55 (s, 3H), 2.30 (s, 3H), 1.44 (t,J= 7.3 Hz, 3H). ESI-MS m / z 580.2 (M+H) +

[0662] Step 4) N1-(1-(6-(((S)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)- N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylsuccinamide Preparation of (Compound 29)

[0663] To a solution of compound 27-2 (28.7 mg, 0.053 mmol) in DMF (0.5 mL) / CH2Cl2 (0.5 mL) at room temperature were added HATU (36.5 mg, 0.096 mmol) and DIEA (42 μL, 0.24 mmol). After stirring for 30 min, compound 29-3 (29.6 mg, 0.048 mmol) was added to the mixture. The reaction mixture was stirred at room temperature for 17 h. The mixture was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x 3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography (MeOH:CH2Cl2 = 1:50 to 1:10) to give compound 29 (28 mg, 53%).

[0664] 1H NMR (400 MHz, DMSO) δ 8.99 (s, 1H), 8.38 (d,J= 7.8 Hz, 1H), 8.10 (s, 1H), 7.96 (s, 1H), 7.86 (d,J= 9.1 Hz, 1H), 7.76 (d,J= 2.3 Hz, 1H), 7.50 (d,J= 2.3 Hz, 1H), 7.44 (d,J= 8.3 Hz, 2H), 7.38 (d,J= 8.2 Hz, 2H), 7.28 (s, 1H), 7.00 (s, 1H), 6.41 (s, 1H), 6.09 (s, 1H), 5.23 (s, 2H), 5.14 (d,J= 29.4 Hz, 1H), 4.92 (t,J= 7.2 Hz, 1H), 4.50 (d,J= 9.6 Hz, 1H), 4.47 - 4.39 (m, 2H), 4.33 (t,J= 10.8 Hz, 1H), 4.29 - 4.22 (m, 3H), 4.14 - 4.08 (m, 1H), 4.02 (q,J= 5.0, 3.0 Hz, 1H), 3.91 (s, 1H), 3.80 (s, 1H), 3.59 (q,J= 10.6, 9.2 Hz, 2H), 3.27 (d,J= 4.2 Hz, 3H), 3.02 (d,J= 11.1 Hz, 4H), 2.88 (s, 1H), 2.73 - 2.66 (m, 1H), 2.46 (s, 3H), 2.43 - 2.34 (m, 1H), 2.18 (s, 3H), 2.03 (d,J= 11.2 Hz, 1H), 1.79 (ddd,J= 12.9, 8.6, 4.7 Hz, 1H), 1.44 (d,J= 7.3 Hz, 3H), 1.38 (dd,J= 6.9, 2.5 Hz, 3H), 0.93 (s, 9H). ESI-MS m / z 1106.4(M+H) +

[0665] Compound 30. (2S,4R)-1-((S)-2-(2-(5-(((S)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0666]

[0667] Step 1) Preparation of Methyl 2-(2-fluoro-5-formylphenoxy)acetate (Compound 30-1)

[0668] To a solution of 4-fluoro-3-hydroxybenzaldehyde (CAS NO. 103438-85-3) (10.0 g, 71.4 mmol, 1.0 equiv) in DMF (180 mL) were added methyl 2-bromoacetate (CAS NO. 96-32-2) (7.43 mL, 78.5 mmol, 1.1 equiv) and K2CO3 (19.7 g, 142.7 mmol, 2.0 equiv). The reaction mixture was stirred at 50°C overnight. The reaction solution was diluted with EtOAc, washed three times with water, and extracted with EtOAc. The combined organic layers were dried over Na2SO4 and concentrated. The crude product was purified by MPLC to give compound 30-1 (10.0 g, 58%).

[0669] 1 H NMR (400 MHz, CDCl3) δ 9.92 (s, 1H), 7.54 (ddd,J= 8.2, 4.4, 1.9 Hz, 1H), 7.46 (dd,J= 8.0, 1.9 Hz, 1H), 7.31 - 7.26 (m, 1H), 4.80 (s, 2H), 3.84 (s, 3H).

[0670] Step 2) Preparation of Methyl (E)-2-(5-((8-bromo-6-methyl-4-oxochroman-3-ylidene)methyl)-2-fluorophenoxy)acetate (Compound 30-2)

[0671] To a solution of 8-bromo-6-methylchroman-4-one (4.6 g, 10.67 mmol, 1.0 equiv) and compound 30-1 (11.65 g, 54.9 mmol, 1.2 equiv) in toluene (165 mL) at room temperature was added TsOH (714 mg, 4.15 mmol, 0.1 equiv). The reaction mixture was stirred at 110 °C overnight. The solvent was removed and filtered through a short pad of silica with EtOAc. The residue was evaporated, and the crude product was purified by recrystallization from EA and heptane to give compound 30-2 (4.64 g, 10.67 mmol, 25.7%).

[0672] 1 H NMR (400 MHz, CDCl3) δ 7.77 - 7.73 (m, 2H), 7.57 (d,J= 2.2 Hz, 1H), 7.17 (dd,J= 10.9, 8.2 Hz, 1H), 6.93 - 6.87 (m, 2H), 5.36 (d,J= 1.9 Hz, 2H), 4.74 (s, 2H), 3.83 (s, 3H), 2.32 (s, 3H).

[0673] Step 3) Preparation of Methyl 2-(5-(((3S,4S)-8-bromo-4-hydroxy-6-methylchroman-3-yl)methyl)-2-fluorophenoxy)acetate (Compound 30-3)

[0674] To a solution of compound 30-2 (4.6 g, 10.67 mmol, 1.0 equiv) in MeCN (43 mL) at 0°C were added DBU (3.2 mL, 21.34 mmol, 2 equiv) and HCO2H (2.0 mL, 53.4 mmol, 5.0 equiv). The reaction flask was degassed at room temperature for 30 min. Then, RuCl(p-cymene)[(S,S)-Ts-DPEN] (679 mg, 0.1 equiv) was added to the solution, and the resulting mixture was stirred at 70°C for 2 h. The solvent was removed, and the mixture was filtered through a short silica pad with EtOAc. The residue was evaporated, and the crude product was purified by MPLC to give compound 30-3 (2.7 g, 58%).

[0675] 1 H NMR (400 MHz, CDCl3) δ 7.25 (s, 1H), 7.01 (ddd,J= 11.2, 8.1, 1.4 Hz, 1H), 6.92 (q,J= 2.6, 2.2 Hz, 1H), 6.84 (ddt,J= 7.9, 6.0, 2.9 Hz, 2H), 4.68 (d,J= 1.4 Hz, 2H), 4.39 (d,J= 3.7 Hz, 1H), 4.20 - 4.04 (m, 2H), 3.77 (d,J= 1.4 Hz, 3H), 2.78 (dd,J= 13.7, 8.5 Hz, 1H), 2.57 (dd,J= 13.6, 7.2 Hz, 1H), 2.20 (s, 3H), 2.15 (t,J= 5.9 Hz, 1H).

[0676] Step 4) Preparation of Methyl (S)-2-(5-((8-bromo-6-methyl-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetate (Compound 30-4)

[0677] Molecular sieves (200 mg) were added to a solution of compound 30-3 (2.7 g, 6.1 mmol, 1 equiv) in CH2Cl2 (30 mL). The mixture was stirred at room temperature for 1 h. NMO (1.44 g, 2.0 equiv) and TPAP (428 mg, 0.5 equiv) were added to the reaction mixture at 0 °C, and the reaction was stirred at room temperature for 2 h. Upon completion of the reaction, the reaction was filtered through Celite. The residue was concentrated under reduced pressure and purified by MPLC to give compound 30-4 (2.3 g, 86%).

[0678] 1 H NMR (500 MHz, CDCl3) δ 7.65 (d,J= 2.2 Hz, 1H), 7.55 (d,J= 2.2 Hz, 1H), 7.06 - 6.99 (m, 1H), 6.85 - 6.76 (m, 2H), 4.70 (s, 2H), 4.45 (dd,J= 11.6, 4.4 Hz, 1H), 4.20 (dd,J= 11.6, 8.8 Hz, 1H), 3.81 (s, 3H), 3.17 (dd,J= 14.1, 4.8 Hz, 1H), 2.88 (tt,J= 9.2, 4.6 Hz, 1H), 2.67 (dd,J= 14.2, 9.8 Hz, 1H), 2.29 (s, 3H).

[0679] Step 5) Preparation of Methyl (S)-2-(5-((8-bromo-6-(bromomethyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetate (Compound 30-5)

[0680] To a solution of compound 30-4 (2.3 g, 5.26 mmol, 1.0 equiv) in MeOAc (21 mL) at room temperature were added NBS (1.03 g, 5.78 mmol, 1.1 equiv) and AIBN (259 mg, 1.58 mmol, 0.3 equiv). The reaction mixture was stirred at 70°C overnight. The solvent was removed, and the residue was partitioned between EtOAc and water. The aqueous phase was extracted twice with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. The crude product was purified by recrystallization from EtOAc and heptane to give compound 30-5 (1.1 g, 40%).

[0681] 1 H NMR (400 MHz, CDCl3) δ 7.88 (d,J= 2.3 Hz, 1H), 7.79 (d,J= 2.3 Hz, 1H), 7.10 - 6.98 (m, 1H), 6.86 - 6.77 (m, 2H), 4.71 (s, 2H), 4.51 (dd,J= 11.6, 4.5 Hz, 1H), 4.43 (s, 2H), 4.26 (dd,J= 11.6, 8.9 Hz, 1H), 3.82 (s, 3H), 3.19 (dd,J= 14.2, 4.8 Hz, 1H), 2.93 (tt,J= 9.2, 4.6 Hz, 1H), 2.70 (dd,J= 14.2, 9.7 Hz, 1H).

[0682] Step 6) Preparation of Methyl (S)-2-(5-((6-((1H-imidazol-1-yl)methyl)-8-bromo-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetate (Compound 30-6)

[0683] To a solution of compound 30-5 (1.0 g, 1.93 mmol, 1.0 equiv) in DMF (15.5 mL) at room temperature was added imidazole (359 mg, 5.8 mmol, 3.0 equiv). The reaction mixture was stirred at 50°C overnight. The reaction solution was diluted with EtOAc, washed three times with water, and extracted with EtOAc. The combined organic layers were dried over Na2SO4 and concentrated. The crude product was purified by MPLC to give compound 30-6 (626 mg, 65%).

[0684] 1 H NMR (400 MHz, CDCl3) δ 7.69 (d,J= 6.7 Hz, 1H), 7.54 (d,J= 2.3 Hz, 1H), 7.12 (s, 1H), 7.04 (dd,J= 11.1, 8.7 Hz, 1H), 6.92 (d,J= 6.7 Hz, 2H), 6.86 - 6.74 (m, 2H), 5.09 (s, 2H), 4.70 (s, 2H), 4.51 (dd,J= 11.7, 4.5 Hz, 1H), 4.25 (dd,J= 11.6, 8.8 Hz, 1H), 3.82 (d,J=6.4 Hz, 3H), 3.18 (dd,J= 14.1, 4.8 Hz, 1H), 2.92 (q,J= 4.5 Hz, 1H), 2.69 (dd,J= 14.2, 9.6 Hz, 1H). ESI-MS m / z 504.5 (M+H) + .

[0685] Step 7) Preparation of Methyl (S)-2-(5-((6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetate (Compound 30-7)

[0686] To compound 30-6 (293 mg, 0.582 mmol) in 1,4-dioxane / H2O (10:1, 6.6 mL) at room temperature were added Cs2CO3 (380 mg, 1.164 mmol) and Pd(amphos)Cl2 (41 mg, 0.058 mmol). After 10 min, (1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)boronic acid (182 mg, 0.873 mmol) was added and stirred at 100 °C for 2 h. After cooling to room temperature, 1,4-dioxane was removed under reduced pressure, and the resulting residue was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, 2% to 10%) to give compound 30-7 (276 mg, 81%).

[0687] 1 H NMR (500 MHz, CDCl3) δ 7.79 (d,J= 2.4 Hz, 1H), 7.59 - 7.57 (m, 1H), 7.48 (dd,J= 4.4, 1.0 Hz, 1H), 7.25 (dd,J= 5.9, 2.4 Hz, 1H), 7.06 (t,J= 1.1 Hz, 1H), 7.03 - 6.96 (m, 1H), 6.91 (dt,J= 6.7, 1.4 Hz, 1H), 6.80 - 6.74 (m, 2H), 5.09 (d,J= 12.0 Hz, 2H), 4.68 (d,J= 22.7 Hz, 2H), 4.34 (dd,J= 11.6, 4.4 Hz, 1H), 4.22 (q,J= 7.3 Hz, 2H), 4.13 (dd,J= 11.6, 8.5 Hz, 1H), 3.76 (d,J= 11.5 Hz, 3H), 3.15 (dd,J= 14.1, 4.7 Hz, 1H), 2.89 - 2.85 (m, 1H), 2.66 (dd,J= 14.1, 9.9 Hz, 1H), 1.55 - 1.50 (m, 3H). ESI-MS m / z 587.1 (M+H) +

[0688] Step 8) Preparation of (S)-2-(5-((6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetic acid (Compound 30-8)

[0689] To a solution of compound 30-7 (161 mg, 0.274 mmol, 1.0 equiv) in H2O:MeOH=1:2 (3 mL) at room temperature was added NaHCO3 (115 mg, 1.372 mmol, 5.0 equiv). The reaction mixture was stirred at 110°C for 3 h using a microwave. The reaction solution was evaporated under reduced pressure, diluted with water, and washed three times with EtOAc. The aqueous layer was acidified to pH=4-5 with 1 N-HCl in H2O at 0°C and extracted with EtOAc. The combined organic layers were dried over Na2SO4 and concentrated to give compound 30-8 (60 mg, 38%).

[0690] 1 H NMR (400 MHz, MeOD) δ 8.97 (s, 1H), 7.94 (dd,J= 20.1, 1.7 Hz, 2H), 7.62 (d,J= 5.5 Hz, 1H), 7.58 (dt,J= 9.8, 2.3 Hz, 2H), 7.04 (dd,J= 11.4, 8.3 Hz, 1H), 6.92 (dd,J= 8.1, 2.1 Hz, 1H), 6.84 (ddd,J= 8.3, 4.2, 2.1 Hz, 1H), 5.49 (d,J= 17.7 Hz, 2H), 4.70 (s, 2H), 4.51 - 4.39 (m, 1H), 4.36 - 4.24 (m, 3H), 3.16 (dd,J= 13.9, 5.3 Hz, 1H), 3.02 (dt,J= 9.3, 4.8 Hz, 1H), 2.78 (dd,J= 14.0, 9.0 Hz, 1H), 1.53 (t,J= 7.3 Hz, 3H). ESI-MS m / z 573.2 (M+H) +

[0691] Step 9) (2S,4R)-1-((S)-2-(2-(5-(((S)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl) -2-fluorophenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide Preparation of (Compound 30)

[0692] To a mixture of compound 30-8 (37.9 mg, 0.066 mmol, 1.0 equiv), (S,R,S)-AHPC-Me HCl salt (35.0 mg, 0.073 mmol, 1.1 equiv), and HATU (50 mg, 0.132 mmol, 2.0 equiv) in DMF (2 mL) at room temperature was added DIEA (57 μL, 0.33 mmol, 5.0 equiv). The reaction mixture was stirred at the same temperature for 15 h, diluted with EtOAc, washed three times with water, and extracted with EtOAc (x2). The combined extracts were dried over Na2SO4 and concentrated. The crude was purified by MPLC to give pure compound 30 (10 mg, 15%).

[0693] 1H NMR (400 MHz, CDCl3) δ 8.13 - 7.93 (m, 1H), 7.80 (q,J= 9.1, 6.9 Hz, 2H), 7.63 - 7.43 (m, 3H), 7.38 (dt,J= 9.3, 4.3 Hz, 6H), 7.01 (dt,J= 10.7, 8.3 Hz, 2H), 6.85 - 6.77 (m, 1H), 6.72 (dd,J= 22.1, 8.2 Hz, 1H), 5.21 (s, 1H), 5.06 (dt,J= 13.7, 7.0 Hz, 2H), 4.89 (s, 1H), 4.83 - 4.71 (m, 1H), 4.63 - 4.55 (m, 1H), 4.52 (dd,J= 8.7, 5.6 Hz, 1H), 4.45 - 4.38 (m, 1H), 4.24 (td,J= 7.5, 4.7 Hz, 3H), 4.11 (dt,J= 16.0, 8.1 Hz, 2H), 3.61 (dq,J= 13.4, 10.4, 9.6 Hz, 2H), 3.11 (t,J= 6.9 Hz, 1H), 2.89 (ddd,J= 28.2, 18.5, 11.2 Hz, 3H), 2.54 - 2.50 (m, 4H), 2.43 (dd,J= 12.3, 4.9 Hz, 1H), 2.17 (s, 1H), 2.13 - 1.98 (m, 3H), 1.54 (ddt,J= 7.4, 5.3, 2.6 Hz, 3H), 1.48 (s, 3H), 1.28 - 1.23 (m, 2H). ESI-MS m / z 999.4 (MS+H)+.

[0694] Compound 31. (2S,4R)-1-((S)-2-(2-(5-(((S)-6-((1H-imidazol-1-yl)methyl)-8-(4-fluoro-2-methylphenyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0695]

[0696] Step 1) Preparation of Methyl (S)-2-(5-((6-((1H-imidazol-1-yl)methyl)-8-(4-fluoro-2-methylphenyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetate (Compound 31-1)

[0697] To a solution of compound 30-6 (323 mg, 0.64 mmol) in 1,4-dioxane / H2O (10:1, 6.6 mL) at room temperature were added Cs2CO3 (417 mg, 1.28 mmol) and Pd(amphos)Cl2 (45 mg, 0.064 mmol). After 10 min, (4-fluoro-2-methylphenyl)boronic acid (148 mg, 0.96 mmol) was added and heated at 100 °C for 2 h. After cooling to room temperature, 1,4-dioxane was removed under reduced pressure, and the resulting residue was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, 2% to 10%) to give compound 31-1 (274 mg, 80%).

[0698] 1H NMR (500 MHz, CDCl3) δ 7.82 (d,J= 2.4 Hz, 1H), 7.58 (dt,J= 8.5, 1.2 Hz, 1H), 7.13 (d,J= 2.4 Hz, 1H), 7.08 - 7.06 (m, 1H), 7.03 (dd,J= 8.4, 5.8 Hz, 1H), 7.00 - 6.85 (m, 5H), 6.78 - 6.73 (m, 2H), 5.09 (s, 2H), 4.64 (s, 2H), 4.37 - 4.30 (m, 1H), 4.14 - 4.06 (m, 1H), 3.74 (s, 3H), 3.16 (dd,J= 14.1, 4.7 Hz, 1H), 2.88 (dq,J= 9.2, 4.5 Hz, 1H), 2.66 (dd,J= 14.2, 9.6 Hz, 1H), 2.09 (s, 3H). ESI-MS m / z 533.1 (M+H) +

[0699] Step 2) Preparation of (S)-2-(5-((6-((1H-imidazol-1-yl)methyl)-8-(4-fluoro-2-methylphenyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetic acid (Compound 31-2)

[0700] To a solution of compound 31-1 (160 mg, 0.30 mmol, 1.0 equiv) in H2O:MeOH=1:3 (5 mL) was added NaHCO3 (126 mg, 1.50 mmol, 5.0 equiv). The reaction mixture was stirred at 110°C for 3 h using a microwave. The reaction solution was evaporated under reduced pressure, diluted with water, and washed three times with EtOAc. The aqueous layer was acidified to pH=4-5 with 1 N HCl in H2O at 0°C and extracted with EtOAc. The combined organic layers were dried over Na2SO4 and concentrated to give compound 31-2 (34 mg, 22%).

[0701] 1H NMR (400 MHz, MeOD) δ 7.98 (d,J= 2.4 Hz, 1H), 7.70 - 7.65 (m, 1H), 7.57 (d,J= 2.0 Hz, 1H), 7.50 (dd,J= 12.7, 2.5 Hz, 1H), 7.15 (dd,J= 8.5, 5.8 Hz, 1H), 7.07 - 6.93 (m, 4H), 6.89 (dd,J= 8.2, 2.0 Hz, 1H), 6.83 (d,J= 5.6 Hz, 1H), 5.49 (d,J= 12.5 Hz, 2H), 4.69 (s, 2H), 4.42 (dd,J= 11.7, 4.5 Hz, 1H), 4.23 (dd,J= 11.7, 8.6 Hz, 1H), 3.22 - 3.12 (m, 1H), 3.02 (dt,J= 9.6, 4.3 Hz, 1H), 2.78 (dd,J= 13.9, 8.8 Hz, 1H), 2.15 (d,J= 4.1 Hz, 3H). ESI-MS m / z 518.8 (M+H) + .

[0702] 단계 3) (2S,4R)-1-((S)-2-(2-(5-(((S)-6-((1H-imidazol-1-yl)methyl)-8-(4-fluoro-2-methylphenyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (화합물 31)의 제조

[0703] To a solution of compound 31-2 (34 mg, 0.065 mmol, 1.0 equiv), (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (VHL ligand, 34 mg, 0.0715 mmol, 1.1 equiv) and HATU (49 mg, 0.13 mmol, 2.0 equiv) in DMF (3 mL) was added DIEA (100 μL, excess) at room temperature. The reaction mixture was stirred at the same temperature for 15 h. The reaction solution was diluted with EtOAc, washed three times with water, and then extracted with EtOAc. The combined organic layers were dried over Na2SO4 and concentrated. The crude product was purified by MPLC to obtain compound 31 (33 mg, 54%).

[0704] 1H NMR (400 MHz, CDCl3) δ 8.66 (s, 1H), 7.97 (s, 1H), 7.83 (dd,J= 14.1, 2.2 Hz, 1H), 7.57 (t,J= 7.2 Hz, 1H), 7.36 (dd,J= 6.7, 4.1 Hz, 5H), 7.22 - 7.10 (m, 2H), 7.06 - 6.89 (m, 5H), 6.76 (d,J= 13.0 Hz, 2H), 5.18 (d,J= 3.4 Hz, 2H), 5.12 - 5.03 (m, 1H), 4.76 (dt,J= 11.7, 7.5 Hz, 1H), 4.60 (dd,J= 8.8, 5.7 Hz, 1H), 4.51 (s, 1H), 4.47 (d,J= 7.7 Hz, 1H), 4.38 (dd,J= 11.5, 4.1 Hz, 1H), 4.20 - 4.04 (m, 3H), 3.64 (dd,J= 11.5, 3.6 Hz, 1H), 3.27 (s, 2H), 3.12 (s, 1H), 2.98 - 2.88 (m, 1H), 2.51 (s, 3H), 2.49 - 2.39 (m, 1H), 2.09 (d,J= 4.1 Hz, 3H), 1.47 (d,J= 7.0 Hz, 3H), 1.05 (d,J= 5.4 Hz, 9H). ESI-MS m / z 943.2 (MH) -

[0705] Compound 32. 2-(5-(((S)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)-N-(1-(6-(((R)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N-methylacetamide

[0706]

[0707] To a solution of compound 30-8 (14.2 mg, 0.0248 mmol) in DMF (0.5 mL) / CH2Cl2 (1 mL) at room temperature were added HATU (19 mg, 0.0496 mmol) and DIEA (13 μL, 0.074 mmol). After stirring at room temperature for 30 min, compound 28-6 (14 mg, 0.0225 mmol) was added to the mixture. The mixture was stirred at room temperature for 17 h. The mixture was diluted with EtOAc, brine, and H2O, extracted with ethyl acetate (x3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (MeOH:CH2Cl2 = 1:50 to 1:10) to give compound 32 (8.2 mg, 32%).

[0708] ESI-MS m / z (M+H) + 1 H NMR (400 MHz, CDCl3) δ 7.91 - 7.74 (m, 4H), 7.55 (d,J= 5.9 Hz, 2H), 7.32 - 7.29 (m, 2H), 7.15 (s, 2H), 7.09 - 6.76 (m, 5H), 6.40 (d,J= 30.2 Hz, 1H), 6.04 (d,J= 22.7 Hz, 1H), 5.31 - 5.10 (m, 5H), 4.80 (d,J= 6.9 Hz, 2H), 4.60 (dd,J= 11.4, 5.1 Hz, 1H), 4.45 - 4.19 (m, 9H), 4.08 - 3.92 (m, 2H), 3.40 (d,J= 10.0 Hz, 1H), 3.34 - 3.25 (m, 1H), 3.20 (d,J= 4.8 Hz, 3H), 3.11 (d,J= 5.5 Hz, 1H), 3.00 - 2.87 (m, 1H), 2.80 - 2.66 (m, 1H), 2.25 (s, 3H), 1.56 (t,J= 7.4 Hz, 6H). ESI-MS m / z 1134 (M+H) +

[0709] Compound 33. (S,E)-N-(2-(2-(2,6-dimethoxy-4-(3-oxo-3-(6-oxo-3,6-dihydropyridin-1(2H)-yl)prop-1-phen-1-yl)phenoxy)ethoxy)ethyl)-2-(5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamide

[0710]

[0711] Step 1) Preparation of (E)-1-(3-(4-hydroxy-3,5-dimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one (Compound 33-1)

[0712] To a solution of (E)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one (Piperlongumine; CAS NO. 20069-09-4) (50 mg, 0.157 mmol) in anhydrous CH2Cl2 (3 mL) was added AlCl3 (210 mg, 1.57 mmol) in an ice bath. The reaction mixture was warmed to room temperature, stirred under N2 for 1 h, and quenched with saturated NaHCO3 solution in an ice bath. The mixture was extracted with EtOAc, and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was purified by MPLC to give pure compound 33-1 (30 mg, 63% yield).

[0713] 1H NMR (400 MHz, CDCl3) δ 7.69 (d,J= 15.5 Hz, 1H), 7.40 (d,J= 15.5 Hz, 1H), 6.94 (dt,J= 9.0, 4.1 Hz, 1H), 6.83 (s, 2H), 6.05 (dt,J= 9.7, 1.9 Hz, 1H), 5.75 (s, 1H), 4.04 (t,J= 6.5 Hz, 2H), 3.92 (s, 6H), 2.48 (tdd,J= 6.4, 4.1, 1.9 Hz, 2H). ESI-MS m / z 304.1 (MS+H)+.

[0714] Step 2) Preparation of tert-Butyl (E)-(2-(2-(2,6-dimethoxy-4-(3-oxo-3-(6-oxo-3,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)phenoxy)ethoxy)ethyl)carbamate (Compound 33-2)

[0715] To a solution of compound 33-1 (30 mg, 1.0 equiv) and tert-butyl (2-(2-hydroxyethoxy)ethyl)carbamate (21 μL, 1.1 equiv) in toluene (2 mL) were added tributylphosphine (36 mg, 1.4 equiv) and DIAD (8.4 μL, 1.3 equiv) in an ice bath. The resulting mixture was warmed to room temperature and stirred overnight under N2. H2O (3 mL) was added in an ice-bath, and the mixture was extracted with EA. The combined extracts were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The resulting crude was purified by MPLC to give compound 33-2 (35 mg, 71%).

[0716] 1H NMR (500 MHz, CDCl3) δ 7.70 - 7.66 (m, 1H), 7.42 (d,J= 15.5 Hz, 1H), 6.95 (dt,J= 9.7, 4.2 Hz, 1H), 6.80 (s, 2H), 6.04 (dt,J= 9.6, 1.9 Hz, 1H), 4.19 - 4.14 (m, 2H), 4.04 (t,J= 6.5 Hz, 2H), 3.88 (s, 6H), 3.78 - 3.72 (m, 2H), 3.59 (t,J= 5.0 Hz, 2H), 3.33 (q,J= 5.3 Hz, 2H), 2.48 (tdd,J= 6.3, 4.1, 1.9 Hz, 2H), 1.44 (s, 9H).

[0717] Step 3) (E)-1-(3-(3,5-dimethoxy-4-(2-(2-((2,2,2-trifluoroacetyl)-λ 4 Preparation of azaneyl)ethoxy)ethoxy)phenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one (compound 33-3)

[0718] To a solution of compound 33-2 (35 mg, 0.08 mmol) dissolved in CH2Cl2 (2 mL) was added TFA (0.5 mL) at 0°C. The reaction was stirred at room temperature for 2 h, and the solvent was removed. The residue was purified by MPLC to give compound 33-3 as a TFA salt (15.3 mg, 43%).

[0719] 1H NMR (400 MHz, MeOD) δ 7.61 (d,J= 15.6 Hz, 1H), 7.37 (d,J= 15.5 Hz, 1H), 7.09 (dt,J= 9.7, 4.2 Hz, 1H), 6.94 (s, 2H), 6.01 (dt,J= 9.7, 1.9 Hz, 1H), 4.18 - 4.09 (m, 2H), 3.99 (t,J= 6.5 Hz, 2H), 3.89 (s, 6H), 3.84 - 3.77 (m, 4H), 3.17 (t,J= 5.0 Hz, 2H), 2.51 (tdd,J=6.4, 4.2, 1.9 Hz, 2H).

[0720] Step 4) (S,E)-N-(2-(2-(2,6-dimethoxy-4-(3-oxo-3-(6-oxo-3,6-dihydropyridin-1(2H)-yl)prop-1-en-1-yl)phenoxy)ethoxy)ethyl)-2-(5-((8-(1-ethy l-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamide Preparation of (Compound 33)

[0721] DIEA (90 μL) was added to a solution of compound 33-3 (15.3 mg, 0.03 mmol), compound 20-5 (17.6 mg, 0.03 mmol), and HATU (29 mg, 0.06 mmol) in CH2Cl2 (2 mL) at 0°C. The reaction mixture was stirred at room temperature for 15 h, and upon completion of the reaction, the solvent was removed, and the crude product was purified by MPLC to obtain compound 33 (7.2 mg, 25%).

[0722] 1H NMR (400 MHz, CDCl3) δ 7.74 (d,J= 2.4 Hz, 1H), 7.67 (s, 1H), 7.61 (d,J= 15.5 Hz, 1H), 7.41 - 7.34 (m, 2H), 7.16 (d,J= 2.0 Hz, 2H), 7.10 (d,J= 2.0 Hz, 1H), 6.96 (ddd,J= 9.7, 6.7, 3.7 Hz, 2H), 6.78 (d,J= 8.0 Hz, 2H), 6.75 (s, 2H), 6.03 (dt,J= 9.6, 1.8 Hz, 1H), 5.19 (s, 2H), 4.51 (d,J= 4.4 Hz, 2H), 4.40 (dd,J= 11.7, 4.5 Hz, 1H), 4.25 (t,J= 7.4 Hz, 2H), 4.17 - 4.13 (m, 2H), 4.02 (t,J= 6.5 Hz, 2H), 3.84 (s, 6H), 3.79 - 3.75 (m, 2H), 3.72 - 3.67 (m, 3H), 3.66 (d,J= 4.6 Hz, 2H), 3.57 (q,J= 5.3 Hz, 2H), 2.94 - 2.87 (m, 2H), 2.70 (dd,J= 14.1, 9.1 Hz, 2H), 2.64 (s, 3H), 2.52 - 2.44 (m, 2H), 1.55 - 1.51 (m, 4H). ESI-MS m / z 959.1 (MS+H) + .

[0723] <실험예 1: MLL1 메틸전달효소 활성 측정>

[0724] The MLL1 core protein complexes used in the experiment were human MLL1 (amino acids 3745-3969, accession number #NM_005933), WDR5 (amino acids 22-334; #NM_017588), RbBP5 (amino acids 1-538, NM_005057), Ash2L (amino acids 2-534, NM_001105214), and DPY-30 (amino acids 1-99, #NM_0325742). These were expressed in E. coli and isolated with N-terminal histidine-tags and dissolved in 20 mM Tris-hydrochloride (pH 7.5), 300 mM calcium chloride, 1 mM tri(chloroethyl)phosphate, 10% (w / v) glycerol, and 1 μM Preserved with zinc chloride.

[0725] Nucleosomes were isolated from HeLa cells, histone H3 protein was purchased from Sigma, and histone H3 peptide amino acids 1-21 (ARTKQTARKSTGGKAPRKQLATKA A-NH2) was purchased from AnaSpec. FlashPlate coated with S-adenosyl-l-[methyl-3H]methionine (3H-SAM) and streptavitin was purchased from PerkinElmer.

[0726] An isotope-based HotSpot format was used to measure histone methyltransferases. The reaction solution for histone methyltransferases was 50 mM Tris-hydrochloride (pH 8.5), 50 mM calcium chloride, 1 mM magnesium chloride, 1 mM dithiothreitol (DTT), and 1 mM phenylmethanesulfonyl fluoride (PMSF).

[0727] Standard substrates used were 5 μM protein substrate and 1 μM S-adenosyl-methionine (SAM), and S-adenosyl-l-homocysteine ​​(SAH) was used as a positive control compound. For IC50 determination, test compounds were diluted two- or threefold in dimethyl sulfoxide and added to nanoliter quantities of enzyme / substrate mixtures using an acoustic technique (Echo550; Labcyte).

[0728] The reaction was initiated by adding S-adenosyl-l-[methyl-3H]methionine (3H-SAM), and after incubation at 30°C for 1 h, the reaction was measured by the filter-binding method. The results were statistically analyzed using GraFit (Erithacus), which uses the ternary complex equation for curve fitting in GraphPad Prism software, and the equation is as follows.

[0729]

[0730] A is S-adenosyl-methionine (SAM); B is the protein substrate; KA and KB are the Michaelis constants for each substrate; KA' is the dissociation constant of SAM.

[0731] Using the compound according to the present invention, MLL1 HMT IC as shown in Table 1 below 50 The activity results were confirmed by measuring the values.

[0732] <Experimental Example 2-1: Acute Myeloid Leukemia (AML) Cell Culture>

[0733] MV-4-11 cells, a human acute myeloid leukemia (AML) cell line, were cultured in Iscove's modified Dubeco's medium (IMDM) supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 5% CO2 at 37°C in a 5% CO2 incubator.

[0734] <Experimental Example 2-2: Triple-negative breast cancer (TNBC) cell culture>

[0735] MDA-MB-231 cells, a human triple-negative breast cancer (TNBC) cell line, were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% penicillin-streptomycin at 37°C in a 5% CO2 incubator.

[0736] <Experimental Example 3-1: Degradation ability in AML cell line (DC 50 ) Evaluation>

[0737] To evaluate the ability of the synthesized WDR5 degrader to degrade WDR5 in the examples, MV-4-11 cells were seeded at 1X10 each in 6-well plates. 6Cells were seeded per well and cultured for 24 hours. After treatment, DMSO or the synthesized lysate was diluted in IMDM at various concentrations and cultured for 18 hours. Cells were washed twice with cold Dulbecco's phosphate buffered saline (DPBS) before cell lysis. To lyse cells, RIPA buffer (lysis buffer; 50 mM Tris-HCl, pH 8.0, 150 mM sodium chloride, 1% NP-40, 0.1% SDS) containing phosphase & protease inhibitor cocktail (Pierce) was treated to cells on ice. Cell lysates were centrifuged at 13,000 X rpm for 15 minutes at 4°C. Only the supernatant was collected, and protein concentration was measured by the Bradford method. 4X SDS loading buffer was added to the cell lysates and heated at 100°C for 5 minutes. Equal amounts of proteins were loaded on 12% SDS-PAGE and transferred to NC membranes. NC membranes were treated with TBST (Tris-stable saline containing 0.01% Tween-20) containing 5% skim milk for 1 hour and treated with primary antibodies (rabbit anti-WDR5 (D9E11) (CST#13105) or mouse anti-Vinculin (Sigma, V9131)) overnight at 4°C. After treatment with HRP-linked secondary antibodies for 1 hour at room temperature, images were obtained by Western blotting with ECL solution. Excess was washed several times with 1X TBST between each treatment. For data quantification and analysis, image results were quantified using the ImageJ program, and the levels of all target proteins were normalized to Vinculin. After quantification and normalization, the 50% degradation concentration (DC) of the compounds used in the experiments of the present invention was determined through nonlinear regression analysis using GraphPad Prism software. 50 ) values ​​were derived.

[0738] The results are shown in Table 1 below.

[0739] <Experimental Example 3-2: Resolution in TNBC cell line (DC 50 ) Evaluation>

[0740] To evaluate the ability of the synthesized WDR5 degrader to degrade WDR5 in the examples, MDA-MB-231 cells were seeded at 3X10 in each 6-well plate. 5 After dispensing cells / well and culturing for 24 h, the cultured cell medium was replaced with RPMI, and DMSO or a synthetic dissociating agent was diluted in RPMI at various concentrations, treated, and cultured for 18 h. The cells were washed twice with cold Dulbecco's phosphate-buffered saline (DPBS) before cell lysis.

[0741] To lyse cells, RIPA buffer (lysis buffer; 50 mM Tris-HCl, pH 8.0, 150 mM sodium chloride, 1% NP-40, 0.1% SDS) containing phosphase & protease inhibitor cocktail (Pierce) was applied to cells on ice. Cell lysates were centrifuged at 13,000 X rpm for 15 min at 4°C. Only the supernatant was collected, and protein concentration was measured by the Bradford method. 4X SDS loading buffer was added to the cell lysates and heated at 100°C for 5 min. Equal amounts of proteins were loaded onto 12% SDS-PAGE and transferred to NC membranes. NC membranes were treated with TBST (Tris-stable saline containing 0.01% Tween-20) containing 5% skim milk for 1 hour and treated with primary antibodies (rabbit anti-WDR5 (D9E11) (CST#13105) or mouse anti-Vinculin (Sigma, V9131)) overnight at 4°C. After treatment with HRP-linked secondary antibodies for 1 hour at room temperature, images were obtained by Western blotting with ECL solution. Excess was washed several times with 1X TBST between each treatment. For data quantification and analysis, image results were quantified using the ImageJ program, and the levels of all target proteins were normalized to Vinculin. After quantification and normalization, the 50% degradation concentration (DC) of the compounds used in the experiments of the present invention was determined through nonlinear regression analysis using GraphPad Prism software. 50 ) values ​​were derived.

[0742] The results are shown in Table 1 below.

[0743] Example MLL1 HMT IC 50 MV4;11 DC 50 MDA-MB-231 DC 50Compound 1 NANDNT Compound 2 NANDNT Compound 3+++NDNT Compound 4+++NDNT Compound 5++++++ Compound 6+NDNT Compound 7 NANDNT Compound 8++NDNT Compound 9+NDNT Compound 10+++++NT Compound 11+++++++++ Compound 12++++++NT Compound 13+++NDNT Compound 14+++++NT Compound 15+++NDNT Compound 16+NDNT Compound 17++++++ Compound 18++++++++ Compound 19+++NDNT Compound 20++++++++ Compound 21+++NDND Compound 22+NDNT Compound 23+NDNT Compound 24+NDNT Compound 25+NDNT Compound 26++++++++ Compound 27+++NDND Compound 28+++++ND Compound 29++++++ Compound 30++++++ Compound 31+++++++ Compound 32+++ND Compound 33++++NTIC 50 Low-resolution DC 50 Resolution+: 1–100 μM IC 50 values+: 5~25 μM DC 50 values++: 100~1000 nM IC 50 values++: 1~5 μM DC 50 values+++: <100 nM IC 50 values+++: < 1 μM DC 50 valuesNA: Not ActiveNA: No DegradationNT: Not Tested

[0744] As shown in Table 1, the compounds of the present invention have excellent MLL1 HMT IC 50 It has the ability to decompose values ​​and WDR5. In particular, through structure-activity comparison of the compounds of the present invention, excellent MLL1 HMT IC was found in compounds in which W in the chemical formula 1 of the present invention is substituted with chemical formulas 2, 3, 4, 5, 6, and 8. 50 It demonstrated the ability to decompose values ​​and WDR5, and its excellent anticancer effect was confirmed in an in vivo animal model.

[0745] <Example 1. Preparation of a powder>

[0746] A powder was prepared by mixing 2 g of the compound 11 of the present invention and 1 g of lactose and filling the mixture into a sealed bag.

[0747] <Example 2. Preparation of tablets>

[0748] 100 mg of the compound 11 of the present invention, 100 mg of microcrystalline cellulose, 60 mg of lactose monohydrate, 20 mg of low-substituted hydroxypropyl cellulose, and 2 mg of magnesium stearate were mixed and then compressed into tablets according to a conventional tablet manufacturing method.

[0749] <Example 3. Preparation of capsules>

[0750] After mixing 100 mg of the compound 11 of the present invention, 100 mg of microcrystalline cellulose, 60 mg of lactose monohydrate, 20 mg of low-substituted hydroxypropyl cellulose, and 2 mg of magnesium stearate, the above ingredients were mixed according to a conventional capsule manufacturing method and filled into a gelatin capsule to manufacture a capsule.

[0751] <Example 4. Preparation of injection>

[0752] After mixing 10 mg of the compound 11 of the present invention, an appropriate amount of sterile distilled water for injection, and an appropriate amount of a pH regulator, the mixture was prepared with the above ingredient contents per 1 ampoule (2 ml) according to a conventional method for preparing injections.

Claims

1. A compound represented by the following chemical formula 1, a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof: [Chemical Formula 1] In the above formula, R1 is hydrogen, NH, N(t-butoxycarbonyl) or C1-C5 alkyl; R2 is hydrogen or C1-C5 alkyl; R3 is or And, The above R3' is hydrogen, C1-C5 alkyl or halo C1-C5 alkyl, The above R3” is independently hydrogen, halogen or C1-C5 alkyl; R4 is hydrogen or halogen; R5 is hydrogen or C1-C5 alkyl; is a single bond or a double bond, and there are only two Not all bonds are double bonds; r is independently 0 or 1, provided that r is not simultaneously 0 and 1; X is CH or N; W is , , , , , , , , , , , , , , or And, The above A, B, C, D, E, F, and G are substituted by the chemical formulas 2 to 8 below, [Chemical Formula 2] Structure A [Chemical Formula 3] B Structure [Chemical Formula 4] C Structure [Chemical Formula 5] D Structure [Chemical Formula 6] E Structure [Chemical Formula 7] F Structure [Chemical Formula 8] G Structure wherein R6 is hydrogen or methyl; m is an integer from 0 to 5; n is an integer from 1 to 3; p is an integer from 0 to 2; q is 0 or 1; 2. In paragraph 1, The above chemical formula 1 is a compound represented by W below, a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof: W is , , , , or And, The above A is substituted with the chemical formula 2 below. [Chemical Formula 2] 3. In paragraph 1, The above chemical formula 1 is a compound represented by W below, a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof: W is or And, The above B is substituted with the chemical formula 3 below. [Chemical Formula 3] 4. In paragraph 1, The above chemical formula 1 is a compound represented by W below, a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof: W is or And, The above C is substituted with the chemical formula 4 below. [Chemical Formula 4] 5. In paragraph 1, The above chemical formula 1 is a compound represented by W below, a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof: W is And, The above D is substituted with the chemical formula 5 below. [Chemical Formula 5] 6. In paragraph 1, The above chemical formula 1 is a compound represented by W below, a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof: W is or And, The above E is substituted with the chemical formula 6 below. [Chemical Formula 6] 7. In paragraph 1, The above chemical formula 1 is a compound represented by W below, a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof: W is And, The above G is substituted with the chemical formula 8 below. [Chemical Formula 8] 8. In paragraph 1, The compound represented by the above chemical formula 1 is tert-Butyl (1-((3-(4-chloro-3-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)benzyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-6-yl)methyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)carbamate (Compound 1); (2S,4R)-1-((2S)-2-(2-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (Compound 2); 2-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)-N-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)acetamide hydrochloride (Compound 3); (2S,4R)-N-(2-(3-(2-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)acetamido)propoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide hydrochloride (Compound 4); (2S,4R)-1-((2S)-2-(5-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)pentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (Compound 5); (2S,4R)-1-((2S)-2-(5-(2-chloro-5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)pentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (Compound 6); 5-(2-chloro-5-((8-(6-fluoro-2-methylpyridin-3-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)-N-(2,6-dioxopiperidin-4-yl)pentanamide hydrochloride (Compound 7); (2S,4R)-1-((2S)-2-(5-(2-chloro-5-((8-(6-fluoro-2-methylpyridin-3-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)pentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (Compound 8); (2S,4R)-1-((2S)-2-(tert-butyl)-14-(5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)-4-oxo-6,9,12-trioxa-3-azatetradecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (Compound 9); N-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)-2-(2-(2-(5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)ethoxy)ethoxy)ethoxy)acetamide hydrochloride (Compound 10); (2S,4R)-1-((S)-2-(2-(2-fluoro-5-(((S)-8-(4-fluoro-2-methylphenyl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (Compound 11); (2S,4R)-1-((S)-2-(2-(5-(((S)-8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (Compound 12); (2S,4R)-N-(2-(3-(2-(2-fluoro-5-(((S)-8-(4-fluoro-2-methylphenyl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)phenoxy)acetamido)propoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide hydrochloride (Compound 13); (2S,4R)-1-((S)-2-(2-fluoro-5-(((S)-8-(4-fluoro-2-methylphenyl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)benzamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (Compound 14); (2S,4R)-1-((S)-2-(3-(2-fluoro-5-(((S)-8-(4-fluoro-2-methylphenyl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)benzamido)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (Compound 15); (2S,4R)-N-(2-((2-(1-(6-(((R)-8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-4-oxo-8,11-dioxa-2,5-diazatridecan-13-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide (Compound 16); (2S,4R)-1-((S)-2-(2-((1-(6-(((R)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)amino)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 17); N-1-((R)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N4-methyl-N4-(1-(4-methyl-6-(((R)-6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)pyridin-2-yl)azetidin-3-yl)succinimide (Compound 18); 2-(4-(2,6-dioxopiperidin-3-yl)phenoxy)-N-methyl-N-(1-(4-methyl-6-(((R)-6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)pyridin-2-yl)azetidin-3-yl)acetamide (Compound 19); (2S,4R)-1-((S)-2-(2-(5-(((S)-8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 20); 5-((8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenyl 2-(3-(2,6-dioxopiperidin-3-yl)phenoxy)acetate (Compound 21); N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethyl)-2-(5-(((S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamide (Compound 22); N1-(1-(6-(((R)-8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-3-fluoropyridin-2-yl)azetidin-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)succinamide (Compound 23); N1-(1-(6-(((S)-8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-3-fluoropyridin-2-yl)azetidin-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)succinamide (Compound 24); (2S,4R)-1-((2S)-2-(3-(3,4-dichlorophenyl)-3-(6-((2-methyl-1H-imidazol-1-yl)methyl)-8-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 25); (2S,4R)-1-((S)-2-(2-((1-(6-(((S)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)(methyl)amino)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 26); N-1-(1-(6-(((S)-8-(1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylsuccinamide (Compound 27); N1-(1-(6-(((R)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylsuccinamide (Compound 28); N1-(1-(6-(((S)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylsuccinamide (Compound 29); (2S,4R)-1-((S)-2-(2-(5-(((S)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 30); (2S,4R)-1-((S)-2-(2-(5-(((S)-6-((1H-imidazol-1-yl)methyl)-8-(4-fluoro-2-methylphenyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (Compound 31); 2-(5-(((S)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)-N-(1-(6-(((R)-6-((1H-imidazol-1-yl)methyl)-8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-4-oxochroman-3-yl)methyl)-4-methylpyridin-2-yl)azetidin-3-yl)-N-methylacetamide (Compound 32); and (S,E)-N-(2-(2-(2,6-dimethoxy-4-(3-oxo-3-(6-oxo-3,6-dihydropyridin-1(2H)-yl)prop-1-phen-1-yl)phenoxy)ethoxy)ethyl)-2-(5-((8-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-6-((2-methyl-1H-imidazol-1-yl)methyl)-4-oxochroman-3-yl)methyl)-2-fluorophenoxy)acetamide (Compound 33); A compound characterized by being selected from the group consisting of a stereoisomer thereof, a solvate thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition for preventing or treating cancer, comprising a therapeutically effective amount of a compound of any one of claims 1 to 8, or an enantiomer, diastereomer, stereoisomer, hydrate, solvate, prodrug or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10. In paragraph 9, A pharmaceutical composition characterized in that the cancer is a solid cancer or a blood cancer.

11. In paragraph 10, The above solid cancers include brain cancer, brain tumor, benign astrocytoma, malignant astrocytoma, pituitary adenoma, meningioma, brain lymphoma, oligodendroglioma, intracranial tumor, ependymoma, brainstem tumor, head and neck tumor, glioma, glioblastoma, laryngeal cancer, oropharyngeal cancer, nasal cancer, nasopharyngeal cancer, salivary gland cancer, hypopharyngeal cancer, tonsil cancer, thyroid cancer, oral cancer, esophageal cancer, eye cancer, thoracic tumor, small cell lung cancer, non-small cell lung cancer, thymic cancer, lung adenocarcinoma, lung cancer, lung squamous cell carcinoma, pleural cancer, mediastinal tumor, breast cancer, male breast cancer, abdominal tumor, stomach cancer, gastric mastoid tumor, liver cancer, hepatoblastoma, gallbladder cancer, biliary tract cancer, pancreatic cancer, small intestine cancer, colon cancer, colon cancer, rectal cancer, duodenal cancer, anal cancer, bladder cancer, kidney cancer, renal pelvis cancer, heart cancer, peritoneal cancer. A pharmaceutical composition characterized in that it is adrenal cancer, spinal cord cancer, bone cancer, genital tumor, penile cancer, prostate cancer, female genital tumor, cervical cancer, endometrial cancer, ovarian cancer, uterine sarcoma, vaginal cancer, female external genital cancer, female urethral cancer or skin cancer.

12. In paragraph 10, A pharmaceutical composition characterized in that the blood cancer is acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, childhood lymphoma, malignant lymphoma, multiple myeloma, or aplastic anemia.

Citation Information

Patent Citations

  • Isoflavones composition and medicine made of same

    CN102949388A

  • Substituted chroman derivatives, medicaments and use in therapy

    US20060074127A1

  • Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives

    US20080070918A1

  • COMPOSITIONS OF POLYGONUM ODORATUM FOR PREVENTION AND TREATMENT OF DISEASE

    WO2001056580A1

Cited By

  • WDR5 inhibitors, compounds, pharmaceutical compositions, and methods of use thereof

    WO2026058961A1